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DEVELOPMENT AND EVALUATION OF NEW LEPROSY SKIN TEST ANTIGENS AS 
DIAGNOSTIC TOOLS 
An early diagnostic test for leprosy that is adequately sensitive and specific to identify 
infected individuals before the onset of clinical symptoms continues to be one of the greatest 
needs in the field.  Preclinical diagnosis would expedite the delivery of chemotherapy to patients, 
prevent disabilities, decrease stigma, intercept transmission, and measure the true incidence of 
disease.  To address this pressing need, three new leprosy skin test antigens were investigated: 
MLSA-LAM [M. leprae soluble antigens devoid of lipoglycans, primarily lipoarabinomannan 
(LAM)], MLCwA (M. leprae cell wall associated antigens), and MLMA-LAM (M. leprae 
membrane antigens devoid of lipoglycans, primarily LAM).  Two of these antigens, MLSA-
LAM and MLCwA, were developed for manufacturing and testing for safety and efficacy in 
phase I and phase II human clinical trials.   
 Skin test antigens were derived from M. leprae purified from experimentally infected 
armadillo tissues under current good manufacturing practice conditions.  A skin test pilot plant 
was created at Colorado State University for this purpose.  Quality control testing of skin test 
antigens included potency and stability testing in guinea pigs, safety testing in guinea pigs and 
mice, integrity testing by gel electrophoresis and immunoblotting, and purity testing for residual 
dextran, collagenase, detergent, and endotoxin.  An investigational new drug (IND) application 
was submitted to the Food and Drug Administration (FDA) and clinical protocols with respective 
informed consent forms were generated. Training in good laboratory, manufacturing, and clinical 
practice (GLP, GMP, and GCP) was a prerequisite for these studies. 
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The phase I clinical trial was conducted at a non-endemic region for leprosy with both 
antigens at 2.5, 1.0, and 0.1 µg dosages.  A randomized double blind phase II clinical trial (stages 
A, B, and C) followed in an endemic region for leprosy with both antigens at 1.0, and 0.1 µg 
dosages.  Antigens were tested in the phase I and phase II, stage A/B trials using the intradermal 
delayed type hypersensitivity (DTH) skin test in healthy subjects without known exposure to 
leprosy, while the phase II, stage C trial compared the DTH skin test to the IFN-γ test and the   
M. leprae specific phenolic glycolipid I antibody test in target populations, including: leprosy 
patients, household contacts of leprosy patients, and tuberculosis patients.   
Both skin test antigens, MLSA-LAM and MLCwA, were found to be safe at each dose tested 
in the phase I and II clinical trials.   The phase II, stage A/B clinical trials showed the baseline in 
healthy endemic controls for both leprosy antigens at the low dose of 0.1 µg was negligible, 
while slightly elevated with the high dose of 1.0 µg.  Efficacy findings from the phase II, stage C 
clinical trial showed that the antigens were immunologically potent; highly specific, but lacked 
sensitivity at the low dose.  The response to PPD did not correlate with either leprosy antigen at 
either dose.  The IFN-γ release test provided the best diagnostic accuracy at the high dose with 
both antigens.  Household contacts with the highest risk of infection reacted in each test. 
MLSA-LAM and MLCwA are the first skin test antigens to show specificity for leprosy in 
the field.  The interferon gamma release assay with MLSA-LAM at the high dose provides the 
best diagnostic accuracy for tuberculoid leprosy patients.  The PGL-I antibody assay provides the 
best diagnostic accuracy for lepromatous leprosy patients.  Optimization of the antigen dosage or 
use of these tests in parallel or combination could lead to enhanced sensitivity, resulting in a 
good early diagnostic test for leprosy.  Results from these research studies prove that a product 
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As a young member of the Brennan Laboratory in the late 1980’s, elucidation of the major 
proteins of Mycobacterium leprae was underway.  My involvement was multifaceted, including 
harvesting bacteria from armadillo tissues; disrupting bacteria by sonication; antigen 
fractionation by centrifugation and high pressure liquid chromotagraphy; analysis by gel 
electrophoresis and immunoblotting, ELISA, and gas chromatography; and, delayed type 
hypersensitivity potency testing in guinea pigs.   
Working together with colleagues in the early days of the Mycobacterial Research 
Laboratories (MRL) to remove immunosuppressive lipoglycan components from subcellular 
fractions resulted in two new leprosy antigens that were potent in guinea pigs.  At the time, 
numerous articles and recommendations by the World Health Organization were being published 
on the urgent need for a diagnostic tool for the detection of asymptomatic  leprosy to aid in the 
elimination and understanding of the disease.  Skin testing had already been discussed as being 
the most feasible method and with the excitement of the two new antigens, efforts towards an 
investigational new drug (IND) application was initiated.  I remember the day, when I naively 
went into Dr. Brennan’s office and suggested that we move these antigens from the bench to the 
clinic.  With enthusiasm about developing the first early diagnostic, yet unaware of the full 
challenges that lay ahead, he agreed.    
Contract manufacturing organizations were not easily identified, due to the cost and fear of 
working with M. leprae, therefore a decision was made to renovate a BSL-3 laboratory in the 
Microbiology building into a pilot manufacturing plant to prepare skin test antigens for phase I 
and phase II clinical trials. With support from our contract sponsor we pressed 
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Forward through a maze of regulations, facility renovations, documentation, documentation, and 
more documentation.  Work through the IND process, manufacturing, phase I and phase II, stage 
A/B clinical trials was performed between 1992 and 2005.   
In 2004, an opportunity to expand cGMP manufacturing capabilities at Colorado State 
University under the Regional Center of Excellence Program prompted a grant proposal for a 
unique academic-based product translational core.  An RCE award was received under the 
direction of Dr. Barry Beaty to support many research investigators and three Core facilities, one 
of which was The Product Development and Manufacturing (PDM) Core. I transitioned into full 
time work with the RMRCE and part-time work as a graduate student in 2005 and continued 
through April, 2012.  The phase II, stage C clinical study was completed in 2011 and the final 
clinical study report was submitted in February 2012.   
Following the completion of this dissertation, my hope is that these new antigens will be 
tested further for diagnostic-epidemiological capabilities of screening individuals infected with 
asymptomatic leprosy.  To have played a small part of such a success story will make every 
ounce of energy expended on this project and my limited life outside of work and school over 
these past 7 years worthy.   Although my “bubbly enthusiasm” as described by one of my 
mentors has waned with work and personal circumstances over this last year, I am confident that 
it will return, and with that surge of effervescent energy, I plan to apply my higher education in 
areas of applied research, where I passionately believe in the need to move product ideas from 






I will never forget my father’s words, “when you do something, do it right.” That has been 
my mantra, my fervor, my dedication throughout my life.  My father was the apple of my eye 
and I wanted to be just like him; hence I was all tomboy and proud of it.  My mother accepted 
the fact, as she had a bit of “tom” in her too.  I always took the dirty jobs, the hard jobs, the 
thankless jobs as a kid.  No reason, other than to say I could do the job and do it well.  My love 
for horses was unlocked when I trotted and galloped in circles for 2 hours, while my youth group 
went on a trail ride.  I didn’t have enough money to go with them, but I had enough coins for 3 
rides in a round pen.  The owner felt sorry for me and let me ride for 2 hours (poor horse).   
School always came easy, and I excelled at math and science.  Nobody in our family had 
ever been to college and therefore the prospect never entered my mind, until I began working on 
my Aunt and Uncle’s farm in Kansas.  I learned that not only did I have a passion for horses, but 
I loved to be around and care for all kinds of animals.  It was clear at that time that I was meant 
to be a veterinarian.  Although my father told me that I shouldn’t go to college, I had already 
decided it was my destiny.   
After four quick years at CSU, I received my Bachelor of Science degree in animal science 
and a minor in biochemistry.  Veterinary Medicine, as it turns out, was not my destiny. After 
graduating in 1981, I started working at Elars cleaning animal cages and quickly advanced up the 
ranks to making monoclonal antibodies, followed by assisting and then running good laboratory 
practice (GLP) animal studies on small and then large animals.   
I met my husband, the new “apple of my eye” in 1980 and married in 1982.  We had two 
wonderful boys in 1984 and -85 that filled our lives with immense joy and agreeably, a new 
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lifestyle.  My husband completed his undergraduate and master’s degree in physical therapy, as I 
worked to support the family and advance my career.  Five years later, with Elars soon to be 
absorbed back into the Tech America parent company, my supervisor, Dr. Yoshio Teramoto 
asked me to visit Dr. Brennan at CSU, who was looking for a technician.  He told me that I was 
the only one at Elars that he recommended, because Dr. Brennan was quite demanding and 
challenging of his staff.  I began working with Dr. Brennan in 1986 on many different projects 
and flourished with the added responsibilities and challenges. 
My hours at work were long, partially because of my mantra and multiple responsibilities. In 
1996, I took a hiatus from mycobacteria and the skin test antigen project to work at Heska 
Veterinary Pharmaceuticals and then Mycos, LLC, with plans to spend more time for my boys.  
Unfortunately, “cookies and milk” were not on their agenda, so I returned to CSU in 2000, when 
given a chance to finish the skin test antigen project.  It was during this time that Dr. Brennan 
suggested that we propose a product development core facility as a unique core to support the 
Regional Center for Excellence proposal.  As my interest in product development had begun to 
blossom, I was very excited about this opportunity.  With painful effort, I wrote my first grant 
proposal and by the grace of Dr. Beaty and Dr. Brennan, ran the Product Development and 
Manufacturing Core.  My heart and soul went into making the Core a nationally recognized 
program, but it was clear that with this vision came the need to further my education.  For that 
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me that I was her hero for going back to school.  In truth, she was my hero for her strength and 
courage exemplified during her short battle with glioblastoma.  Her jovial and loving spirit will 
live in my heart forever. 
Additionally, I dedicate this work to the sisters, brothers, fathers, mothers, sons, and 
daughters afflicted with the terrible disease of leprosy.  Their physical, social, and psychological 
suffering is incomprehensible.  It is my greatest desire that the results of this research will in 














TABLE OF CONTENTS 
 
ABSTRACT .................................................................................................................................... ii 
ACKNOWLEDGMENTS ............................................................................................................. iv 
PREFACE ....................................................................................................................................... v 
AUTOBIOGRAPHY .................................................................................................................... vii 
DEDICATION ............................................................................................................................... ix 
TABLE OF CONTENTS ................................................................................................................ x 
LIST OF KEY WORDS .............................................................................................................. xvi 
 
CHAPTER ONE: LITERATURE REVIEW 
TAXONOMY AND GENERAL CHARACTERISTICS OF MYCOBACTERIUM LEPRAE ...................... 1 
LEPROSY DISEASE.................................................................................................................. 1 
CLINICAL DIAGNOSIS AND DISEASE CLASSIFICATION ............................................................ 2 
TREATMENT ........................................................................................................................... 4 
LEPROSY REACTIONS ............................................................................................................. 4 
GENETIC SUSCEPTIBILITY ...................................................................................................... 5 
TRANSMISSION ....................................................................................................................... 5 
VACCINES .............................................................................................................................. 6 
EPIDEMIOLOGY ...................................................................................................................... 6 
DIAGNOSTIC METHODS .......................................................................................................... 7 
xi 
 
Serology ............................................................................................................................ 7 
T-cell Assays ..................................................................................................................... 8 
PCR ................................................................................................................................... 9 
Intradermal DTH Skin Test .............................................................................................. 9 
HISTORY OF LEPROSY SKIN TEST ANTIGENS ....................................................................... 10 
NEW LEPROSY SKIN TEST ANTIGENS ................................................................................... 13 
RESEARCH OBJECTIVES ....................................................................................................... 15 
Personal Statement .......................................................................................................... 15 
Hypothesis and Aims ...................................................................................................... 16 
Research Responsibilities ............................................................................................... 17 
Dissertation Organization ............................................................................................... 18 
REFERENCES ........................................................................................................................ 20 
 
CHAPTER TWO: THE CHALLENGE OF PRODUCING SKIN TEST ANTIGENS WITH 
MINIMAL RESOURCES SUITABLE FOR HUMAN APPLICATION AGAINST A 
NEGLECTED TROPICAL DISEASE; LEPROSY 
SYNOPSIS ............................................................................................................................. 28 
AUTHOR SUMMARY ............................................................................................................. 29 
INTRODUCTION .................................................................................................................... 29 
METHODS ............................................................................................................................ 32 
Propagation of M. leprae in Armadillos ......................................................................... 32 
Tissue fractionation ......................................................................................................... 33 
Bacterial fractionation ..................................................................................................... 36 
xii 
 
Residual Collagenase Assay ........................................................................................... 38 
Residual SDS Assay ....................................................................................................... 38 
Residual Triton X-114 Assay.......................................................................................... 38 
Evaluation of Protein and Soluble Carbohydrate Identity .............................................. 39 
General Sterility Test ...................................................................................................... 39 
General Safety Test ......................................................................................................... 40 
Assay for Endotoxin Content .......................................................................................... 40 
DTH Guinea Pig Potency Assay ..................................................................................... 40 
Stability Testing .............................................................................................................. 40 
Adventitious Agent (Virus) Testing................................................................................ 41 
RESULTS .............................................................................................................................. 41 
Choice and Characterization of Antigen Preparations .................................................... 41 
Leprosy Skin Test Antigen Pilot Plant............................................................................ 42 
Quality Management System .......................................................................................... 45 
Pre-IND ........................................................................................................................... 46 
Manufacturing of Antigens ............................................................................................. 47 
Quality Control of Antigens............................................................................................ 48 
IND Application.............................................................................................................. 50 
DISCUSSION ......................................................................................................................... 51 




CHAPTER THREE: SAFETY ASSESSMENT OF TWO NEW LEPROSY SKIN TEST 
ANTIGENS IN HEALTHY SUBJECTS WITHOUT KNOWN EXPOSURE TO LEPROSY: 
RANDOMIZED DOUBLE BLIND CLINICAL STUDY 
SYNOPSIS ............................................................................................................................. 63 
REGISTRATION ..................................................................................................................... 64 
AUTHOR SUMMARY ............................................................................................................. 64 
INTRODUCTION .................................................................................................................... 65 
METHODS ............................................................................................................................ 66 
Interventions and Control Products ................................................................................ 66 
Human Subjects Recruitment ......................................................................................... 67 
Sample Size ..................................................................................................................... 67 
Antigen Administration .................................................................................................. 68 
Read-Out Measurements ................................................................................................. 68 
Institutional Review Boards ............................................................................................ 70 
Safety Monitoring Committee ........................................................................................ 70 
Documentation ................................................................................................................ 71 
Data Capture, Analysis and Reporting............................................................................ 71 
Reactogenicity................................................................................................................. 73 
Participants ...................................................................................................................... 74 
Ethics............................................................................................................................... 75 
Risks and Benefits........................................................................................................... 76 
Randomization and Blinding .......................................................................................... 76 
Statistical Considerations ................................................................................................ 77 
xiv 
 
RESULTS/DISCUSSION .......................................................................................................... 77 
Study Design ................................................................................................................... 77 
Study Outcome................................................................................................................ 80 
Conclusion ...................................................................................................................... 88 
REFERENCES ........................................................................................................................ 90 
 
CHAPTER FOUR: SAFETY AND EFFICACY ASSESSMENT OF TWO NEW LEPROSY 
SKIN TEST ANTIGENS: RANDOMIZED DOUBLE BLIND CLINICAL STUDIES 
SYNOPSIS ............................................................................................................................. 93 
REGISTRATION: .................................................................................................................... 94 
AUTHOR SUMMARY ............................................................................................................. 95 
INTRODUCTION .................................................................................................................... 95 
METHODS ............................................................................................................................ 96 
Skin Test Antigens and Control Products ....................................................................... 96 
Human Subjects Recruitment ......................................................................................... 97 
Sample Size ..................................................................................................................... 98 
Antigen Administration and Read-out Measurements .................................................... 98 
Regulatory Boards, Documentation, and Reporting ....................................................... 99 
Ethics............................................................................................................................. 100 
Risks and Benefits......................................................................................................... 100 
Randomization, Blinding, and Statistical Considerations............................................. 100 
Laboratory Assays ........................................................................................................ 101 
RESULTS ............................................................................................................................ 102 
xv 
 
Study Design ................................................................................................................. 102 
Study Outcome.............................................................................................................. 104 
Safety ........................................................................................................................ 104 
Safety Analysis ......................................................................................................... 106 
Efficacy ..................................................................................................................... 106 
DISCUSSION ....................................................................................................................... 121 
REFERENCES ...................................................................................................................... 127 
 
CHAPTER FIVE: CONCLUSIONS 
SUMMARY .......................................................................................................................... 130 
EVALUATION ..................................................................................................................... 131 
FUTURE DIRECTIONS.......................................................................................................... 133 
 
APPENDICES 
APPENDIX 1: PHASE II CLINICAL SITE, STAFF, AND LEPROSY PATIENTS PHOTOGRAPHS ... 134 
APPENDIX 2: CHAPTER THREE SUPPLEMENTARY DATA..................................................... 136 
APPENDIX 3: CHAPTER FOUR SUPPLEMENTARY DATA ...................................................... 141 
 
GLOSSARY ............................................................................................................................... 161 










Skin Test  
Delayed Type Hypersensitivity 







CHAPTER ONE: LITERATURE REVIEW 
 
TAXONOMY AND GENERAL CHARACTERISTICS OF MYCOBACTERIUM 
LEPRAE 
The etiological agent of leprosy is of the suborder Corynebacterineae, family 
Mycobacteriaceae, genus Mycobacterium, and species leprae. [1]  M. leprae was identified by 
Gerhard Armauer Hansen in 1873 as the first bacterium to cause human disease. The bacteria are 
straight or slightly curved rod-shaped organisms.  They are 1-8um long and 0.3um in diameter, 
and divide by binary fission.  M. leprae is gram-positive, but also acid fast due to the presence of 
mycolic acids in the waxy coating on the surface of the organism.  The pathogen is an obligate 
intracellular parasite, predominantly found in macrophages and Schwann cells.  M. leprae cannot 
be grown axenically, but can be grown to concentrated levels in the nine banded armadillo and 
nude mouse foot pad. [2,3]  The preferred growth temperature is between 30-34°C, supported by 
the low body temperature of the armadillo and mouse foot pad.  This temperature preference is 
also reflected clinically, as the cooler areas of the body such as the skin, nasal mucosa, and 
peripheral nerves are predominant sites of infection.  
LEPROSY DISEASE 
Leprosy was referred to as the “aristocrat of diseases” in colonial and imperial medical 
exchanges in the 19th century, because it was the oldest and most mysterious disease. [4] The 
first evidence of leprosy disease is 2000 BC, as found in ancient skeletal remains from India.[5] 
Single nucleotide polymorphism analysis suggests that Eastern Africa or the Near East was the 
origin of leprosy, and that it spread with human migration.[6] Leprosy disease, also called 
Hansen’s disease, presents with different clinical manifestations, depending on the host response 
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to the organism.[7]  Mycobacteria survive and multiply in phagocytes.  They evade microbicidal 
host defense systems and interfere with the antigen presentation by macrophages, leaving the 
immune system defective and unable to mount a concerted protective immune response.[8,9]  
The clinical spectrum of leprosy disease is directly related to the strength of activation of the 
immune system, which is critical to protection from leprosy.[10] The innate immune response is 
directly correlated with development of leprosy disease and disease type. [11] 
Leprosy affects the skin, nerves, limbs, and eyes.  Early clinical symptoms include loss of 
feeling for heat followed by touch and pain, beginning at the extremities. Skin lesions appear 
later during the course of the disease. Hansen's disease of PB type is associated by one or more 
hypopigmented skin macules, while MB type is associated with symmetric skin lesions, nodules, 
plaques, thickened dermis, and frequent involvement of the nasal mucosa resulting in nasal 
congestion and epistaxis.[12]  Advanced leprosy leads to paralytic or other neurologic 
disabilities, observed as physical deformities of the extremities or ocular degeneration.[13] 




CLINICAL DIAGNOSIS AND DISEASE CLASSIFICATION 
Leprosy diagnosis is currently based on clinical symptoms. An individual in an endemic area 
is diagnosed with leprosy based on one of two cardinal signs, 1) a skin lesion consistent with 
leprosy and with definite sensory loss, with or without thickened nerves, or 2) positive skin 
smears. [18]  Clinical leprosy is a polar disease with limited pathogenesis on one pole and severe 
pathogenesis on the other pole.  Classification of the disease spectrum was first described by 
Ridley and Jopling.  [19] Britton and Lockwood have summarized the clinical 
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immunopathological range of leprosy in a diagram, shown as Figure 1. [18]  Assignment of 
disease type was based on the number of lesions, lepromin response, and number of bacteria in a  
 
Figure 1: Clinical Immunopathological Range of Leprosy 
The full spectrum of leprosy disease and clinical manifestation of disease; ENL: erythema 
nodosum leprosum leprosy reaction. 
 
slit skin smear.  Tuberculoid leprosy (TT) and lepromatous leprosy (LL) where the extreme types 
at each pole and borderline tuberculoid (BT), borderline leprosy (BB), and borderline 
lepromatous leprosy (BL) were between the polar ends.  Polar TT patients have a high degree of 
cell-mediated immunity (CMI), usually with a single lesion that is well demarcated with a central 
hypopigmentation and hypoesthesia.  Biopsies contain developed granulomatous inflammation 
and rarely contain acid fast bacteria.  On the opposite end of the spectrum are Polar LL patients 
who do not have resistance to M. leprae and as a result develop multiple poorly demarcated, 
raised or nodular lesions on all parts of the body.  Biopsies contain sheets of foamy macrophages 
in the dermis and a large number of acid fast bacilli.  LL patients are anergic to M. leprae 
antigens, but do retain the immunological capacity to mount a humoral response to M. leprae 




Disease classification was simplified by the WHO for implementation of multi-drug therapy 
(MDT: clofazimine, rifampicin, and dapsone).  Paucibacillary (PB) leprosy patients presented 
with 1-5 skin lesions and multibacillary (MB) presented with > 5 skin lesions.  The PB subtype 
is reflective of a Th1 (cell-mediated) immune response and MB subtype is reflective of a Th2 
(humoral) immune response. [7]
  
Adult leprosy patients with MB leprosy receive a 12 month 
treatment regimen of 600 mg rifampicin once per month, 100 mg dapsone daily, 300 mg 
clofazimine once per month and 50 mg daily.  Leprosy patients with PB leprosy receive a 6 
month regimen of 600 mg rifampicin once per month and 100 mg dapsone daily. MDT is 
provided in pre-dose blister packs, free of charge, by the WHO.[20] 
LEPROSY REACTIONS 
Leprosy patients can also develop painful immune-mediated reactions that may lead to added 
neurological disabilities.  There are two primary types of leprosy reactions, Type 1 (Reversal 
Reaction) and Type 2 (Erythema Nodosum Leprosum).  Type I reactions can occur in any type 
of leprosy, with a sudden increase in cell mediated immunity against M. leprae antigens and an 
increase in Th1 cytokines including IL-1 beta, TNF alpha, IL-2 and INF-γ, and a decrease in Th2 
cytokines IL4, IL5, and IL10.   Inflammatory reactions result in pressure on the nerve axon, 
resulting in nerve cell death.  Type 2 reactions only occur in BL/LL leprosy and are thought to be 
related to an Arthus reaction involving the complement system. Research in this area is limited, 
although it is known that physical stress such as viral infections and pregnancy[21] or 






Host genetics appear to play a two stage role.  The PARK2, LTA, 13q22.1, or 20p12.3 genes 
confer susceptibility or resistance. For the approximate 5-10% of infected individuals who 
develop leprosy, HLA-DRB1*15 or 10p13 genes determine the type of host immune response 
elicited and subsequent clinical manifestation.[24]  Polymorphism have been found in some of 
these same genes and others, such as RIPK2, TNFSF15, LRRK2, C13orf31/CCDC122, 
NOD2;[25] TLR1, C13orf31 and, CDDC1222.[26] Genetic makeup is one risk factor for the 
development of leprosy. 
TRANSMISSION 
M. leprae is not highly infectious, but is pathogenic depending on the form of disease.  
Evidence suggests that bacteria are carried through nasal droplets and infect the upper respiratory 
tract.  Infection requires more than just casual contact with infected patients.  Living in a 
household with a patient that has high bacillary loads over long periods presents 8-fold higher 
risk of contracting the disease.[27,28] 
The incubation period from infection to clinical manifestation of disease varies from several 
months to 30 years, depending on the type of leprosy. [29]  On average, TT patients develop 
clinical symptoms within 4 years and LL patients develop clinical symptoms within 10 years.  
With the long incubation period from infection to manifestation of disease, a low rate of 
transmission can continue for many years.  Risk factors include genetic susceptibility, age under 
14 years or older adults, male gender, antibody response to the M. leprae specific antigen, 
phenolic glycolipid I (PGL-I), and lepromin negative response. [30] As a result, contacts of 
patients, especially MB patients, are at an 8-fold higher risk of contracting leprosy compared to 
non-contacts.  Contacts of PB patients are only slightly more at risk than non-contacts.  
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Intercepting human to human transmission of infectious bacilli is critical for preventing leprosy 
disease, nerve damage, stigmatization by local communities, and disabilities. [29]  
VACCINES 
With issues complicating the development of early diagnostic tests for leprosy, a protective 
vaccine with higher efficacy than that seen with BCG would be useful.  Alternatively, identifying 
protective correlates of immunity to identify those individuals who are/are not infected, but self-
cured, would be beneficial.  The vaccine trial in Karong District, Northern Malawi showed that a 
single dose of BCG provided greater than 50% protection against leprosy, but not tuberculosis.  
These results were consistent with the study in Venezuela.[31,32]  The role of the BCG 
vaccination was verified with an analysis of 19 observational and 7 experimental papers.  Age is 
not a predictor of protective effect, but an additional dose was more protective in prevention 
compared to one dose.[33]  The hope for the field of leprosy is that the intensive efforts to find a 
better vaccine for tuberculosis will also have cross-protective characteristics and protect 
individuals, especially children who have an increased incidence, from leprosy.  A concern is 
that as the tuberculosis vaccines become more specific, cross-reactive epitopes to protect against 
leprosy may be lost.[34] 
EPIDEMIOLOGY 
Detection of asymptomatic leprosy has been identified by the World Health Organization 
(WHO) as an important need.[35]  Emphasizing this point, the need for a diagnostic test for early 
leprosy infection has been reported by the scientific community for more than 90 years, since 
Mitsuda tested the value of a skin reaction using a suspension of leprosy nodules termed 
Lepromin-H.[36]  With the introduction of multiple drug therapy (MDT) by the WHO in 1982 to 
prevent Mycobacterium leprae resistance to dapsone monotherapy, leprosy prevalence began a 
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dramatic decline. [37]  Over the past 30 years, the prevalence of leprosy has dropped 98.3% from 
an estimated 11.5 million cases, of which only 5.3 million cases were registered in 1983, to the 
current figure in 2010 of 192,246.[35,38]  Contrary to this remarkable achievement, leprosy 
incidence or new case detection remained relatively constant or increased slightly from 1985 at 
555,188 new cases in the top 33 endemic countries [39] to 571,792 new cases in 1990 [40] and 
620,672 new cases in 2002.[41]  A significant decline of 51.4% in leprosy incidence was 
observed between 2002 to 2005 at 299,036 new cases, followed by another decline of 23.6% to 
the current 2010 figure of 228,474. [35]  A total decline of 58.8% in detection of new cases from 
1985 to 2010 has been observed.  Although many investigators have questioned the value of 
these numbers based on confounding operational factors, one basic fact remains.  Incidence has 
exceeded prevalence, and therefore transmission of M. leprae from infected individuals to 
susceptible individuals remains a serious concern. [42] 
DIAGNOSTIC METHODS 
Multiple test methods are being investigated in the field for the diagnosis of asymptomatic 
leprosy including: serology, IFN-γ assays, polymerase chain reaction (PCR) with M. leprae 
specific gene primers, and intradermal DTH skin test. [43-47]  All of these methods have shown 
some level of diagnostic potential, however, none to date perform at a sensitive and specific level 
across the complicated spectrum of leprosy disease.   
Serology 
The most notable contribution in serological detection of M. leprae was the discovery of 
phenolic glycolipid I (PGL-I) as a specific cell surface marker of M. leprae. [48]  Translation of 
this IgM antibody detection method into a lateral flow immunodiffusion test was accomplished 
for ease of testing in the field.  Numerous studies have been performed with PGL-I enzyme 
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linked immunoadsorbant assays in the native form and synthetic ND-O-BSA/HSA forms. 
[30,49] The test does not detect early infection, but has been shown to classify BL/LL from 
BT/TT leprosy disease.  
Serology has been attempted on a vast number of native proteins, recombinant proteins, and 
synthetic peptides such as the serine rich 45 kDa protein, ESAT-6, CFP-10, 35 kDa major 
membrane protein, antigen 85 proteins, hypothetical proteins, etc. [43,50-52] derived by 
conventional identification, and in silico analysis of the M. leprae genome, and/or use of 
specialized software programs to detect T- and B- cell epitopes, secretory sequences, lipoprotein 
sequences, sequences specific to M. leprae, etc.  More recently combinations of peptides and 
expression of PGL-I/peptide conjugates have proven useful [example: LID-1 (ML0405 and 
ML23310). [43]  
T-cell Assays  
Early studies to identify a diagnostic test for asymptomatic leprosy included T-cell 
proliferation assays [53,54], while later studies used T cell cytokine detection assays, specifically 
interferon gamma.[42]  Cell mediated immunity against M. leprae was measured by the level of 
IFN-γ present following in vitro T-cell stimulation. [55,56] Gene’s specific to M. leprae have 
been identified and respective proteins expressed or peptides synthesized for testing in whole 
blood or peripheral blood monocyte assays.[57,58]   Present day focus on interferon gamma 
release assays (IGRA) providing some level of early diagnostic capabilities is actively 





PCR assays have shown promise in detecting M. leprae DNA from nasal swabs.  This 
method holds promise for detecting both forms of disease at an early stage, because it is sensitive 
and specific to the organism.  The concern is that it might be too sensitive, as it detects M. leprae 
in nasal carriages of healthy controls.  It is also not able to distinguish between viable and non-
viable bacilli, and a test for mRNA is not yet developed.  Moreover, this test requires an even 
higher skill set, expensive equipment, and costly reagents.  The likelihood that a diagnostic test 
would ever be commercialized for leprosy is very low, because the people and governments 
living in leprosy endemic regions would not be able to afford an expensive test.  [66,67] 
Intradermal DTH Skin Test 
The intradermal DTH test measures cell-mediated immunity (CMI). [68] Based on 
experience with the Tuberculin PPD skin test for tuberculosis, subjects must be exposed to the 
infectious agent for at least 4-6 weeks prior to testing for antigen recall. [69]  A DTH type IV 
reaction is initiated when antigen is injected into subcutaneous tissue and processed by antigen 
presenting cells.  A TH1 effector cell recognizes the antigen and releases cytokines IL-2, IFN-γ, 
and TNF, which act on vascular endothelium causing erythema and recruitment of T-cells, 
phagocytes, fluid, and protein which causes a measurable induration response within 48-72 hours 
in humans.  A lack of DTH response to recall antigen is evidence of anergy.   
Sensitivity of the DTH test method has been proven with Purified Protein Derivative (PPD) 
prepared from secreted antigens of the culture filtrate of M. tuberculosis and employed as a DTH 
diagnostic test for Tuberculosis. [70]  The Tuberculin Mantoux response is highly sensitive in 
detecting exposure or infection with M. tuberculosis, however, the test is not very specific in 
endemic regions for tuberculosis or in populations that have been vaccinated against Bacillus 
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Calmette Guerin (BCG) and exposed to related mycobacteria.  On the contrary, it is specific for 
tuberculosis in non-endemic regions where subjects have not been exposed or vaccinated. [71] 
Tuberculin PPD has been used across the world with an exceptional safety record.[72,73] 
HISTORY OF LEPROSY SKIN TEST ANTIGENS 
The earliest published information on leprosy skin test antigens was by Mitsuda in 1919 [36] 
where an autoclaved suspension of macerated nodules from untreated leprosy patients termed 
Lepromin-H was administered to volunteers.  Lepromatous leprosy patients did not respond, but 
tuberculoid leprosy patients and a certain percentage of indeterminate and borderline patients 
produced a nodule varying in size from 3 to 4 mm on day 21 - 30.  This nodule was termed the 
Mitsuda reaction.  This reaction is unique and considered to be a measure of response capability 
to M. leprae antigens; however, because about 90% of normal subjects in endemic areas produce 
a positive response the test is not considered useful for diagnosing leprosy. In 1940, 
Fernandez[74] described another response produced by this antigen, which appeared 48 hours 
after injection in those individuals with tuberculoid leprosy and in a certain number of normal 
people who had been in contact with leprosy patients.  The presence of a Fernandez reaction was 
considered indicative of CMI against M. leprae.  A derivative of Lepromin-H, consisting of a 
chloroform ether extracted suspension of M. leprae, named Dharmendra Lepromin, produces 
only the 48 hour reaction.[75]  The protocol for this leprosy skin test antigen is on file with the 
FDA under Investigation New Drug (IND) number: BB-IND-2399.  
As leprosy declined and MDT was widely implemented, the number of patients with 
fulminating leprosy declined and the availability of human lepra nodules was reduced 
dramatically.  As a result, it became important to find another source of antigen.  In 1975, 
investigators demonstrated that armadillo-derived Lepromin-A elicited a DTH and Mitsuda 
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reaction equal to or better than Lepromin-H in human clinical studies. [76-78]  These results led 
to the submission of an IND for Lepromin-A (IND number: BB-IND 2401) in 1981 by Dr. W. A. 
Krotoski and Dr. R. C. Hastings at the Gillis W. Long Hansen’s Disease Center (GWLHDC), 
Louisiana State University, Baton Rouge, LA.[79,80]  Lepromin-A, like previous Lepromins, 
has prognostic value for classifying disease.  By January 1993, under a contract with the WHO, 
approximately one million doses of Lepromin-A had been distributed to physicians and 
institutions in leprosy endemic areas.  Its general safety and effectiveness are well established, 
however, two unfavorable results are apparent.  First is the appearance of a nodule and/or 
necrosis, 3-4 weeks following injection, a.k.a. Mitsuda reaction, and second, the material itself 
can act as a weak vaccine and immunologically disturb any population receiving this 
reagent.[81] 
By 1984, it became apparent that a skin test reagent capable of specifically diagnosing 
leprosy without undesirable affects would have to come from fractionated M. leprae.  To mimic 
the classical Tuberculin PPD in which activity and specificity are related to low molecular 
weight secretory proteins in the culture filtrate,[82] efforts were directed to the soluble fraction 
of the leprosy bacilli, since M. leprae is not cultivable.  Two laboratories formulated different 
subcellular skin test antigens at the same time.  Convit’s antigen was designated Soluble Protein 
Antigen (SPA) or Soluble Antigen (SA), while the Rees Antigen was designated M. leprae 
soluble antigen (MLSA) or Leprosin.[83] Convit’s SPA was prepared from bacilli purified from 
M. leprae infected armadillo tissues using the 1/79 Draper protocol.[84]  Purified bacilli were 
disrupted by French Press and centrifuged at 48,000 x g for 1 hour.  The supernatant containing 
cytosolic and membrane components were filtered through a 0.45µm filter, diluted in borate 
buffer, and bottled in vials.  Vials were then autoclaved, cooled, and stored at -20 °C.  The Rees 
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antigen was prepared from bacilli purified from gamma-irradiated M. leprae infected armadillo 
tissues using the 3/77 Draper protocol.[85]  Purified bacilli were disrupted by sonication and 
centrifuged at 27,000 x g to remove the cell wall and a 105,000 x g to remove the membrane.  
The supernatant containing cytosolic components was filtered through a 0.8µm and 0.2µm filter, 
diluted in borate/Tween buffer, and bottled in vials.  Vials were stored at 4°C.   
Extensive testing of human subjects with both the Rees and Convit antigens was undertaken 
in Malaysia, Malawi, Venezuela, and India with no adverse effects. [31,83,86-88]  Reactions 
observed in these studies ranged from soft, meaning that the reaction merged almost 
imperceptibly with the surrounding skin to hard, meaning that the reaction was quite distinct in 
the margins.  Reactions to Tuberculin are hard in consistency.  The reason for the soft reaction is 
unknown, but obviously makes the test extremely difficult to read consistently.[86]
  
Results from 
these studies indicated that the Rees and Convit antigens are not useful in the identification of M. 
leprae infection or in the confirmation of leprosy diagnosis in a leprosy endemic population with 
a high prevalence of non-specific sensitivity.[87]
  
Promising features of both antigens showed 
that neither exhibited sensitizing potential, both were very potent immunologically, and could 
classify leprosy in human vaccine trials in Venezuela, Malawi, and India.[31,83]    
Both antigens were found to be safe, and in a limited sense, useful.  Samuel, et al. 
documented
 
that the Rees antigen reactions were positive in highly resistant forms of leprosy and 
negative in low-resistant lepromatous forms of leprosy
 
in India, Uganda, Kenya, Nepal, and 
Bhutan.  Wide variations in response to both of these antigens was well documented by Gupte, 
et. al.[87]
 
 Reasons for these differences could be the use of different batches of antigens with 
suspected variability of protein content of the earlier preparations, prevalence in different areas, 
non-specific desensitization, and geographical differences.  In general, the results of these studies 
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indicate that the Convit and Rees antigen skin test response are variable due to product or 
population variation, may not be sensitive enough to detect leprosy, and do not appear to be 
specific enough to confirm clinical diagnosis of leprosy.[47]  Both antigens meet the ideal for 
potency while falling short in terms of sensitivity and specificity. 
NEW LEPROSY SKIN TEST ANTIGENS 
Criteria for a useful early diagnostic test for leprosy had been established. To have any 
chance of successful implementation, the test must be able to detect an early and specific 
immunological response, be simple to implement in the field, and be inexpensive.  Information 
gained from preparation and testing of the Rees and Convit skin test antigens provided a frame-
work in the early 1990’s for the development of two new leprosy skin test antigens.[47,89]  
Elucidation of the major proteins of the M. leprae bacillus was underway.  Subcellular fractions 
were being prepared by ultrasonication and centrifugation and lipoglycans were extracted with 
detergent to visualize and enable N-terminal sequencing of major proteins resolved by reduced 
acrylamide gel electrophoresis. [90-92]  Subcellular fractions and purified proteins were tested in 
the delayed type hypersensitivity (DTH) guinea pig animal model to assess their ability to 
stimulate a cell mediated immune response in M. leprae sensitized compared to M. tuberculosis 
infected or naïve animals. [93] 
The first new antigen candidate was modified from the Rees MLSA by removing 
immunosuppressive and cross-reactive components (LAM, LM, PIMS, and other lipids) to 
produce MLSA-LAM. [94,95] The second new antigen consisted of cell wall associated 
antigens, which were found to be powerful immunogens in extensive immunological studies and 
skin testing in guinea pigs.[96,97]  Both MLSA-LAM and MLCwA were found to strongly 
induce proliferation of lymphocytes and stimulate secretion of IFN-γ from immune cells.[98,99]  
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An equivalent M. leprae membrane antigen (MLMA-LAM) was also developed, but was not 
moved forward due to low yields. 
In 1992, a decision was made to take the two new leprosy antigens forward as skin test 
antigens in human clinical trials.  Multiple preclinical batches were prepared to optimize and 
refine the production process, test stability, and to provide ample material for developing assays 
for assessing quality.  Preparation of early batches also showed that the process was reproducible 
and potency between batches was consistent and that the antigens were active.   
A rational approach to moving these two antigens from the bench to the clinic involved 
intense and frequent discussions with our National Institutes of Health (NIH) sponsor who 
funded the project under Dr. Brennan’s Leprosy Support Contract.  Of importance was the need 
to produce these new skin test antigens under the rigor of cGMP for consistency and 
reproducibility between batches, based on the variability of protein content seen in earlier Rees 
and Convit preparations. The regulatory scenario had advanced dramatically contributing to a 
higher quality product for first in human phase I clinical trial. Considerable effort to identify a 
contract manufacturing organization (CMO) was initiated, but exorbitant cost and the fear of 
working with M. leprae prohibited use.  As a result, the laboratory embarked on the monumental 
task of creating a current good manufacturing practices (cGMP) skin test pilot plant in the 
microbiology department building at Colorado State University to prepare material for phase I 
and phase II human clinical trials. 
Applied research efforts progressed with the anticipation of developing an early diagnostic 
test for leprosy.  Between 1992 and 2005, the following achievements occurred: 1) candidate 
antigens were identified; 2) concerted decision to move forward with product translation of 
MLSA-LAM and MLCwA; 3) Renovation of a cGMP Pilot Plant Facility dedicated to the 
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production of new leprosy skin test antigens; 4) Creation of a Quality System, batch records, and 
supporting standard operating procedures (SOPs); 5) pre-IND meetings; 6) manufacturing; 7) 
submission of the IND; 8) completion of a phase I clinical trial at Colorado State University, Fort 
Collins, Colorado, USA, a nonendemic region for leprosy; and, 8) completion of a phase II, stage 
A/B clinical trial on healthy subjects without known exposure to leprosy at Anandaban Hospital, 
Kathmandu, Nepal, an endemic region for leprosy. A visit to the phase II clinical site took place 
on November 17-19, 2004 by Dr. Brennan, Research Principal Investigator, Ms. Rivoire, 
Research Study Coordinator, and Dr. Robert Gelber, Safety Monitoring Committee Chair, to 
meet regulatory and clinical staff, discuss proposed protocol changes, and to tour the hospital.  
With permission, photographs of staff and patients were taken to document participants in the 
clinical trial (Appendix 1).   
RESEARCH OBJECTIVES 
Personal Statement  
Product translation from discovery to first-in-human testing is a challenging and difficult 
road for academicians working on a product idea without commercial interest.  Such was the 
situation with the two new leprosy skin test antigens, as leprosy was a disease of mostly poor, 
developing countries, also experiencing a rapid decline in prevalence (registered cases) following 
the implementation of MDT.  Incidence (new case detection) however; remained constant 
suggesting that transmission was still occurring.  The desperate need for an early diagnostic test 
for leprosy to allow chemotherapeutic intervention prior to debilitating clinical manifestation of 
disease and to prevent transmission remained a concern then, as it does today. 
 The Leprosy Skin Test Initiative was launched following a passionate plea to advance two 
scientifically sound diagnostic skin test antigen candidates from the bench to the clinic.  Without 
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a pharmaceutical partner and failed attempts at finding a CMO, product translation had to come 
from within the university or be abandoned. The potential prospect of these two skin test 
antigens being efficacious as early diagnostic tools for leprosy was a strong motivator. 
I embarked on this very unique project with a focus on translational research, rather than pure 
basic research to apply the knowledge we had at the time.  This special dissertation was agreed 
upon and supported by my graduate committee members and represents the first product 
translational project within the department.  The work presented here validates the 
appropriateness of product translation in an academic environment for medical interventions that 
have potential use, but lack commercial sponsorship.  Prospective products should not be left on 
the shelf, when people are suffering or are at risk of contracting or already suffering from a 
debilitating disease. 
Hypothesis and Aims 
This graduate program formally began in the Spring of 2005, following the Phase II, Stage B 
clinical trial study and continued through February, 2012, the end of the phase II, stage C-1 
clinical trial.  The hypothesis of this research was that the new leprosy skin test antigens, MLSA-
LAM and MLCwA, at doses of 1.0μg and/or 0.1μg, would be safe and efficacious as diagnostic- 
tools to detect leprosy and allow treatment of patients earlier and to measure the extent of leprosy 
infection in human subjects living in a leprosy endemic area. There were three specific aims: 1) 
assess both antigens and antigen doses for safety and efficacy in leprosy patients, household 
contacts of leprosy patients, and tuberculosis patients in an endemic region for leprosy; 2) 
compare the skin test method against two in vitro test methods, IFN-γ assay and PGL-I antibody 
assay; and, 3) successfully complete product translation within an academic environment under 
government support.   
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My involvement with this project started in 1992, upon the launch of the Leprosy Skin Test 
Initiative, providing laboratory research and management skills to move this project forward. 
Under this graduate program, my role was the primary study coordinator, responsible for 
creating, updating, and reviewing regulatory documents, reporting to institutional review boards 
(IRB), in vitro laboratory assay procedures, communications, data analysis, and publications.  
This dissertation is the culmination of translational research of MLSA-LAM and MLCwA as 
potential asymptomatic leprosy diagnostic tests.   
Research Responsibilities 
A timeline of the Leprosy Skin Test Initiative can be seen in Figure 2. A significant amount 
of the work was performed by me and coworkers from 1992 through the inception of this 
program in 2005.  I left the project from 1996 through 2000 for personal reasons, and Dr. 
Stephen Terlow performed the manufacturing of new skin test antigens, Dr. Patrick Brennan 
submitted the IND, and Dr. Terlow served as research coordinator of the phase I study.  Upon 
Dr. Terlow’s exit in 2001, I resumed the coordinator position on the Leprosy Skin Test Initiative 
project.  Formulation of antigens was performed from stock vials to increase our clinical 
supplies, prior to the phase II, stage B studies and verification of stability at 2 and 6 years post-
manufacturing was performed in guinea pig potency assays.   
In 2005, the phase II protocol was rewritten using the NIH Clinical Trial Protocol Template. 
[100]  Development and preparation of reagents for the IFN-γ assay and PGL-I Antibody assay 
were performed, and related standard operating procedures were created for approval by the 
team, prior to implementation in the Stage C study.  Document control, ethical review board 










Figure 2: Leprosy Skin Test Initiative Timeline 
Product translation of MLSA-LAM and MLCwA from discovery to pilot scale clinical trials 
spanned 20 years. 
 
and the final comprehensive report were reviewed.  Statistical data analysis and drafting of 
manuscripts was the final momentous task of the first part of this research study.  As described in 
the background of new leprosy skin test antigens, discovery, manufacturing, IND, phase I, and 
phase II, stage A/B clinical trials were completed prior to the initiation of this research program.  
Studies covered under this program include the phase II, stage C-1a/b clinical trials, final report 
review, data analysis, and publication of the Leprosy Skin Test Initiative. 
Dissertation Organization 
Product translation of the two products under investigation could not be reported until the 
closure of the phase II protocol, to prevent compromising on-going studies.  Consequently, this 
dissertation includes full reporting of the translational process from discovery through phase I 
and phase II clinical trials.  Chapter 1 provides a literature review and background work 
supporting this dissertation. Details of key personnel responsible for background work have been 
provided under research responsibilities.  Chapter 2 provides a concise report of developing 
products suitable for human testing with minimal resources.  This work occurred between 1992 
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and 1998, primarily by me, Dr. Steve Terlow and Dr. Patrick Brennan. Chapter 3 covers the 
phase I and phase II, stage A and B clinical trials to assess safety of these skin test antigens in 
healthy contacts living in a nonendemic region or endemic region for leprosy.  This work 
occurred between 1999 and 2004, primarily by Dr. Terlow, Dr. Brennan, CSU Hartshorn Health 
Center staff, and me.  Chapter 4 describes the phase II, stage C-1a and C-1b clinical trials to 
assess both safety and efficacy in target populations, including leprosy patients, household 
contacts of leprosy patients, and tuberculosis patients.  The work occurred between 2005 and 
2012, primarily by me, Dr. Brennan, and the Anandaban Hospital clinical team. Chapter 5 
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CHAPTER TWO: THE CHALLENGE OF PRODUCING SKIN TEST ANTIGENS WITH 
MINIMAL RESOURCES SUITABLE FOR HUMAN APPLICATION AGAINST A 
NEGLECTED TROPICAL DISEASE; LEPROSY 
 
SYNOPSIS 
True incidence of leprosy and its impact on transmission will not be understood until a tool is 
available to measure subclinical infection. Diagnosis is currently based on clinical symptoms, 
which on the average take 3-10 years to manifest. The fact that incidence as judged by new case 
detection equates with prevalence i.e., registered cases, suggests that the cycle of transmission 
has not been fully intercepted by implementation of multiple drug therapy. This is supported by 
high incidence of childhood leprosy. Epidemiological evaluation of asymptomatic leprosy in 
large endemic populations is required to facilitate targeted chemoprophylactic interventions. 
Such a test must be sensitive, specific, simple to administer, cost-effective, and easy to interpret. 
The intradermal skin test method that measures cell mediated immunity was deemed the best 
option. Prior knowledge on skin testing of healthy subjects and leprosy patients with whole or 
partially fractionated Mycobacterium leprae bacilli, such as Lepromin or the Rees’ or Convit’ 
antigens has established an acceptable safety and potency profile. These data, along with 
immunoreactivity data, laid the foundation for two new leprosy skin test antigens, MLSA-LAM 
(M. leprae soluble antigen devoid of mycobacterial lipoglycans, primarily lipoarabinomannan) 
and MLCwA (M. leprae cell wall antigens). In the absence of commercial interest, the challenge 
was to develop these antigens under current good manufacturing practices in an acceptable local 
pilot facility and submit an Investigational New Drug Application to the Food and Drug 
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AUTHOR SUMMARY 
Despite reaching the global elimination target for leprosy, the need for a diagnostic tool to 
detect asymptomatic disease remains. Transmission has not been completely intercepted despite 
over 30 years of extensive curative treatment. With limited resources, two new leprosy skin test 
antigens MLSA-LAM and MLCwA, suitable for human application were developed and 
manufactured in a local pilot plant. Requirements for manufacturing and clinical testing were 
met and an Investigational New Drug Application was established with the Food and Drug 
Administration to test both antigens in a phase I clinical trial for safety in a non-endemic region 
for leprosy and a phase II clinical trial for safety and efficacy in an endemic region for leprosy. 
INTRODUCTION 
Detection of subclinical leprosy continues to be identified by the World Health Organization 
(WHO) as a priority. [1] With the introduction of multiple drug therapy (MDT) by the WHO in 
1982 to prevent M. leprae resistance to dapsone monotherapy, the prevalence of leprosy began a 
dramatic decline. [2] Over the past 30 years, prevalence has dropped by about 98% from an 
estimated historical high of 11.5 million cases in 1983 [3] to the current figure of 192,246 
registered cases. [1] Contrary to this remarkable achievement, leprosy incidence or new case 
detection remained relatively constant or increased slightly from 1985 at 555,188 new cases in 
the top 33 endemic countries [4] to 571,792 in 1990 [5] and 620,672 in 2002. [6] A significant 
decline of 51.4% in new cases was then observed between 2002 and 2005 to 299,036, followed 




detection of new cases from 1985 to 2010 has been observed. Although many investigators have 
questioned the value of these numbers based on confounding operational factors [7], one fact 
remains; incidence has generally exceeded prevalence. Of concern is the increased number of 
childhood leprosy observed in India signifying active and recent transmission of disease. [8,9] 
These findings provide evidence that transmission of M. leprae from infected to susceptible 
individuals remains a problem.   
Little is known of the extent of leprosy in the endemic regions of the world, or reservoirs of 
infection, or bacterial or immunological basis of the distinctive pathogenesis of leprosy, notably 
nerve damage; [10,11] however, we do know that early detection and treatment does reduce 
transmission [12] and disease sequelae [13-15]. MDT is curative for leprosy disease, and if 
administered early during infection can prevent transmission from individuals harboring M. 
leprae bacilli. [16,17]  
Classification of leprosy was first described by Ridley and Jopling based on the number of 
lesions, lepromin skin test response, and number of bacteria in a slit skin smear. [18] Clinical 
leprosy is an immunologically polar disease with limited pathogenesis on the tuberculoid (TT) 
pole and severe pathogenesis on the lepromatous (LL) pole; borderline tuberculoid (BT), 
borderline (BB), and borderline lepromatous (BL) leprosy fall between the polar ends. [10] 
BT/TT leprosy patients typically exhibit few lesions (five or less), high cell-mediated immunity 
(CMI), and few if any detectable bacteria (paucibacillary), whereas BL/LL leprosy patients 
exhibit multiple lesions (greater than five), specific T cell anergy, and large numbers of bacteria 
(multibacillary). [2]
 
This spectrum of disease is determined by the immunological status of the 
host, [19] wherein the effectiveness of the adaptive T-cell response is dependent on instruction 




The incubation time of infection is difficult to assess due to the slow and variable onset of 
disease and the lack of adequate immunological tools.[11] Likewise, details of the early CMI 
events are unknown.  Patients with borderline forms of leprosy, who are considered 
immunologically unstable, downgrade toward the lepromatous pole when immunocompromised. 
[19] Also, T cell anergy/hyporesponsiveness has been shown to result from immunological 
deregulation during leprosy progression. [21] These changes in the immune response along the 
continuum of disease suggest that a CMI test may be adequate to detect subclinical leprosy. 
Our approach has been focused on the CMI delayed hypersensitivity (DTH) immune 
response. A DTH type IV reaction is initiated when antigen is injected into subcutaneous tissue 
and processed by antigen presenting cells. A Th1 effector cell recognizes the antigen and releases 
cytokines IL-2, IFN-γ, and TNF, which act on vascular endothelium causing erythema and 
recruitment of T-cells, phagocytes, fluid, and protein which causes a measurable induration 
response within 48-72 hours in humans. A lack of DTH response to recall antigen is evidence of 
anergy. [22]  
Early skin test studies with whole bacilli preparations such as Lepromin-H (Mitsuda) [23] 
and Lepromin A (Krotoski, Hastings) [24,25] had proven utility in classification of disease with 
the 21 day Mitsuda reaction, but the Lepromin antigen immunologically primed the immune 
response and was not specific for leprosy. Lepromin Dharmendra (Dharmendra) [26], Soluble 
Protein Antigen (SPA) or Leprosin (Convit) and Mycobacterium leprae soluble antigens 
(MLSA) (Rees) [27] measured the Fernandez 48 hour DTH reaction and have shown potency, 
but fall short of sensitivity and specificity. [28-31] Leprosy patients classified as tuberculoid 
leprosy (TT) have a characteristic DTH response to leprosy skin test antigens Lepromin A, SPA 




antigens, but not other mycobacterial antigens [32]. The DTH response of borderline patients 
typically fall within the spectrum of their disease classification, however, there are a few, albeit 
low number of outliers. [29,31]  
Two refined leprosy skin test antigens: MLSA-LAM (M. leprae soluble antigen devoid of 
lipoglycans, primarily the immunosuppressive and cross-reactive lipoarabinomannan (LAM), 
and also lipomannan (LM), and phosphatidylinositol mannoside (PIM) and other lipids [33-35], 
and MLCwA (M. leprae cell wall antigen consisting of the powerful immunogens of the cell 
wall) [36,37] were identified [38]. Both antigens strongly induce proliferation of lymphocytes 
and stimulate secretion of IFN-γ from immune cells [39,40]. These early research studies led to 
the development and manufacturing of these antigens suitable for first-in-human clinical trials. 
[38] 
METHODS 
Propagation of M. leprae in Armadillos 
M. leprae cannot grow axenically, but can be propagated in the nine-banded armadillo, 
Dasypus novemcinctus, [41] which are numerous and highly inbred in Florida. At the Florida 
Institute of Technology (FIT), Melbourne, Florida, Eleanor. E. Storrs and subsequently Arvind 
Dhople, et al. under National Institutes of Allergy and Infectious Diseases (NIAID) captured 
armadillos from state or nationally managed land areas in Central Florida. The following 
information was supplied by FIT. Upon arrival at the FIT facility, armadillos were placed in 
quarantine and dipped in 50% malathion initially and every 6 months to kill external parasites. 
Equizole A liquid was administered initially and every 6 months to treat for internal parasites. 
The following tests were performed before releasing armadillos from quarantine: 1) acid fast 




blood sample for sterility in Trypticase Soy Broth and thioglycollate broth, 3) hematology, 4) 
serodiagnosis for IgM antibodies to phenolic glycolipid-I, and 5) Lepromin test to determine 
susceptibility to M. leprae. [41,42] Armadillo quarantine ranged from 3 to 6 months.  
The source of M. leprae was an untreated individual from Guyana with large numbers of 
highly bacilliferous subcutaneous nodules and lepromas. Genetic evidence has since indicated 
that M. leprae isolates were antigenically homogeneous. [43,44] Infected armadillos were 
sacrificed and the livers and spleens were homogenized and fractionated to separate M. leprae 
bacilli to serve as the Master Seed Stock in 2 ml volumes (3 x 10
8  
bacilli/ml) frozen at -70 °C. 
Master Seed Stock (1 ml) was inoculated into each armadillo. Infected armadillos with 
disseminated leprosy were sacrificed and the tissues (liver and spleen) aseptically removed. 
Samples from each tissue were tested for bacterial quantitation and sterility (Lowenstein-Jensen 
agar, Middlebrook 7H11 agar, nutrient broth, Trypticase Soy Broth, and thioglycollate broth at 
32 °C and 37 °C for eight weeks). The infected armadillo tissues were shipped to the Pilot Plant 
Skin Test Antigen Facility at Colorado State University (CSU). The FIT armadillo facility was 
in-compliance with United States Department of Agriculture-American Public Health 
Association, United States Public Health Service-Office for Protection from Research Risks, and 
Institutional Animal Care and Use Committee standards. 
Tissue fractionation  
A total of 242 g of M. leprae infected tissue (spleen, 19 g; liver, 223 g) from three infected 
armadillos [animal nos. A563 (19 g spleen, one preparation), A572 (109 g liver, divided into 
three preparations), and A581 (114 g liver, divided into three preparations)] were fractionated 
using a modified 3/77 Draper protocol, [45] (Figure 3) except for omission of the step involving 




digestion of homogenate was removed since no difference was seen between treated and 
untreated tissue preparations in terms of purity, protein content, and immunological potency of 
the recovered M. leprae.  
 
 
Figure 3: Tissue Fractionation Flow Chart 
M. leprae was purified from the tissues of experimentally infected armadillos. A total of seven 
batches were prepared to generate an adequate quantity of bacteria (128.4 mg) for bacterial 
fractionation.  
 
In brief, tissue sections ranging from 19 g to 36.5 g were homogenized with 10 mM disodium 
ethylenediaminetetraacetic acid (EDTA, Sigma, St. Louis, Mo.), pH 8.0 at 3 ml/g of tissue; 
homogenates were tested for sterility on brain heart infusion agar, blood agar, and Lowenstein-
Jensen agar (BD, Franklin Lakes, NJ). Tissue fragments were pelleted and washed twice with 10 
mM EDTA by centrifugation (Sorvall RC5, Thermo Fisher Scientific, Inc., Rockford, IL) at 
15,000 x g for 10 min at 4 °C in 50 ml Teflon Oakridge tubes, followed by extraction with 0.1M 




room temperature for 2 h to remove pigment and to separate M. leprae from tissue. The 
suspension was pelleted and washed twice with 0.1mM sodium phosphate/0.1% Tween 80 
(Mallinckrodt/Fisher) designated buffered water followed by digestion with 20 mg collagenase 
(Sigma, St. Louis, Mo.) and 0.23 mM calcium chloride (Sigma) in 200 ml buffered water while 
stirring overnight at 37 °C.  
Sonicate M. leprae
27 kg spin
Cell Wall Cytosol & Membrane
100 kg spin SDS Extraction
Extract Lipoglycans
Remove TX-114






Figure 4. Bacterial Fractionation Flow Chart 
Bacteria were sonicated and fractionated into subcellular components: cell wall, cytosol, and 
membrane.  The membrane antigen was a by-product saved for next generation skin test antigen 
studies. Cell wall associated proteins were extracted with SDS and both the cytosol and cell wall 
fractions were then extracted with TX-114 to remove immunosuppressive lipoglycans. Residual 
detergent was removed by affinity chromatography. Antigens were diluted to prescribed 
concentrations, vialed, labeled, and autoclaved.   
 
The digest was again pelleted and washed prior to two-phase extraction with 6% 
polyethylene glycol 6,000 and 8% Dextran T-500 (Sigma) in 0.1M sodium phosphate/150 mM 
sodium chloride at 10 ml/g of tissue in a separatory funnel. The upper phase containing bacteria 
was removed and an equal volume of 0.2% Tween 80 added prior to centrifugation at 27,000 x g 




and the concentration of bacilli estimated with a 1:100 and 1:200 dilution by optical density at 
A540 using an empirically determined conversion factor of 0.362 based on dry weight, i.e., A540 of 
1.0 = 0.362 mg M. leprae/ml multiplied by the dilution factor. Samples of the bacilli were tested 
for sterility by culturing on brain heart infusion agar, blood agar, and Lowenstein-Jensen agar. 
Purity was subjectively determined by acid fast staining using methlyene blue as a counterstain 
for residual tissue, with acceptance criteria of > 90%. [46,47] 
Bacterial fractionation 
M. leprae (128.43 mg) from seven such preparations were pooled and washed twice with 25 
ml phosphate buffered saline (PBS) by centrifugation at 27,000 x g for 15 min at 4 °C (Figure 
4). Bacteria were suspended in 5 ml PBS and disrupted by sonication on cold packs with an 
ultrasonic processor (Sanyo Soniprep 150, MSE Ltd., Lower Sydenham, London) at 1.5 MHz, 
50% duty, and 1 second pulse intervals over six 5 min cycles with 5 min cooling between each 
cycle. Pre and post-sonicated bacteria were stained using the TB Acid Fast Stain Kit (Thermo 
Fisher Scientific Inc.) for counting to verify greater than 80% breakage.  
Disrupted bacteria were centrifuged at 27,000 x g for 30 min. Supernatant consisting of 
cytosol and membrane was transferred to a fresh tube and centrifugation repeated. The pellet 
consisting of M. leprae cell wall was washed three times with 10 ml PBS. The cytosol/membrane 
containing supernatant was transferred to an Ultra Clear 5 ml (13 x 51 mm) tube and 
ultracentrifuged (Optima TLX 120, Beckman Coulter Inc., Brea, CA) at 100,000 x g for 2 h at 4 
°C to pellet the membrane. To remove lipoglycans [48] cold 20% condensed Triton X-114 
(Baxter, Deerfield, IL) was added to the supernatant (cytosol) to a final concentration of 4%, 
followed by rocking at 4 °C overnight. The tube was placed in a beaker of water at 37 °C for 10 




to separate detergent and aqueous layers. The top layer was transferred onto tandem 1 ml 
Extracti-gel D (Fisher) columns to remove residual detergent. Extraction and removal of residual 
detergent was then repeated.  
Cell wall pellet was resuspended with 2 ml of 2% sodium dodecyl sulfate (SDS, Fisher)/PBS 
and stirred while heating at 56 °C for 1 h followed by centrifugation for 15 min at 27,000 x g at 
22 °C to remove the SDS solubilized M. leprae cell wall antigens; the residual M. leprae cell 
walls consisting of the mycolylarabinogalactan has been the subject of much research. [49,50] 
The supernatant was transferred to a fresh tube and the extraction was repeated.  MLCwA 
preparation was passed over two 1 ml Extracti-gel D columns to remove residual SDS and 
finally subjected to two rounds of TX-114 extraction followed by removal of residual detergent 
as described above. 
The protein concentration of each of the antigen preparations was assessed by the 
Bicinchoninic Acid assay (Fisher). The process yielded 4.6 mg of MLSA-LAM and 5.0 mg 
MLCwA.  Antigens were diluted with phosphate buffered saline containing 0.0005% Tween 80 
to a final dosage of 10.0, 5.0, 2.5, 1.0, and 0.1 g protein per 0.1 ml followed by 0.2 µm 
filtration to remove residual particulates. A total of 1 ml of each of the antigen doses was 
aliquoted into prewashed and sterilized 2 ml borosilicate vials with 13 mm silicon rubber 
stoppers and aluminum caps (Wheaton, Millville, NJ). Vials were labeled in accordance with 
FDA labeling requirements, including the statement, “Caution: New Drug-Limited by Federal 
Law to Investigational Use”[51], autoclaved for 20 min at 121 °C; cooled at room temperature, 
and placed at -70 °C for storage as MLSA-LAM and MLCwA batch no. 23 and lot no. 051297. 




trial were sent to Fisher Bioservices Repository (Rockville, MD) for relabeling with randomly 
assigned codes and shipment to the phase II clinical site (Figure 5). 
 
Figure 5: Packaged and Labeled Leprosy Skin Test Antigens 
Product interventions, MLSA-LAM and MLCwA, each at 1.0 µg and 0.1 µg, and control 
antigens saline and Tuberculin 5 TU were coded by Fisher Bioservices Repository prior to 
shipment to the phase II clinical site for blinding blinded applications. 
 
Residual Collagenase Assay 
A collagenase enzymatic assay adapted from Sigma was used to test for residual collagenase 
in skin test antigen preparations. [52,53] A single unit of collagenase liberates 1 µmole of 4-
phenylazobenzyloxycarbonyl (Pz)-Pro-Leu from the substrate Pz-Pro-Leu-Gly-Pro-dArg in 15 
minutes at pH 7.1 at 37 °C. [54] Collagenase was not detectable in the final products within the 
assay sensitivity limit of 2.0 µg/ml. 
Residual SDS Assay 
Residual SDS was measured by the Anionic Detergent Assay using methylene blue and 
chloroform. [55,56] Both skin test antigens contained less than 5 ng/ml SDS. 
Residual Triton X-114 Assay 
Residual Triton X-114 was measured by the Nonionic Detergent Assay using 
dichloromethane and cobaltothiocyanate reagent. [57] Triton X-114 was not detectable in either 




Evaluation of Protein and Soluble Carbohydrate Identity 
Following filtration and prior to dose formulation, a sample was removed from each antigen 
to evaluate the protein profile by separation of proteins on reduced 15% polyacrylamide gel 
electrophoresis gels [58] and staining with silver nitrate to detect proteins [59] or sliver nitrate 
with periodate to detect glycans [60]. Antigens were loaded onto gels at 1.0, 0.5, 0.25, 0.1, and 
0.01 µg/lane. M. leprae whole sonicate (2 µg) was used as a reference standard.  Antigens were 
transferred to nitrocellulose in Tris, glycine, methanol transfer buffer for 1 h at 50 V. [61] 
Nitrocellulose panels were blocked with 1% Bovine Serum Albumin (Sigma) in Tris buffered 
Saline (TBS)/0.05% Tween 80 as diluent for 1 h at room temperature and then incubated in one 
of the following primary antibodies for 1 h at room temperature: mouse monoclonal antibody 
(mab) anti-LAM (CS-35), mab anti-GroES (CS-01), mab anti-superoxide dismutase (SOD), (CS-
18), mab anti-major membrane protein-I (MMP-I), (CS-38), mab anti-GroEL (CS-43), and rabbit 
polyclonal antibody against non-infected armadillo liver. All antibodies were prepared in-house. 
After washing three times in TBS/0.05% Tween 80, a dilution of goat anti-mouse IgG or goat 
anti-rabbit IgG conjugated to alkaline phosphatase were added to each panel following 
incubation for 1 h at room temperature. Panels were washed 3 times with TBS and once with 
water prior to developing in NBT-BCIP substrate (Sigma) for approximately 3 min before 
stopping the reaction with water.  
General Sterility Test 
The General Sterility Test procedure specified in Title 21 of the Code of Federal Regulations 
(CFR) Part 610.12 was performed. [62] A total of 10 vials of each dosage to be tested in humans 
(2.5, 1.0, and 0.1 µg/ml) was tested with fluid thioglycollate medium at 30 – 35 °C and soybean 




growth within 2-4 days and all vials tested in both medium conditions were negative for growth 
at each observation point. 
General Safety Test 
The General Safety Test procedure specified in 21 CFR 610.11 was performed in mice and 
guinea pigs with the 5.0 µg/0.1 ml dosage of each antigen preparation. [63] No adverse reactions 
were observed and all animals increased in weight by the end of the study. All animal studies 
were conducted at CSU, adhering to Institutional Animal Care and Use Committee guidelines for 
animal husbandry. 
Assay for Endotoxin Content 
The Limulus Amebocyte Lysate third generation pyrogen test from BioWhittaker, License 
No. 709 was used for this test. [64] The standard concentration range was 0.1 – 1.0 EU/ml. All 
vials of antigen preparations had endotoxin concentrations less than the limit of detection. 
DTH Guinea Pig Potency Assay 
Guinea pigs of the outbred Hartley strain were sensitized by subcutaneous injection in the 
base of the neck with M. leprae inactivated at 80 °C and suspended in Freund’s Incomplete 
Adjuvant. After 4-8 weeks, 0.1 ml skin test antigens were administered intradermally on the 
freshly shaven back of each animal. Induration was measured at 24 and 48 hours post-injection. 
A measurement over 5 mm was considered positive. [65] 
Stability Testing 
Skin test antigen batch no. 9, prepared in the general research laboratory was used for 
preliminary stability testing. Each antigen was diluted with PBS or borate buffer to a dosage of 
10.0 µg/0.1 ml and either filtered or filtered and terminally sterilized. Immediately after 




stability in the DTH Guinea Pig Potency Assay on days 45, 90, 120, and 360 at 1.0 µg and 0.1 
µg doses. Abbreviated stability testing was performed on the cGMP batch no. 23, lot no. 051297. 
Antigens vialed at doses of 1.0 µg and 0.1 µg were tested at 4 °C and 20 °C against equivalent 
antigens stored at -70 °C for 90 d, 120 d, 360 d, 2 y and 4 y.  
 Adventitious Agent (Virus) Testing 
Liver homogenates from each tissue fractionation and MLSA-LAM and MLCwA final 
product at 10.0 and 5.0 µg/0.1 ml were tested for human viral pathogens using cell based assays 
and polymerase chain reaction (PCR). Viral identification by cytopathic effect for Adenovirus; 
Parainfluenza 1, 2, and 3 Viruses; Influenza Virus; Poliovirus; Cytomegalovirus; Herpes 
Simplex 1, and 2 Viruses; and Respiratory Syncytial Virus was conducted at the University of 
Colorado Diagnostic Virology Laboratory (Boulder, Colorado). Positive and negative controls 
were included during testing. PCR for Hepatitis B Virus and Human Immunodeficiency Virus 
was performed by Specialty Laboratories, Inc.[66]. 
RESULTS 
Choice and Characterization of Antigen Preparations 
Similar antigen preparations, forerunners of the present ones were tested in guinea pig DTH 
potency studies to evaluate their skin test potential and an in vitro whole blood T cell assay to 
evaluate their ability to stimulate a response from healthy subjects and leprosy patients. [39] The 
M. leprae membrane antigen (MLMA) was immunoreactive, but contained too little protein 
content after removal of lipoglycans to proceed further.  Although use of subcellular fractions 
was the only viable choice at the onset of this project, it was not without the realization that use 




Tuberculin PPD, a decision was made to move forward with development of MLSA-LAM and 
MLCwA to establish a prototype for next generation skin test antigen candidates. 
The active ingredients of these two intradermal skin test antigens are protein antigens of M. 
leprae. MLSA-LAM contains the soluble protein antigens of M. leprae; over 100 individual 
proteins were initially recognized on two-dimensional gels, and about 30 of these had been 
sequenced and the immunological responses studied in part. [67,68] Foremost among these 
antigens are the 70 kDa (DnaK), 65 kDa (GroEL), 45 kDa, 38 kDa, 35 kDa (MMP-I), 23 kDa 
(SOD), 18 kDa small heat shock protein (SmHSP), 18 kDa bacterioferritin (Bfr), 10 kDa 
(GroES), and the ribosomal proteins S7/S12. [69-74] More recently, the full spectrum of proteins 
in soluble and insoluble subcellular fractions of M. leprae have been demonstrated and many 
more identified through the modern-day “proteomics” approach. [75-77] MLCwA contains many 
of the same proteins as MLSA-LAM, particularly the 70 kDa and 65 kDa kDa and degradation 
products of these, the export/secretory proteins (notably the 30/31 kDa, multigene antigen 85 
complex), and also some larger, uncharacterized proteins. [76] Details of the full spectrum of 
MLCwA constituent proteins have since been published. [77] 
Leprosy Skin Test Antigen Pilot Plant 
Options for manufacturing the two new leprosy skin test antigens under current good 
manufacturing practices (cGMP), suitable for human application were limited. Costs for using a 
contract manufacturing organization (CMO) was prohibitive; it was difficult to find any with an 
open schedule, and few had biosafety level 2 (BSL-2)/cGMP clean rooms required for safe 
manufacturing of these antigens. In addition, service providers acknowledged that they were 
fearful of working with M. leprae. Consequently, a retired BSL-3 research laboratory was 




these leprosy skin test antigens. To this end, the manufacturing and testing process for MLSA-
LAM and MLCwA was developed to meet 21 CFR part 210, 211 for current Good 
Manufacturing Practices. [78,79] 
The Pilot Facility consisted of a suite of five rooms, 1) Gowning and Material Transfer 
Room, 2) Manufacturing Suite A, 3) Manufacturing Suite B, 4) Quarantine/Released Goods 
Room, and 5) Quality Control Laboratory. Both the manufacturing and quality control rooms 
were under positive pressure cascading from the innermost room to the entry foyer. Air was 
supplied by a dedicated heating ventilation air conditioning system with single pass air flow 
monitored with gauges in the entry room and with an anemometer prior to entry of the 
manufacturing suite. High efficiency particulate air filters were positioned on both the supply 
and exhaust air streams to purify air entering and exiting the clean rooms. The manufacturing 
rooms were classified [80] as international standard organization (ISO) 7 clean rooms. The 
innermost manufacturing room was used for downstream processing (antigen purification, 
formulation, and vialing), while the outermost manufacturing room was used for upstream 
processing (tissue fractionation and bacteria sonication). The gowning and material handling 
room was classified as an ISO8 clean room for personnel aseptic tyvek gowning, wipe down and 
transfer of materials and equipment into the manufacturing area, and entering and exiting of 
personnel. The innermost quality control room, an ISO8 clean room was used for testing raw 
materials, intermediate product, and final product, while the quarantine/released goods room was 





Figure 6. Leprosy Skin Test Antigen Pilot Facility 
Five room cGMP suite consisting of 1) Gowning and Material Transfer (GMT) Room for entry 
and exit of personnel, materials, equipment, product, and product into manufacturing suites - 
ISO8 clean room; 2) Manufacturing Suite A (MF A) for tissue fractionation – ISO7 clean room; 
3) Manufacturing Suite B (MF B) for bacterial fractionation, purification, formulation, and 
vialing – ISO7 clean room; 4) Quarantine/Release Goods Room (Q/RG) for quarantine and 
release of raw materials, buffers, and media – clean/non-classified clean room; and, 5) Quality 
Control Laboratory (QC) for laboratory testing of raw materials, intermediate product, and final 
product – ISO8 clean room. 
 
Renovation of the Pilot Plant Facility to meet cGMP regulations involved firstly, replacement 
of the heating, ventilation, air conditioning system with a new unit for dependability; due to cost 
restraints and limited use, a redundant system was not installed. High efficiency particulate air 
filter casings were resealed and new filters installed. The air flow direction was switched to 
positive pressure and balanced to supply adequate air exchange and a pressure differential 
cascading from the most inner room to the entry room on each side of the suite to reduce the 
potential for product contamination during processing. Ceilings and wall surfaces were already 
non-porous and therefore only required cleaning and a fresh coat of paint.  The floor was cleaned 
and resealed with an epoxy floor coating. A biosafety cabinet (Forma Scientific, class II/AB3) 




rooms and the inner most laboratory for handling open product or quality control testing, 
respectively. All processing equipment was dedicated during the manufacturing campaign. 
Quality Management System  
A quality system [81] was created for processing and testing leprosy skin test antigens in the 
renovated pilot plant. [82] The system covered six parts: facility and equipment, materials, 
production, product labeling, laboratory control, and quality. [83] Two batch records were 
written, one for tissue fractionation and one for bacteria fractionation. A total of 255 supporting 
standard operating procedures (SOPs) were written to cover the quality system and manufacture 
of antigens. Facility and equipment SOPs were written for operation, maintenance, and 
calibration of dedicated equipment. SOPs for directing and tracking the chain of custody for raw 
materials transferred through purchasing, receiving, quarantine, release, and storage were 
created. Process directives supporting environmental monitoring, gowning, transferring material, 
manufacturing, in-process testing, and release testing were written into SOP format with data 
forms to collect relevant information. Explicit details for product labeling were captured in the 
batch record. All levels of training, including equipment use, biosafety, good laboratory practice, 
cGMP, and good clinical practice were directed through SOPs. Logs were created to track part 
numbers, documents, raw materials, sample submission, equipment usage and room usage. 
Documents were subjected to the mandated review and approval process prior to 
implementation. [84] 
Finally, commissioning of the cGMP Pilot Plant for manufacturing skin test antigens was 
performed. Rooms were decontaminated with para-formaldehyde.The Pilot Plant was cleaned 
and the environment was monitored on three consecutive days and three consecutive weeks 




airborne organisms was performed with the Rotary Centrifugal Air Sampler (Biotest Diagnostics, 
Brooklyn Park, MN) and settling plates, both using Trypticase Soy Agar strips/plates.  
Monitoring viable surface organisms was performed with Rodac plates containing Trypticase 
Soy Agar and neutralizer for cleaning agents. Isolates were identified to the genius and species 
level using API Test Kits (Biomerieux, Etolile, France; distributed by VWR).  Total particle 
counts in each clean room were measured using a Particle Counter (Metone Instruments, Grants 
Pass, Oregon). Acceptance criteria were met with each test enabling release of the Pilot Plant for 
cGMP manufacturing. Data was filed reported and then filed at CSU with original records. 
Pre-IND  
Prior to manufacturing skin test antigens, a draft Investigational New Drug (IND) application 
[85] and specific questions related to IND enabling studies, manufacturing, and phase I clinical 
trial design was sent to our NIH, NIAID, Division of Microbiology and Infectious Diseases 
(DMID) program officer at the time (the late Dr. Darryl Gwinn) and Regulatory Affairs 
Specialist (Ms. Carol Manning) for a preliminary review prior to submission to the FDA Center 
for Biologics and Evaluation Research (CBER) for review and comment.  A comprehensive list 
of queries were received and addressed prior to submission of the IND application. The first 
topic of focus was the armadillo infected tissue and included questions on the following subject 
matters: 1) the origin, isolation, and characterization of the M. leprae strain; 2) creation, storage, 
maintenance, and viability testing of the master seed stock; 3) armadillo quarantine, test for 
human pathogens, and general health status; 4) potential human infectivity of indigenous 
armadillo microorganisms; 5)  armadillo inoculation procedures and biosafety procedures for 
staff; and 6) test for viral adventitious agents. The second topic of focus was the manufacturing 




known human toxicities and quantitative tests for reagents used in the manufacturing process; 3) 
qualitative compositional analyses for each skin test antigen; 4) presence of cross-reactive 
antigens; 5) level of host contamination, endotoxin, and sterility; 6) in-vitro and in-vivo potency 
assays conforming to intended clinical use in humans; 7) stability testing prior to clinical studies; 
and 8) preclinical testing of clinical lots for safety, activity, and skin test conversion in a dose 
ranging study. The last topic of focus was the clinical phase I study design, including the 
following issues: 1) clinical study details; 2) potential impact of anergy regarding leprosy and 
HIV patients; 3) consent form and Institutional Review Board for each study site; 4) Case Report 
Forms for data collection; 5) references supporting related antigens and clinical studies; and 6) 
distinguishing subjects that are infected or harboring live bacilli from those who are infected and 
cured.  A response to the FDA Response Letter was satisfactory and a Pre-IND Meeting 
followed. The following is an outcome of that meeting. 
Manufacturing of Antigens 
The manufacture of antigens was a two step process beginning with receipt, tracking, and 
release of raw materials. The primary raw material was spleen and liver tissues laden with M. 
leprae propagated in armadillos at FIT. Upon aseptic harvest, tissues were tested for the presence 
of contaminating bacteria using microbiological medium and then sent to the Pilot Plant, where 
they were frozen at -70 °C in a qualified freezer until used. SOPs covering each step of the 
propagation process were provided by FIT. All other reagents were United States Pharmacopeia 
grade or equivalent, if available. Otherwise the highest purity was specified. Each reagent was 
released for use based on a certificate of analysis provided by the vendor, per an approved in-




Tissue fractionation under the respective Master Production and Control Record (MPCR) 
was performed to release and purify M. leprae from the armadillo tissue as the intermediate 
product. A total of 7 tissue runs were performed to accumulate 100 – 150 mg bacteria. Tissue 
weights ranged from 19 – 36.5 g for manageability and to maximize yields. A total of 128.4 mg 
M. leprae was purified from 242 g tissue, resulting in a yield of 0.05% (Table 1). Sterility testing 
was performed on each bacterial lot and material was stored at -70 °C until use. Bacterial 
fractionation under the respective MPCR was performed using the pooled intermediate product. 
A total of 4.6 mg of MLSA-LAM and 5.0 mg of MLCwA was obtained representing a yield of 
3.57% and 3.88% from intact bacteria, respectively. Quality control was performed on the final 
product. 
Quality Control of Antigens 
Assays to assess MLSA-LAM and MLCwA critical quality attributes of identity, purity, 
sterility, potency, and safety were performed. [86] Ten vials of each antigen dose (2.5, 1.0, and 
0.1 µg/0.1 ml) planned for clinical studies were tested on all assays with two exceptions. Identity 
testing by gel electrophoresis and immunoblotting was performed on samples taken prior to 










1 Tissue Spleen A563 (19 g) --- --- 
 Tissue Liver A572 (109 g)
a
 --- --- 
 Tissue Liver A581 (114 g)
a
 242.0 g --- 
2 M. leprae --- --- 128.4 mg 0.05% 
3 MLSA-LAM --- --- 4.6 mg 3.57% 
 MLCwA --- --- 5.0 mg 3.88% 
a 





autoclaving, which degrades proteins resulting in smearing of bands on gels and immunoblots. A 
representative silver stained gel of both antigen preparations is shown in Figure 7.  
 
Figure 7. Protein Profile of MLSA-LAM and MLCwA  
Leprosy skin test antigens MLSA-LAM and MLCwA (pre-autoclaved; 2 µg load) were separated 
on a 15% reduced polyacrylamide gel and visualized by staining with silver nitrate. Proteins 
which reacted by immunoblot are depicted. The SOD protein is a 23 kDa protein based on amino 
acid sequence, but resolves at 28 kDa under reduced gel electrophoresis conditions.  
 
Immunoblotting results showed that neither antigen preparation had detectable armadillo 
tissue or LAM present, both contained MMP-I, and only MLSA-LAM contained GroES and 
SOD, while only MLCwA contained GroEL proteins. Purity testing for adventitious agents was 
performed on tissue homogenates and concentrated final product (10.0 µg and 5.0 µg/0.1 ml); 
both were free of detectable human viral pathogens.  
Purity was also assessed by measuring endotoxin concentration and running specific assays 
for residual excipient, unless justified otherwise. Collagenase, Triton X-114, and SDS were 
tested and found to be lower than the limit of detection for each assay. Extracti gel D ligand was 
not tested, because if detached, would be removed by filtration prior to vialing. Calcium chloride 




concentration in the purified bacteria suspension had decreased by 46-fold to 5 µM and was 
found to be harmless as demonstrated in animal safety studies. This was equally the case for 
polyethylene glycol, Dextran T-500, and sodium hydroxide excipients. 
Antigen preparations were found to be sterile under aerobic and anaerobic conditions and 
potent when assessed for a DTH response in guinea pigs sensitized with M. leprae or infected 
with M. tuberculosis. Stability, although not a critical quality attribute was assessed during 
product development using a research batch and prior to and during clinical testing, resulting in 4 
years of satisfactory results. The Lot Release Summary and stability results for both MLSA-
LAM and MLCwA can be found in Table 2. 
IND Application 
The IND chemistry, manufacturing, and control section was updated following antigen 
manufacturing and testing. Our DMID Study Sponsor submitted the IND Application to CBER 
for review and allowance of the clinical investigation of two new drugs, MLSA-LAM and 
MLCwA, each at 3 doses (2.5, 1.0, and 0.1 µg) initially in a phase I clinical trial with ten healthy 
subject residing in a non-endemic region for leprosy, and subsequently in a phase II clinical trial 
with healthy subjects, leprosy patients, leprosy patient contacts, and tuberculosis patients 










Table 2. Lot Release and Stability Summary: MLSA-LAM and MLCwA Batch No. 23,  
Lot No. 051297 
Quality   
Attribute 






Protein Concentration Diluted to 
concentration 
Pass Pass 




 Immunoblots Expected profile Pass Pass 
Purity 
Viruses: Culture for 
CPE,  PCR 
Not detected 
Pass Pass 
 Endotoxin Concentration < 0.5 EU/mL Pass Pass 
 Collagenase Not detected Pass Pass 
 Residual SDS < 0.001% Pass Pass 
 Residual Triton X-114 Not detected Pass Pass 
Potency DTH in Guinea Pigs  Induration at 
1µg/0.1mL 
Pass Pass 
Sterility 21 CFR 610.12 No growth Pass Pass 
Safety 21 CFR 610.11, guinea 
pigs & mice 
All survive, no 





DTH in Guinea Pigs  
Temp: 4 °C and 20 °C  
Time:  d90, d120, d360, 






Development of two new leprosy skin test antigens, MLSA-LAM and MLCwA, began in 
1992. A tool for detection of subclinical leprosy was then, as it is now, an urgent need. [87,88] 
Serological and gene approaches had not proven satisfactory for this purpose. [89] Even so, these 
and other test methods are continually being refined and evaluated today, including: antibodies 
[90,91], M. leprae specific DNA polymerase chain reaction [92-94], and cell mediated immune 




have found favor for certain applications, most are not suitable for mass epidemiological 
application. [97] 
With our focus on the cell mediated immune response for detection of asymptomatic leprosy, 
historical data from early leprosy skin test antigens [98] established precedence for these studies. 
Promising features of the Rees MLSA and Convit SPA included: neither had sensitizing 
potential like Lepromin A [99]; both were potent immunologically; and, both were found to be 
safe in human vaccine trials in Venezuela, Malawi, and India. [30,100] Shortcomings included 
inconsistent readings due to soft rather than hard DTH reaction in some individuals; variations in 
potency between batches due to quality control issues; and, lack of adequate sensitivity and 
specificity. A more refined skin test antigen was needed.  
Sensitivity of the skin test method for detecting infection has been proven with Tuberculin 
PPD skin test antigen for tuberculosis. [101] Tuberculin PPD has been used across the world 
with an exceptional safety record. Specificity, however, depends on age, genetic factors, certain 
medical conditions, climate, geography and other factors such as vaccination with bacilli 
Calmette Guerin (BCG). [102]  Depending on the location, exposure to local environmental 
mycobacteria may cross react with the antigen and obscure test results. The antigen consists of a 
mixture of soluble, low molecular weight, secreted proteins of M. tuberculosis, precipitated from 
culture broth filtrate. [103]  
Our goal was to produce a leprosy skin test antigen equal to the sensitivity and better than the 
specificity of Tuberculin PPD. Two leprosy skin test antigens were chosen as candidates for 
development based on prior knowledge, adequate yield, a robust DTH response in M. leprae 
sensitized compared to M. tuberculosis infected guinea pigs, and in vitro stimulation of TT 




MLSA-LAM was modified from Rees MLSA by removing immunosuppressive and cross-
reactive components (LAM, LM, and PIMs) and other lipids. The second antigen, MLCwA 
contained powerful cell wall derived immunogens. Since these antigens were identified, further 
characterization has shown that each are made up of complex protein mixtures. [76,77]  
Developing and manufacturing MLSA-LAM and MLCwA investigative products suitable for 
human application for leprosy was challenging without industry expertise and funding. Attempts 
to identify a qualified, willing, and reasonably priced CMO failed, leading to the decision to 
manufacture the skin test antigens within an academic setting.   
Deducing the product development process and related regulatory requirements was daunting 
in the early days.  A product development roadmap [104] or FDA Translational Critical Path 
[105] was not available.  There were FDA guidelines on some topics and a consultant was used 
to jump start the skin test initiative.  Our NIH, NIAID, DMID study sponsor provided guidance 
and regulatory assistance and served as a conduit to the Food and Drug Administration (FDA) 
for cGMP questions covering construction, equipment, raw materials, production, testing, and 
quality; IND questions covering chemistry, manufacturing, and control; and, GCP questions 
covering clinical studies and required documentation.  
Keeping the project on-schedule during edification and formulation of systems supporting 
facilities and equipment, raw materials, the manufacturing process, quality control, 
documentation, and quality assurance in-compliance with cGMP regulations [78,79] was 
challenging. With limited resources, renovating and commissioning a BSL-2/cGMP pilot plant, 
establishing batch records and supporting SOPs, performing IND enabling studies as an outcome 




and approval were time consuming and onerous.  The immensity of the project led to prolonged 
timelines. 
As challenges were overcome, the draft IND was submitted by our study sponsor to the FDA 
for comment in April, 1994; antigens were successfully manufactured in May, 1997; and the 
IND Application was submitted to the FDA in September, 1998 for allowance to move clinical 
trials forward to assess the safety and efficacy of MLSA-LAM and MLCwA as early diagnostic 
tools for leprosy.  This work also provides a generalized template supporting product translation 
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CHAPTER THREE: SAFETY ASSESSMENT OF TWO NEW LEPROSY SKIN TEST 
ANTIGENS IN HEALTHY SUBJECTS WITHOUT KNOWN EXPOSURE TO LEPROSY: 
RANDOMIZED DOUBLE BLIND CLINICAL STUDY 
 
SYNOPSIS 
Background: A diagnostic tool for asymptomatic leprosy is needed to treat patients earlier 
during infection and to measure the extent of leprosy in endemic regions of the world. To 
address this need, two new skin test antigens, MLSA-LAM and MLCwA, were developed and 
manufactured for clinical testing; initially to assess safety in healthy subjects without known 
exposure to leprosy in endemic and non-endemic regions.  
Methods: A phase I clinical trial was first conducted in a non-endemic region for leprosy 
followed by a randomized double blind phase II, stage A and B clinical trial in an endemic 
region for leprosy. The phase I study consisted of two groups, whereby 10 healthy non-exposed 
subjects received three titrated doses (2.5 µg, 1.0 µg and 0.1 µg) of MLSA-LAM (n=5) or 
MLCwA (n=5) and control antigens [Rees MLSA Antigen (1.0 µg) and saline]. The phase II, 
stage A (n=10) and stage B (n=90) studies were an expansion of the phase I study, except only 
the 1.0 µg (high dose) and 0.1 µg (low dose) of each antigen, and 5TU dose of Tuberculin PPD 
were tested. The primary outcome measure was induration induced by a delayed type 
hypersensitivity reaction. 
Findings: In the phase I trial, reactogenicity was primarily against the 2.5 µg dose of both 
antigens and Rees control antigen, which consequently were not tested further; seven adverse 
events were deemed unrelated to the study products. In the phase II study, 20% of subjects 




reacted to the low dose of MLSA-LAM with minimal pain or itching; one adverse event was 
possibly related to MLCwA, while fourteen adverse events and two serious adverse events were 
deemed unrelated to the study products. 
Interpretation: MLSA-LAM and MLCwA at both the 1.0 µg and 0.1 µg doses were found 
to be safe for use in humans without known exposure to leprosy. Assessment of safety and 
efficacy in target populations was subsequently undertaken. 
 
Funding: Leprosy Research Support, Contract NO1 AI-25469; National Institute of Allergy and 
Infectious Diseases (NIAID), National Institutes of Health (NIH) 
 
REGISTRATION 
Phase I Clinical Trial:  
 Registry: none 
Phase II Clinical Trial, Stages A/B:  
Registry name: ClinicalTrials.gov  
Registry number: NCT00128193  
URL: http://clinicaltrials.gov/ct2/show/NCT00128193?term=leprosy&rank=3 
AUTHOR SUMMARY 
Given the pressing need for a diagnostic tool to detect asymptomatic leprosy, two new skin 
test antigens, MLSA-LAM and MLCwA, were assessed for safety in healthy subjects (n=10) 
without known exposure to leprosy in a phase I trial performed at the leprosy non-endemic site 
of manufacture (Fort Collins, Colorado, USA), followed by a phase II, two-part trial, stages A 




antigens and antigen doses, 1.0 µg and 0.1 µg, were considered to be safe for use in humans 
without known exposure to leprosy, allowing further testing for safety and efficacy in patient 
populations.  
INTRODUCTION 
Diagnosis of subclinical leprosy remains difficult, despite being recognized as one of the 
missing elements in eliminating this debilitating disease. [1,2]
,
Early diagnosis would enable 
earlier treatment and prevent disabilities, reduce social stigma, and intercept transmission of 
disease; [3] breaking the incessant pattern of incidence exceeding prevalence. [4,5] Until there is 
a shift in the incidence gridlock, nearly a quarter of a million new patients will continue to be 
diagnosed annually with leprosy. 
With a focus on the attributes of a functional early diagnostic test for leprosy in countries 
with limited resources, we surmised that such a test must be sensitive to an early response to 
infection, inexpensive, and simple to implement in large epidemiological studies. Historically, 
mycobacterial skin test antigens for both leprosy (Lepromin A, Rees Antigen, Convit Antigen) 
[6] and tuberculosis (Tuberculin PPD) [7,8] were safe when used in humans. The immensity of 
data on their use over 37 years for Lepromin A[9,10]; 6 years for the Rees and Convit antigens 
[11-14]; and 73 years for a purer and more standardized preparation of PPD in the context of 
Tuberculin [15] provides a solid foundation of safety for refined leprosy skin test antigens. Two 
partially fractionated antigens, Mycobacterium leprae soluble antigens (MLSA) devoid of 
lipoglycans, particularly lipoarabinomannan (LAM) called MLSA-LAM and M. leprae cell wall 
associated antigens called MLCwA were developed and then manufactured at Colorado State 




practices (GMP) for first-in-human clinical studies. [17,18] Commercial development of 
products supporting early diagnosis of leprosy, a neglected tropical disease, was not feasible. 
Clinical safety assessment of investigational products, MLSA-LAM and MLCwA, was 
required by law under the United States Federal Food, Drug, and Cosmetic Act codified in Title 
21 Code of Federal Regulations (CFR) part 312.21. [19] Data and historical information were 
supplied to the Food and Drug Administration (FDA) in an Investigational New Drug (IND) 
Application [20] supporting the premise that the product will not expose humans to unreasonable 
risks when used in limited early stage clinical studies. IND permission allowed the transfer of 
experimental products to the clinical investigator for initial testing of small numbers of healthy 
subjects without known exposure to leprosy, first in a nonendemic region for leprosy under a 
phase I clinical trial, and subsequently in an endemic region for leprosy under a phase II, stage A 
and then stage B clinical trial. The primary goal was to determine if the products were 
reasonably safe for humans and if they exhibited any pharmacological activity that justifies 
further development. 
METHODS  
Interventions and Control Products 
Two medical interventions were tested, MLSA-LAM and MLCwA. A detailed description of 
each antigen can be found in chapter 2.[16] Three control products were used in these studies: 1) 
0.9% sterile saline, approved for human use (Abbott Laboratories Inc., Abbott Park, IL) for use 
in the phase I and phase II, stage A trials, 2) Rees MLSA antigen [21], 20 x 1.0 ml vials at 1.0 
µg/0.1 ml dose were received as a gift from Philip Draper and the late Joseph Colston (National 
Institute Medical Research, Mill Hill, UK) for use in the phase I trial, and, 3) Tubersol®, 




and B trials. Phosphate buffered saline containing 0.0005% Tween 80 was the diluent used to 
manufacture both new leprosy skin test antigens. At the time of manufacturing, diluent was not 
vialed; therefore, 0.9% saline for use in humans was used as a control. 
Human Subjects Recruitment  
Phase I study participants were recruited from the Mycobacterial Research Laboratories, 
Department of Microbiology, CSU, by posting notices in the department building. Phase II study 
participants were recruited from the Lalitpur Nursing Campus, Sanepa, Kathmandu, following 
delivery of a recruitment talk by a senior member of the research team from Anandaban 
Hospital, Kathmandu, Nepal, using the local Nepali language or English with immediate 
translation to Nepali. Attendees were contacted directly and invited to participate in the study 
one week prior to antigen administration.  
Sample Size 
In the phase I clinical trial, the total sample size was 10 subjects divided between two antigen 
groups; 5 subjects received titrated doses of MLSA-LAM or MLCwA, plus control antigens. The 
phase II, stage A/B clinical trial was identical to the phase I clinical trial, except that the sample 
size was 100 subjects divided between two antigen groups; 50 subjects received titrated doses of 
MLSA-LAM and MLCwA, plus control antigens. Stage A was a preliminary safety screen with 
10 subjects, while stage B completed the study with 90 subjects. In the Kathmandu region of 
Nepal, experience in clinical trials suggested that no more than 10% of subjects were expected to 
be lost to follow-up. Sample size consideration analysis indicated that the study would be able to 




Antigen Administration  
In the phase I clinical trial, each participant received five 100 µl intradermal injections of 
titrated doses (2.5 µg, 1.0 µg, and 0.1 µg) of one of the two skin test antigens, one injection of 
0.9% sodium chloride, and one injection of Rees MLSA control leprosy skin test antigen at a 1.0 
µg dose, between both forearms. Injections were administered on the flexor surface of both 
forearms, about 2 inches, 3 inches, and 6 inches below the bend of the elbow on one forearm, 
and about 3 inches and 6 inches below the bend of the elbow on the other forearm. The skin of 
the forearm was cleansed with alcohol and allowed to dry and the test dose was administered 
with a sterile 1 ml syringe calibrated in tenths and fitted with a sterile, one-half inch, 26 or 27 
gauge needle. The point of the needed was inserted into the most superficial layers of the skin 
with the needle bevel pointing upward. A definitive raised bump or bleb was observed at the 
needle point about 10mm in diameter, which disappeared within minutes.  
In the phase II, stage A/B clinical trial, each participant received four 100 µl intradermal 
injections of titrated doses (1.0 µg and 0.1 µg) of one of the two skin test antigens, one injection 
of 0.9% sterile saline (stage A only), and one injection of Tuberculin/PPD Tubersol® 5TU, 
between both forearms. Injections and readings were performed as described for the phase I trial, 
except that the test dose was administered with a sterile 1 ml Tuberculin syringe calibrated in 
tenths and fitted with a sterile, one-quarter inch, 30 gauge needle 
Read-Out Measurements 
Each antigen site was evaluated for reactogenicity, defined as a reaction at the site of 
injection that is common and reasonably expected for the intervention being studied. 
Specifically, the maximal diameter of induration and erythema, and presence of pain, pruritis 




Tuberculin skin testing.[22,23] The method for measuring induration was adapted from 
“Guidelines for Conducting Skin Test Surveys in High Prevalence Countries,” issued by the 
International Union Against Tuberculosis and Lung Disease.[22] In brief, skin test sites were 
palpated, the limits of the induration determined with the fingers, and the largest transverse 
diameter measured with calipers or a soft, flexible, transparent ruler. 
Measurements were taken by one reader in the phase I clinical trial and two independent 
readers in the phase II clinical trial. When two readers were used, readings from both readers 
were analyzed for correlation (the most experienced administrator/reader was used as the ‘gold 
standard’). In case of systematic reading errors or terminal digit preference on the part of the 
second reader, the reader was given more supervision or further training without explaining the 
reason, in order to avoid correcting one bias by potentially introducing another. Training of 
readers occurred prior to study initiation. 
DTH responses were read at ~15 min, 48 + 3 h and 72+ 3 h in the phase I and phase II, stage 
A trials and ~15 min, 72+ 3 h, and 7 + 1 d in the phase II, stage B trial. The 15 min observation 
was primarily a safety measure to watch for immediate adverse events, such as anaphylaxis. If a 
subject was observed to have an induration greater than 10 mm at any injection site and either 
study visit, they were asked to return at 28 + 3 d for a final induration measurement. Any 
persistent reaction was followed-up until resolved or stabilized.  
The protocol was amended before starting stage B to delete the 48 h reading and to add a 7 d 
reading. This change was recommended by the clinical staff for two reasons: 1) during stage A, 
maximal induration was typically observed at 72 h, with 48  h readings being nearly equivalent, 
and 2) there was a concern about the prolonged time between the last reading at 72 h and day 28 




Institutional Review Boards  
The phase I clinical trial was locally monitored by the CSU Institutional Review Board (IRB) 
[24] under the U.S. Department of Health and Human Services/U.S. Public Health 
Service/National Institutes of Health (DHHS/PHS/NIH) assurance identification no. M-1153 and 
CSU IRB no. 01. The phase II clinical trial was locally monitored by both the CSU IRB and the 
Nepal Health Research Council (NHRC) under the Office for Human Research Protections 
(OHRP) single project assurance no. S-017469-02 issued at the beginning of the study, followed 
by a federal wide assurance no. FWA 00000647 and CSU IRB no. 00000202. A letter stating the 
equivalent assurance of protection for human subjects in international research was also obtained 
from the NHRC. IRBs provided protocol and informed consent form approval, protocol 
amendment approvals, safety monitoring report reviews, and annual approval to perform 
respective trials. 
Safety Monitoring Committee 
The Safety Monitoring Committee (SMC) [25] for the phase I study consisted of two off-site 
physicians. The phase II, stage A/B study SMC consisted of 4 physicians: three off-site, and one 
on-site who served as the independent safety monitor (ISM). The ISM reviewed all adverse 
events (AEs) and serious adverse events (SAEs) and reported the findings to the clinical 
principal investigator, who then forwarded reports to the study sponsor, Data Control Center 
(DCC); The EMMES Corporation, Rockville, MD), SMC, and pharmacovigilance contractor 
(PPD Development, Inc., Wilmington, NC). The SMC reviewed all SAE and Safety Monitoring 
Reports and made recommendations to the study sponsor and both IRBs, as to whether the study 





Regulatory documentation for the Phase I clinical trial included an FDA IND Application 
Form 1571, IND Application [20], an Investigator’s Brochure [26], an FDA Statement of 
Investigator Form 1572, Phase I Study Protocol [27], and Informed Consent Form. [28] All 
documentation was submitted to our study sponsor for review and submission to the FDA. 
Likewise, a Study Protocol for the Phase II clinical trial (stages A, B, and C) [29] prefaced with 
the Principal Investigator FDA Form 1572 with associated Informed Consent Forms were 
submitted to our study sponsor. The current phase II protocol titled, Two New Leprosy Skin Test 
Antigens: MLSA-LAM and MLCwA in a Leprosy-Endemic Region; version 9.0, dated March 2, 
2009 has been attached as a supplement.   
Data Capture, Analysis and Reporting 
Case report forms (CRFs) for the phase I trial consisted of an Eligibility Checklist, 
Demographic Information Form, Clinical Evaluation Form, Adverse Events Form, Study 
Termination Form, and Volunteer Symptom Diary. The Clinical Evaluation Form was used by 
medical staff to record antigen administration, induration and erythema measurements, side 
effects, and other observations. The Adverse Event Form was completed by the clinical principal 
investigator and covered the event, outcome, severity, seriousness, causality, and action taken for 
adverse events, including serious adverse events. The Volunteer Symptom Diary was used by 
volunteers to record the site, reaction, and severity of a response for each day of the study. 
Similarly, the phase II, stage A/B study CRFs included an Eligibility Checklist, Demographics 
and Medical History Form, Antigen Administration Form, Follow-up Examination and Reaction 
Form, Skin Test Reading Forms for each time point, Study Termination Form, Adverse Event 




study personnel qualifications, roles and responsibilities; approved standard operating procedures 
(SOPs), CRF guidelines, and, CRF templates were developed to provide additional quality 
control for the phase II clinical trial.  
The phase I clinical trial data was captured on CRF source documents from which Zerox 
copies were made for analysis by both the clinical and scientific investigators. An Adverse 
Events Report and a Phase I Clinical Trial Report was sent to the study sponsor and CSU IRB for 
review. The study sponsor submitted a final Study Report to the FDA. The phase II, stage A/B 
clinical trial data was captured on CRF source documents printed on two-ply-no-carbon required 
(NCR) paper. Data entry was verified by the study coordinator and a copy of each CRF was sent 
to the DCC. The DCC analyzed blinded data from stage A and submitted a Safety Monitoring 
Report to the study sponsor, SMC, and both IRBs. Following the completion of stage B, data 
from both stages A and B were unblinded and a final Safety Monitoring Report for stages A and 
B was submitted.  
Classification of reactogenicity by grade was outlined in the Clinical Study Reactogenicity 
Assessment Table (Table 3), present in the phase II clinical protocol. Reactions were graded as 
mild (1), moderate (2), severe (3), or life-threatening (4). Severe reactions were recorded as 
adverse events, while life-threatening reactions were recorded as severe adverse events. Adverse 
events (AEs) were coded by the Medical Dictionary for Regulatory Activities (MedDRA®) [30] 
for preferred term and system organ class (SOC). In addition, AEs were tabulated by possible 
relationship to antigen and greatest reported intensity, and listed by subject identification code, 
antigen injection date, event description, MedDRA® preferred term, onset date and time, end 


































exfoliative dermatitis, mucous 
membrane involvement or 
erythema, multiforme or suspected 






Induration < 15mm  15-30 mm >30mm N/A 








Prevents minimal activity 
Erythema < 15mm  15-30 mm >30mm N/A 
Edema < 15mm  15-30 mm >30mm N/A 
Rash at Injection Site 
Other than Erythema 
< 15mm  15-30 mm >30mm N/A 
Pruritus slight itching  













 A total of ten participants between the ages of 18 and 40 years and with a weight greater 
than 100 lbs (45 Kg) for females and 140 lbs (64 Kg) for males were enrolled in the phase I 
clinical trial. All were U.S. citizens, healthy, and free of evidence of leprosy or tuberculosis by 
clinical examination. Females were certified as not being pregnant, by urine pregnancy testing 
within 7 days of skin test administration. All were Tuberculin skin test negative when tested 3 
weeks prior to study initiation and did not have any known hypersensitivities or allergies. 
Females who were lactating, or any individual who was currently on oral corticosterioid 
treatment, had a chronic illness or immunosuppressive condition, or had extensive travel (2-3 
trips/year) in a leprosy and/or tuberculosis endemic region were excluded from the study. 
A total of 100 participants were enrolled in the phase II, stage A (n=10) and B (n=90) clinical 
trial. All were healthy Nepali residents, including expatriates from India, without any known 
contact with tuberculosis or leprosy patients. To assess eligibility, volunteers were asked a series 
of health related questions, given a general physical exam (vital signs and body weight) and 
standard examination for signs of leprosy, including skin lesions associated with leprosy and 
palpation of the greater auricular nerve, ulnar nerve at elbows, radial nerve at wrists, lateral 
popliteal nerve at the back of the knees, and posterial tibial nerve at the heel. [31,32]  
Overall, 70% were males and 30% females, between the ages of 18 – 54 years, with the 
average age of 29 years. All participants had a weight greater than 30 Kg for females and 38 Kg 
for males. Females who were pregnant as determined by a urine pregnancy test or lactating on 
day 0 of the study, or individuals who were on corticosterioid or other immunosuppressive 
treatment, had cancer, diabetes, extra-pulmonary tuberculosis, or other chronic illness, or had a 




expatriates other than those from India, had participated in an earlier stage of this study, or was 
concurrently participating in another clinical trial were excluded from this study.  
A Tuberculin test was not part of the screening process, because it was used in the clinical 
trial as a comparator to the medical interventions. Females were tested for pregnancy. 
Demographic information was collected, and BCG scar measured across the diameter (if 
present). A medical officer, nurse, or paramedic reviewed the screening data, demographics, and 
medical history forms against a checklist to determine eligibility. 
Ethics 
The phase I and phase II, stage A/B clinical trials were conducted in full conformity with the 
principles set forth in The Belmont Report: Ethical Principles and Guidelines for the Protection 
of Human Subjects of Research [33] and codified in 45 CFR Part 46, [28] the International 
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) Good Clinical Practice ICH E6 regulations and guidelines, [34] and the 
Declaration of Helsinki. [35] The present studies included women, but excluded special minority 
populations, including children. Minors were excluded, because the research involved greater 
than minimal risk and there was no direct benefit to the participants at this stage of the study, 
thus not satisfying federal regulations for inclusion of children. [36] 
For the phase I study, the informed consent form was written in English and approved by the 
study sponsor and CSU IRB prior to subject recruitment and enrollment. For the phase II, stage 
A/B study, informed consent forms were written in English, translated to Nepali, and back-
translated to English. All versions were submitted to the study sponsor and each IRB for 
approval prior to subject recruitment and enrollment. .The informed consent form for the phase 




Subject confidentiality was strictly held in trust by the investigators, their staff, and the study 
sponsor. Confidentiality was described to potential subjects during the recruitment talk, and 
mentioned again in the informed consent document. In summary, the subject was informed that 
results from these research studies may be published, but their name or identity would not be 
revealed. To maintain subject confidentiality, each volunteer who agreed to enter the study and 
signed a consent document, was assigned a study number. The number and the name of 
volunteers were recorded in a log, which was kept in a locked file by the study coordinator. Files 
will be held for a minimum of 5 years following the end of this study. 
Risks and Benefits 
Anticipated risks were the same as those encountered with other intradermal skin test 
antigens such as Tuberculin/PPD. [22,23] Localized areas of erythema, induration, itching, and 
pain were expected to occur in those responding to the antigens, but were not expected to cause 
significant discomfort. For strongly reactive individuals, blistering and ulceration was a 
possibility at the injection site. Individuals sensitive to Tween 80 were expected to exhibit 
additional reactions and discomfort at the injection site for approximately 24 h after 
administration. Medical personnel and equipment were available for those subjects who might 
experience adverse reactions caused by the procedures. Participation in this study did not directly 
benefit the volunteers; however, the information gained about the early detection of individuals 
infected with leprosy is hoped to benefit others with this affliction.  
Randomization and Blinding 
Phase I subjects were assigned to either the MLSA-LAM or MLCwA antigen group based on 
a random sequence of integers. Phase II, stage A/B subjects, were assigned an antigen and 




.Phase II study antigens were concealed by antigen codes randomized for each antigen and 
antigen dose by the DCC. The phase II study was a double blind study; both randomization 
schemes were sent to the clinical study principal investigator in the event that unblinding was 
necessary. Antigen codes were provided in separate envelopes, such that if only one antigen 
required unblinding, the others were not compromised. Unblinding did not occur until stage B 
data were analyzed.  
Statistical Considerations 
For the phase I clinical study, both antigens at each dose were not expected to elicit a DTH 
skin test response, therefore a sample size of 10 subjects (5 per group) was expected to be 
satisfactory as a preliminary safety screen in a non-endemic region for leprosy. For the phase II, 
stage A clinical study, both antigens and antigen doses were expected to show minimal reactions, 
if any, and therefore a sample size of 10 subjects was expected to uncover any major safety 
concerns. For the phase II, stage B clinical study, the sample size was increased by 40 subjects 
for each antigen, to generate statistically significant data. A power analysis was not required for 
these pilot scale studies. 
RESULTS/DISCUSSION  
Study Design  
Phase I Trial  
The phase I clinical trial was performed at Hartshorn Health Center at CSU. Eleven 
volunteers were recruited from the Mycobacterial Research Laboratories on campus as depicted 
in the Phase I Consort Flow Diagram (Figure 8). Ten volunteers met the inclusion criteria and 
were enrolled in the study; one volunteer was unable to participate. Study objectives were two-




antigen, and 2) to determine that the range of concentrations chosen for skin testing did not elicit 
a reactive response in a negative control group of human subjects living in a non-endemic region 
for leprosy. 
 
Figure 8. Phase I Clinical Trial Consort Flow Diagram 
The expected outcome for the phase I clinical trial was that all three concentrations of the 
two leprosy skin test antigens, saline, and control Rees MLSA leprosy antigen would not evoke a 
skin test antigen response. Any untoward local reaction such as severe erythema or necrosis 
would result in those antigen doses being dropped from further testing. 
Phase II, Stage A/B Trial 
Phase II, stage A and B clinical trials were performed by staff from Anandaban Hospital. To 
recruit adequate numbers of healthy subjects without exposure to leprosy, the trials were 
performed at Lalitpur Nursing Campus, Sanepa, Kathmandu, Nepal. One hundred and one 




Diagram (Figure 9) and one declined participation. Phase II, stage A/B study objectives were to 
evaluate the safety and to select a dose of MLSA-LAM and MLCwA causing minimal induration 
in healthy subjects without known exposure to clinical leprosy or tuberculosis, living in a region 
endemic for leprosy. 
 
Figure 9. Phase II, Stage A/B Consort Flow Diagram 
The expected outcome for the phase II, stage A/B clinical trial was that subjects would have 
a small (less than 10mm) induration reaction to the leprosy skin test antigens, due to cross-
reactivity with M. tuberculosis, BCG vaccination, and/or environmental mycobacteria [37-39] 
Known environmental mycobacteria present in soil and water include: M. avium-intracellulare, 
M. kansasii, M. xenopi, M. ulcerans, M. marinum, M. malmoense, M. fortuitum, and M. 
chelonei. Since tuberculosis is prevalent in Nepal and many individuals were vaccinated with 
BCG, most subjects were expected to respond to Tuberculin PPD; hence, Tuberculin PPD testing 
was a measure of not only exposure to tuberculosis, but also BCG vaccination, and non-




Study Outcome  
Phase I Trial  
Safety was analyzed by reactogenicity, i.e., the proportion of study participants with 
erythema, itching, pain/tenderness, bleeding, urticaria, infection and blistering for each time 
point and antigen concentration; and frequency, severity, and relationship of adverse events to 
the products under investigation. Reactogenicity observations were tabulated in Table 4 by 
maximum number of events across all readings by antigen, except the 15 minute reading post 
injection, which was merely the raised bleb on the skin from product administration. The 48 and 
72 hour induration measurements were very similar; hence, since the 48 hour reading was 
dropped from the phase II, stage B study, only the 72 hour values have been provided as 
supplementary data in Appendix 2.  
Table 4. Phase I – Maximum Reactogenicity  
Reaction No. Subjects with Reactions Across All Study Visits 
 
















Induration 0 0 0 1 0 0 1 0 
Erythema 5 3 0 3 2 2 8 1 
Pruritis 
(itching) 






2 2 9 1 
Total No. that 
were AE 
0 0 0 0 0 0 0 0 
 
Of the ten participants tested with titrated doses of MLSA-LAM or MLCwA, only one 
subject elicited a DTH skin test response of induration against the 2.5 µg dose of MLCwA at 48 
h and 72 h readings. This particular individual worked with Mycobacterium species on a daily 




that this individual was the only one of ten subjects to also elicit a positive induration reaction to 
the Rees control antigen. Adverse events from the phase I study are listed by the MedDRA® 
SOC in Table 5. A total of 7 adverse events were recorded, all of which were deemed not related 
to the investigational products. 
Both skin test antigens were found to be safe at all doses tested, but the 2.5ug dose of both 
MLSA-LAM and MLCwA were responsible for 100% (1//1) of induration events, 53% (8/15) of 
erythema events and 100% (1/1) of itching events noted with investigative products. Although 
these events were expected skin test reactions, they were not expected in healthy controls; 
therefore, as a precaution, the 2.5 µg dose was dropped from further testing. It should be noted 
that the Rees antigen at the 1.0 µg dose produced 8 erythema events; yet historically has been 
shown to be safe for use in humans across multiple vaccine and skin test clinical trials. [40] A 
final study report was submitted to the study sponsor and CSU IRB with recommendations to 
test the new leprosy skin test antigens in an endemic region for leprosy at 1.0 µg and 0.1 µg 
doses. Following FDA review of the study report, the next stage was initiated. 






Grade     









Common cold 2 1 1 Probably not 
Nervous system 
disorders 




Mild Rash – both 
forearms 
1 1 --- Probably not 
Redness, itching 
under wristwatch 
1 --- 1 Probably not 
Vascular disorders Tender occipital node 2 --- 1 Probably not 





Phase II, Stage A/B Trial 
Phase II, stage A maximum reactogenicity observations are tabulated in Table 6. The 72 
hour induration measurements are tabulated as a supplement in Appendix 2. Of participants 
tested in the phase II, stage A study, only one subject in each group elicited a DTH skin test 
response of induration against the high (1.0 µg) dose of MLSA-LAM and MLCwA. Three 
subjects exhibited erythema against both antigens at the high dose and 1 subject exhibited 
erythema against the low dose of MLCwA only. Itching was observed in one subject from the 
low dose of MLSA-LAM. Nearly all subjects responded to Tuberculin PPD by induration and 
erythema, with some exhibiting pain, urticaria, and one subject exhibiting blistering at the skin 
test site.  
Table 6. Phase II, Stage A - Maximum Reactogenicity 
Reaction No. Subjects with Reactions Across All Study Visits 
 





1.0 µg 0.1 µg 5TU N/A 
Induration 1                    0 1                    0 8 (3 AE) 0 
Erythema 3 0 3 1 9 0 
Pruritis (itching) 1 0 1 0 5 0 
Pain 0 1 0 0 4                                   1 
Bleeding 0 0 0 0 0 0 
Urticaria (hives) 0 0 0 0 2 0 
Infection 0 0 0 0 0 0 
Blistering 0 0 0 0 1                                    0 
Other 0 0 0 0 0 0 
  Total No. Events 5 1 5 0 29 1 
  Total No. AE 0 0 0 0 3 0 
 
Potential adverse events are listed by the MedDRA® SOC in Table 7. Three adverse events 




the study blind for submission to the SMC, study sponsor, FDA, and both IRBs. Both antigens 
and both the high and low doses were found to be safe for use in humans and phase II, stage B 
clinical trial was allowed to proceed.  








Grade     























3 --- --- 1 Probably  
Erythema > 
30 mm  















































1 --- 1 --- Possibly 
Total No. of AE   3 3 9  
 
The phase II, stage B maximum reactogenicity observations are tabulated in Table 8. The 72 




participants tested in the phase II, stage B study, 10 and 8, respectively, elicited induration and 
10 and 11, respectively, showed erythema for the high dose of MLSA-LAM and  
Table 8.  Phase II, Stage B - Maximum Reactogenicity  
Reaction No. Subjects with Reactions Across All Study Visits 
 
MLSA-LAM MLCwA Tuberculin Saline 
 





10 2 8 0 67 (1 AE) 0 
 
Erythema 10 3 11 1 67 (5 AE) 0 
Pruritis (itching) 0 0 1 0 34 0 
Pain 3 1 2 0 25 2 
Bleeding 0 0 0 0 0 0 
Urticaria (hives) 0 0 0 0 1 0 
Infection 0 0 0 0 0 0 
Blistering 0 0 0 0 5 0 
  Total No. Events 23 6 22 1 199 2 
  Total No. AE 0 0 0 0 6 0 
 
MLCwA. Only 2 subjects showed induration at the high dose of both antigens and 3 and 1 
subjects respectively showed erythema at the low dose of both antigens. Itching was only 
observed in one subject at the high dose of MLCwA and pain was observed in 3 and 2 or 1 and 0 
subjects in the high and low dose of MLSA-LAM and MLCwA, respectively. Again, significant 
reactions were observed with the Tuberculin PPD control, of which 6 were recorded as AEs. At 
the end of this stage of the study, the clinical team requested that a lower dose of Tuberculin 
PPD control antigen be used in stage C to save the participants from unnecessary pain and 
suffering. Phase II, stage A/B adverse events, including serious adverse events, are listed by the 
MedDRA® SOC in Table 7. All adverse events resulting from reactogenicity were related to the 




lymphangitis was listed as possibly being related to the study product. The subject who 
experienced this adverse event was administered MLCwA and Tuberculin PPD. With the strong 
reactions seen with Tuberculin, it is possible that this event could be related to either or both the 
study product or control antigen.  
Two SAEs were observed and procedures for treating, monitoring, recording, and 
notification of regulatory officials were followed. Although the appendicitis hospitalization was 
after the 28 day study period, the subject’s medical condition was still monitored by the clinical 
staff.The subject had no past medical, surgical, and allergy histories and was not on any 
concomitant medications prior to this event. He underwent an appendectomy on day 34, with 
surgical findings consistent with uncomplicated appendicitis. The event was considered resolved 
without sequelae on day 38. The clinical investigator and medical monitor assessed the event as 
not associated to the study product. The second SAE involved a death due to cerebral 
hemorrhaging possibly secondary to an A-V anerurymsm. The subject was hospitalized two days 
prior with seizures, headache, blurred vision and chest pain and a CT scan confirmed the 
diagnosis of intracranial bleeding secondary to an arterio-venous aneurysm. This individual was 
on concomitant medications. The subject’s condition deteriorated and he died on day 25 of the 
study. Both the investigator and medical monitor assessed the event as serious and not associated 
with the study drug.  
Data from both stage A and B were unblinded and a safety report was created by the DCC for 
submission to the SMC, study sponsor, FDA, and both IRBs. Results showed that Tuberculin 
PPD, as opposed to one of the study products was responsible for the high degree of 
reactogenicity and adverse events. Both study antigens and doses were found to be safe for use in 





A baseline can be derived for each antigen at each antigen dose based on phase II, stage A/B 
data from healthy controls in an endemic region without known exposure to leprosy. Induration 
measurements (mm) are graphed for each subject; Figure 10 depicts data for MLCwA (low dose 
and high dose), while Figure 11 depicts data for MLSA-LAM (low dose and high dose). 
Tuberculin results are graphed in Figure 12 as a comparator. MLCwA low dose did not elicit an 
induration response in any of the 50 subjects, whereas the high dose caused induration in 8/50 
subjects, with one falling below 5 mm. MLSA-LAM low dose elicited an induration response in 
2/50 subjects, with one subject below 5 mm, whereas the high dose caused an induration 
response in 10/50 subjects, with two subjects below 5 mm. Tuberculin PPD elicited a reaction in 
67/100 subjects, with 33 subjects below 5 mm. Both leprosy skin test antigens are showing 
potency at the high dose and a level of specificity at the low dose, when compared to Tuberculin 
PPD. 
 
Figure10. Phase II, Stage A/B - MLCwA Induration by Subject  
Phase II, stage A/B graph depicting DTH induration elicited by MLCwA. A) The low dose 
antigen did not elicit an induration response in any of the 50 subjects. .B) The high dose antigen 






Figure 11. Phase II, Stage A/B - MLSA-LAM Induration by Subject 
Phase II, stage A/B graph depicting DTH induration elicited by MLSA-LAM. A) The low dose 
antigen elicited an induration response in 2/50 subjects, with one subject below 5 mm. B) The 




Figure 12. Phase II, Stage A/B - Tuberculin 
Phase II, stage A/B graph depicting DTH induration elicited against Tuberculin PPD by subject 
number. 
 
The frequency of distribution for induration is graphed for both antigens and antigen doses, 
and Tuberculin PPD as a comparator in Figure 13 to discern a cut off value based on biomodal 
distributions. Results suggest that a cut off value for MLCwA low dose would be any reaction 
greater than 0 mm with 100% confidence; MLCwA high dose would be 5 mm with 86% 
confidence; MLSA-LAM low dose would be 5 mm with 98% confidence; and, MLSA-LAM 




would be 5 mm with 34% confidence or 10 mm with 37% confidence. These results require 
further analysis following collection of data from testing leprosy and tuberculosis patients. 
 
Figure 13. Phase II, Stage A/B - Distribution Frequency of Induration 
The distribution curve: A) comparing frequency of induration between antigen preparations and 
dosage suggests that the cut off value for MLCwA and MLSA-LAM low dose is 0 mm with 
100% of subjects (50/50) and 96% of subjects (48/50) falling at or below the baseline, 
respectively. The high dose of each antigen have an estimated cut off value of 5 mm with 86% of 
subjects (43/50), and 84% of subjects (42/50) falling below the baseline, respectively. B) 
Distribution frequency of induration response against Tuberculin PPD. 
 
Conclusion 
The phase I clinical trial commenced in December 1998 and was completed in February 
1999. It was the first-in-human study with MLSA-LAM and MLCwA at three concentrations. 
Both antigens at each dose were found to be safe, but the highest dosage caused reactogenicity 
and was therefore not tested in the phase II clinical trial. The Rees MLSA leprosy control antigen 
was a good comparator, as shown when the only individual who responded by induration was the 




commercially available or registered under a U.S. IND, therefore it was not allowed to be used as 
a control antigen in the phase II clinical study. Tuberculin PPD, the skin test antigen for 
tuberculosis, was therefore used as a control for the phase II clinical trials. 
The phase II, stage A clinical trial commenced in April 2002 and was completed in July 
2002, and the stage B trial commenced in May 2003 and was completed in January 2004. These 
trials reflect the first testing of MLSA-LAM and MLCwA in an endemic region for leprosy. As 
summarized in Figure 13, thirty individuals did not respond to either intervention or Tuberculin 
PPD, three responded to one or the other interventions, but not Tuberculin PPD, 52 responded to 
Tuberculin PPD only, and 15 responded to both the intervention and Tuberculin PPD. These 
results suggest that the leprosy antigens may provide specificity, which was missing from the 
Rees MLSA or Convit antigens.  
All the objectives of the phase I and phase II, stage A/B clinical trials were met. The antigens 
have been shown to be safe for use in healthy individuals, without known exposure to leprosy. In 
addition these studies show that the new leprosy skin test antigens are immunologically potent in 
humans and may provide a level of specificity in subsequent studies to establish safety and 
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CHAPTER FOUR: SAFETY AND EFFICACY ASSESSMENT OF TWO NEW LEPROSY 
SKIN TEST ANTIGENS: RANDOMIZED DOUBLE BLIND CLINICAL STUDIES 
 
SYNOPSIS 
Background: The extent of true leprosy infection will not be revealed until a sensitive and 
specific test is identified and developed for field use. Detection of leprosy prior to the onset of 
clinical symptoms would prevent disabilities by earlier implementation of chemotherapy and 
reduce the number of new cases by intercepting transmission Continuation of the phase II 
clinical trial of the leprosy skin test antigens MLSA-LAM and MLCwA was implemented to 
assess both the safety and efficacy in target populations. 
Methods: A randomized double blind phase II, stage C-1 clinical trial was conducted in 
Kathmandu, Nepal, following a phase II, stage A and B safety study in healthy subjects without 
known exposure to leprosy.  Stage C-1 was divided into two parts to test the high dose (1.0µg) 
and low dose (0.1 µg) of each leprosy skin test antigen; Tuberculin PPD (2TU) served as a 
control.    Each study enrolled 80 participants, including 20 BL/LL leprosy patients, 20 BT/TT 
leprosy patients, 20 BL/LL leprosy patient household contacts, and 20 tuberculosis patients.   A 
whole blood interferon gamma release assay (IGRA) and phenolic glycolipid-I (PGL) antibody 
assay were directly compared to the skin test.  The primary outcome measure for the skin test 
was delayed type hypersensitivity induration, the IGRA test was IFN-γ concentration, and the 
PGL-I test was color intensity. Gold standard 
Findings:  Diagnostic test performance of MLSA-LAM and MLCwA at the low dose 
exhibited high specificity at 100% and 95%, but low sensitivity at 20% and 25% in tuberculoid 




83%, while the negative predictive value was 81% and 82%, respectively. The high dose of both 
antigens showed lower specificity (70% and 60%) and sensitivity (10% and 15%). Lepromatous 
patients were completely anergic to the leprosy antigens, with one exception. In contrast, the 
IGRA showed the low dose of both antigens to be moderately sensitive at 83% and 72% with a 
specificity of 53% at a cut off value of 1.3 and 1.2 IU/mL.  Surprisingly, the high dose of both 
antigens displayed 95% specificity at a cut off value of 0.14 and 0.22, respectively.   The PGL 
antibody assay exhibited moderate specificity and sensitivity (77% and 80%) in BL/LL leprosy 
patients. 
Interpretation: In small scale sample sizes, MLSA-LAM and MLCwA at 1.0 µg and 0.1 µg 
dosages were found to be safe for human use in target populations. Efficacy of both antigens in 
terms of sensitivity was poor in the skin test and IGRA; however, specificity was high for 
tuberculoid leprosy patients. These native antigens represent a step forward in the critical search 
for an early diagnostic tool for leprosy. 
Funding: Leprosy Research Support, Contract NO1 AI-25469; National Institute of Allergy and 
Infectious Diseases (NIAID), National Institutes of Health (NIH)  
REGISTRATION: 
Phase I Clinical Trial: Not registered  
Phase II Clinical Trial, Stages A/B:  
Registry name: ClinicalTrials.gov  







The aim of this work was to assess the safety and efficacy of two new leprosy antigens, 
MLSA-LAM and MLCwA, as diagnostic skin tests for the detection of asymptomatic leprosy. 
The resulting test must be sensitive enough to detect infection prior to manifestation of clinical 
symptoms and specific enough to differentiate between leprosy, tuberculosis, vaccination with 
BCG, and exposure to environmental mycobacterium. Phase I and phase II, stage A/B clinical 
trials showed that these two new skin test antigens were safe for use in humans in a nonendemic 
and endemic area for leprosy.
 
The phase II, stage C clinical trial followed to provide preliminary 
data on safety and efficacy of these two leprosy antigens at high and low doses in small groups 
(n = 20) of leprosy patients and their contacts and tuberculosis patients. 
INTRODUCTION 
Leprosy transmission continues today with new cases occurring in high pockets of burden 
against low burden background in nearly all endemic countries, further emphasizing the 
importance of early detection. [1] Without a prophylactic vaccine better than the incomplete 
protection provided by the BCG vaccine for tuberculosis, [2] a tool for detecting asymptomatic 
leprosy is paramount. A sensitive and specific test would facilitate early detection allowing 
earlier treatment to interrupt disease pathogenesis; thus, a reduction of patient disabilities, 
reservoir of infection, and level of transmission. [3] Likewise, understanding the true incidence 
of leprosy may reveal underlying factors related to disease persistence; shifting public health 
resources back to this neglected tropical disease for full elimination. [4] 
To address detection of subclinical leprosy, the cell mediated immune response (CMI) 
against Mycobacterium leprae was targeted for measurement by a delayed type hypersensitivity 




MLSA-LAM (M. leprae soluble antigens devoid of lipoglycans, primarily lipoarabinomannan; 
LAM) and MLCwA (M. leprae cell wall proteins) were developed for testing in humans. 
(Chapter 2) [5] Phase I and phase II, stage A/B safety studies were successfully conducted on 
both antigens at the high (1.0 µg) and low (0.1 µg) dosages in healthy subjects without known 
exposure to leprosy. (Chapter 3) [6] 
Continuation of the phase II clinical trial included compulsory testing for safety and efficacy 
of MLSA-LAM and MLCwA in target populations: borderline tuberculoid/tuberculoid (BT/TT) 
and borderline lepromatous/lepromatous (BL/LL) leprosy patients, household contacts of BL/LL 
leprosy patients (HC), and tuberculosis patients (TB). Prior to initiation, the protocol was 
amended: 1) to allow testing in smaller group sizes (n = 20) to assure safety before ramping and 
to improve the likelihood of recruiting the requisite number of subjects; 2) to decrease the 
number of injections for subject comfort and to aid recruitment; and, 3) to add comparative in 
vitro assays to maximize the potential of this study. Stage C was divided into stage C-1 for small 
scale studies and stage C-2 for ramping to achieve statistical significance. Stage C-2 was not 
feasible, due to cessation of dedicated funding. Stage C-1 was divided into two parts, a and b, to 
test the high dose and low dose of each antigen subsequently. This protocol change enabled both 
the reduction of sample size and number of injections per subject, while remaining within the 
scope of the original protocol. The phase II, stage C-1a/b clinical trial was performed at 
Anandaban Leprosy Hospital and Patan Hospital Tuberculosis Clinic, Kathmandu, Nepal.    
METHODS 
Skin Test Antigens and Control Products 
Two skin test antigens were tested, MLSA-LAM and MLCwA. A detailed description of 




Pasteur Inc., Swiftwater, PA) served as the control antigen for preliminary testing of stage C-1a. 
Strong reactogenicity readings prompted unblinding and SMC review for this one product. The 
outcome was a recommendation to use a lower dose for the remainder of stage C-1 a/b studies; 
this change was not expected to significantly impact the study results. Following a protocol 
amendment and proper approvals, the proposed change was authorized. The lower dose was not 
available from the same vendor; therefore, Tuberculin PPD RT 23, 2 TU dose, solution for 
injection, Statens Serum Institute (SSI), Copenhagen, Denmark was used.  
Human Subjects Recruitment  
Leprosy patients and their household contacts were recruited at Anandaban Hospital, 
Kathmandu and tuberculosis patients were recruited at Patan Hospital, Lagankhel, Lalitpur, 
Kathmandu. Recruitment was informal between the study investigator and interested individuals. 
Explanation of the study was guided by use of a flip chart and the appropriate consent form 
translated into the native language, either Nepali or Hindi. In the case of illiterate subjects, 
information was read to them by a staff member. Recruits were encouraged to ask questions prior 
to signing the informed consent form.  
A total of 160 participants were enrolled in the phase II, stage C-1a/b clinical trials. All were 
healthy Nepali residents, including expatriates from India. Details, including exclusion criteria 
were described in chapter 3. [6] The Kruskal-Wallis test was used to compare age by study 
group; age did not vary significantly across study groups for stages A, B, or C.  
Leprosy patients had one of the hallmark symptoms of leprosy including: hypopigmented or 
erythematous skin lesion(s) with definite loss of sensation; damage to the peripheral nerves as 
demonstrated by palpable thickening with or without impairment of sensation and/or weakness 




changes diagnostic of leprosy in a skin biopsy, receiving standard multi-drug therapy (MDT) 
treatment for leprosy, or completed treatment for leprosy no more than 4 years prior to study 
enrollment. [7,8] Household contacts were determined to be healthy by history and physical 
examination and have resided in the same residence as the BL/LL leprosy index case for at least 
6 months duration and within 6 months of this study, or a person professionally exposed to 
BL/LL leprosy for at least 5 years duration, and within 6 months of this study.  
Tuberculosis patients had active tuberculosis defined by a culture positive test; a productive 
cough of more than 3 weeks duration accompanied by night sweats, loss of appetite, 
haemoptysis, weight loss, chest pain, shortness of breath and sputum smear positive, or sputum 
smear negative with x-ray evidence consistent with pulmonary tuberculosis that does not clear 
with non-tuberculous antibiotics; or, culture positive for M. tuberculosis. All patients had 
completed the intensive phase of chemotherapy for tuberculosis, but were still undergoing the 
continuation phase of therapy. 
Sample Size  
A total of 160 participants were enrolled in the phase II, stage C-1clinical trial. Stage C-1a 
(n=80) and stage C-1b (n=80) each included 20 BT/TT leprosy patients, 20 BL/LL leprosy 
patients , 20 HC, and 20 TB patients. Based on prior clinical trial experience in the Kathmandu 
region, subject loss to follow-up was not expected to exceed 10%, which was within sample size 
consideration to meet study objectives. 
Antigen Administration and Read-out Measurements 
Antigen administration and read-out measurements were identical to those described for the 
phase II, stage B clinical trial. (Chapter 3) [6] Briefly, stage C-1a subjects received 100 µl 




ml Tuberculin syringe calibrated in tenths and fitted with a sterile, one-quarter inch, 30 gauge 
needle.  
Each antigen site was evaluated for reactogenicity, defined as a reaction at the site of 
injection that is common and reasonably expected for the intervention being studied. 
Specifically, the maximal diameter of induration and erythema, and presence of pain, pruritis 
(itching), bleeding, urticaria (hives), infection, or blistering were possible reactions based on 
Tuberculin skin testing. [9,10] The method for measuring induration was adapted from 
“Guidelines for Conducting Skin Test Surveys in High Prevalence Countries,” issued by the 
International Union Against Tuberculosis and Lung Disease.[9] 
DTH responses were read at ~30 min, 72 + 3 h, and 7 + 1 d. The 30 min observation was 
changed from the 15 min observation in the phase II, stage B study to assure subjects were not 
adversely affected from the added blood draw for in vitro testing. If a subject was observed to 
have an induration greater than 10 mm at any injection site, they were asked to return at 28 + 3 d 
for a final induration measurement. Any persistent reaction was followed-up until resolved or 
stabilized.  
Regulatory Boards, Documentation, and Reporting 
Details were identical to those provided for the phase II, stage A/B trial, with two exceptions. 
(Chapter 3) [6] One member of the Safety Monitoring Committee (SMC) could not participate 
and was therefore replaced. The new committee consisted of three off-site and one on-site 
physician who served as the independent safety monitor (ISM). Subjects were not asked to 
complete a Volunteer Symptom Diary, because entries did not add value when used in the phase 





Compliance with regulatory requirements for the protection of human subjects enrolled in the 
phase II, stage C-1a/b study was described. (Chapter 3) [6] Three flip charts and three informed 
consent forms were written in English, translated to Nepali and Hindi, and back-translated to 
English. Each supported recruitment of leprosy patients; TB patients and HC; or, access to 
medical records of the HC index case. All versions were submitted to the study sponsor and each 
IRB for approval prior to subject recruitment and enrollment.  Informed consent forms, version 
5.0, dated December 22, 2005 and flip charts, dated April 20, 2005 have been attached as 
supplements.  
Risks and Benefits 
Details were identical to those provided for the phase II, stage A/B trial. (Chapter 3) [6] 
Randomization, Blinding, and Statistical Considerations 
The phase II, stage C-1a/b trial was a randomized double blind study, as described. (Chapter 
3) [6]. The study was designed to assess the safety and primary response measure of induration 
resulting from skin test antigen DTH responses in small numbers (n=20) of participants within 
each of four different groups that theoretically may be at higher risk of serious adverse responses 
to novel antigens. A power analysis was not required for this pilot scale study. The probability of 
observing one or more serious adverse event related to antigen administration was calculated. If 
the true serious adverse event rate is 10% then there is an 85% chance of observing one or more 
serious adverse events in any one of the four groups with loss during follow-up of 10% of the 
subjects, or 88% if there is no loss during follow-up. 
Efficacy analyses were performed using the receiver operating characteristic (ROC) curve. 




new leprosy skin test antigens. The Kruskal-Wallis test was used to compare ages between phase 
II, stages A, B, and C. [12] Graph Pad, Prism for Windows, version 5.04 (La Jolla, CA) was used 
for graphing and analyzing ROC curves.  
Laboratory Assays 
The QuantiFERON-CMI kit (Cellestis Limited, Valentia, California) was the IGRA of choice 
used to quantify IFN-γ following stimulation with each of the skin test antigens and antigen 
dosages or PPD.  Mitogen was included with the test kit as a positive control and Aims V media 
(Life Technologies, Grand Island, NY) was used to prepare antigen dilutions at 10x 
concentration and as nil control.  Antigens were aliquoted and lyophilized for shipment in a one 
batch and single use vials.  An SOP was written and approved prior to use.   
Due to limited blood collected, a single test well was run for each sample.  Approximately 
10-12 ml blood was collected and 3 ml was aliquoted for the PGL assay, while the remaining 
was added to a BD heparinized tube to prevent clotting.  Blood was then transferred at RT to the 
laboratory for aliquoting 0.5 mL/well into 48 well plates within 6-12 hours of collection and any 
extra blood was sterilized and disposed per request by the NHRC. Antigen, mitogen, or Aims V 
media were added (50 µl/well) and wells were mixed by consistent pipetting.  Plates were 
incubated at 37 °C overnight and approximately 200 µl/well plasma was collected in a 48 well 
plate.  The ELISA was performed per the test kit instructions: 1) conjugate was added to ELISA 
wells at 50µl/well, 2) Plasma or IFN-γ standards were then added to appropriate wells at 50 
µl/well, 3) Plate was incubated for 120 minutes at 20-25 °C, 4) wells were aspirated and washed 
6 times with diluted buffer provided with the kit, 5) Kit substrate was added at 100 µl/well and 
incubated for 30 min at 20-25 °C, 6) stop solution was added at 50 µl/well, and 7) plate was read 




The lateral flow immunodiffusion PGL-I Rapid Antibody Test Kits were provided by Dr. 
Sang Nae Cho, Seoul, South Korea.  An SOP was written and approved prior to use.  A total of 3 
ml of blood was allowed to clot and serum was removed following centrifugation.  Serum was 
diluted 1:10 in phosphate buffered saline and apply 100 µl to the sample well of the test cassette.  
A control line verified the test ran properly.  Results were read at 10 minutes + 1 minute as 
negative, weak positive, moderate positive, or strong positive.  Remaining serum was aliquoted 
and stored frozen until the end of the study, at which time it was proper discarded at the request 
of the NHRC. 
RESULTS 
Study Design 
Stage C-1 was designed as a preliminary safety and efficacy study for evaluating the high 
dose (1.0 µg) and low dose (0.1µg) of MLSA-LAM and MLCwA in small scale sized groups of 
subjects who were expected to respond to the products under investigation. Although not 
statistically relevant with 20 subjects per group, these ramping studies were justified as being 
satisfactory for initial evaluation of safety and for identifying trends for efficacy. Both studies 
were performed by staff from Anandaban Hospital. Leprosy patients and their contacts were 
mostly recruited at Anandaban Hospital and tuberculosis patients from Patan Hospital. The 
Phase II, stage C-1a/b Consort Flow Diagram is shown in Figure 14. Over two subsequent 
studies, one-hundred sixty-one subjects (81 for stage C-1a and 80 for stage C-1b) were recruited; 
one household contact in stage C-1a declined participation.  
Eighty subjects (20 in each of four groups: BT/TT, BL/LL, HC, and TB) for each study were 
randomized to receive antigens in different patterns, according to different templates. 




and the pattern of antigen delivery. Volunteers’ participation in each study lasted for 7 ± 1 d, 
unless induration greater than 10 mm was observed, an additional study visit occurred on day 28. 
Total time involvement for each participant for all visits was approximately 5 h. 
The primary objective of the phase II, stage C-1 study was safety assessment of the two skin 
test antigens by measuring reactogenicity and adverse events. The secondary objective was 
efficacy assessment of the two skin test antigens by comparing induration measured at 72 + 3 h 
following skin test administration. Results from leprosy patients and HC were compared to those 
of EC (phase II, stage A/B) and TB patients to: 1) quantify the number of positive reactors and 
mean induration between groups; 2) to identify an induration size that defines a positive skin test 
reaction in leprosy patients; and, 3) to assess sensitivity and specificity of both antigens and 
antigen doses.  
 
Figure 14. Phase II, Stage C-1 a/b Consort Flow Diagram 
The expected safety outcomes were that both antigens and antigen dosages would be deemed 




the skin test reactions would vary among the groups participating. It was expected that BT/TT 
leprosy patients and some healthy contacts of leprosy patients would have large indurations at M. 
leprae-derived antigen sites and a variable reaction at the Tuberculin PPD site due to prior BCG 
vaccination or exposure to related environmental mycobacteria, including M. tuberculosis. [13-
15]. BL/LL leprosy patients would have negative indurations at all leprosy skin test sites due to 
M. leprae specific T-cell anergy with a variable reaction at the Tuberculin PPD site. Tuberculosis 
patients were expected to react with a large induration at the Tuberculin PPD site and may react 
with an induration less than 10 mm at the other sites.  
Study Outcome  
Safety 
Product safety was assessed by the number and severity of reactogenic events and adverse 
events, as described for the phase II, stage A/B trials. (Chapter 3) [6] Reactogenic events were 
tabulated as the maximum number of events by subject, antigen, and antigen dose. Stage C-1a 
and C-1b reactogenic events are listed as supplements in Appendix 3; a summary of this data is 
provided in Table 9. Most reactions consisted of mild to moderate induration and erythema with 
only a few cases of mild pruritis and pain and one case of urticaria, infection, and blistering with 
MLSA-LAM at both the high and low dose. One case of bleeding was seen with MLSA-LAM at 
the low dose. The HC and TB groups had the highest number of reactions in the high dose study, 
whereas the BT/TT and HC groups had more reactions in the low dose study. The BL/LL group 
had the lowest number of reactions across both the high and low dose of each leprosy antigen. A 
total of 55 and 68 reactogenic events were observed with MLSA-LAM and MLCwA at the high 




respectively. No adverse events (AE) were observed based on reactogenicity at the site of 
injection for either intervention. 
A significantly greater number of reactogenic events were observed with Tuberculin PPD 
over prescribed study visits. A total of 182 and 152 reactogenic events were observed in stage C-
1a and C-1b, respectively. Most were mild and moderate induration and erythema; however, 14 
events were classified as severe reactions and therefore recorded as mild AEs. The number of  
Table 9. Maximum Reactogenicity
a
 by Subject Across all Visits (Summary) 
a
 Maximum reactogenicity is the no. of subjects exhibiting specific reactions across all visits.  
b
 Summary includes all target groups: BT/TT, BL/LL, HC, and TB; tabulated as supplements 
 
reactogenic events caused from Tuberculin PPD was nearly three times the number observed for 
the products under investigation at the high dose and four times that observed at the low dose. 
Each AE was graded and coded by the MedDRA® SOC (Chapter 2) [16]; presented as a 
supplement in Appendix 3, because none were found to be associated with the investigative 
Summary
 b
 No. Subjects with Reactions Across All Study Visits 
 









1.0 µg 1.0 µg 5 TU 0.1 µg 0.1 µg 5 TU 
Induration 16 22 61 6 12 55 
Erythema 29 29 62 15 23 61 
Pruritis (itching) 5 12 29 2 3 25 
Pain 2 5 27 1 0 10 
Bleeding 0 0 0 1 0 0 
Urticaria (hives) 1 0 0 1 0 0 
Infection 1 0 0 1 0 0 
Blistering 1 0 3 1 0 1 
 Total No. Sites 80 80 80 80 80 80 
 Total No. 
Events 
55 68 182 28 38 152 




products. A total of 14 AEs were observed as a result of severe reactogenicity reactions; 10 AEs 
in Stage C-1a and 4 
AEs in Stage C-1b. All were assigned an AE maximum severity level of mild and were found 
to have an antigen association with Tuberculin PPD. Two subjects in the BL/LL group and one 
subject in the HC group experienced blistering and received treatment with resolution, except for 
a dark or hypopigmented spot by day 28. One unexpected AE described as a type I 
hypersensitivity reaction was observed in stage C-1b in a BT/TT subject on day 12. The event 
was assigned an AE maximum severity level of mild and was found to probably not be related to 
the study treatments. The subject was given prednisolone and the event was ongoing upon 
termination.  
Safety Analysis  
Maximum reactogenicity measured across all study visits (day 3, 7, and 28) was greater with 
MLCwA compared to MLSA-LAM and the high dose compared to the low dose. Reactions were 
most prevalent in the TB group at the high dose of both antigens. There were no AEs observed 
for either study intervention. Tuberculin PPD control antigen elicited considerably more 
reactions of greater severity in subjects across all groups, resulting in a total of 14 AEs. Dropping 
the Tuberculin PPD dose from 5TU to 2TU did help decrease the number of reactions and AEs 
in the low dose study. Following review of unblinded data presented in the Safety Monitoring 
Reports, the SMC found the two new antigens at both doses to be safe for use in humans.  
Efficacy  
Stage C-1a (high dose) and C-1b (low dose) 72 + 3h induration measurements are listed as a 
supplement in Appendix 3. A dot plot of these induration measurements across cohorts tested 




result of these analyses was the near total lack of response of the BL/LL subjects to the skin test 
antigens, yet a vigorous response to Tuberculin PPD. The leprosy antigens were behaving 
according to precedent. [17] The low number of positive responders in the BT/TT group could be 
related to the choice of antigen, immune status of the patient since treatment, or lack of 
sensitivity. Leprosy patients were allowed in the study after receiving MDT treatment up to 4 
years.  
 
Figure 15. Dot Plot of Induration Measurements 
Induration results are provided across five subject groups, including ECs ( n = 50), BT/TT 
leprosy patients ( n = 20), BL/LL leprosy patients ( n = 20), HC (n = 20), and TB (n = 20). EC 
data was presented in a parallel article describing the phase II, stage A/B safety study. Mean and 




Proportion of Positive Reactors.  
A direct comparison of the proportion of positive reactors and mean induration for each study 
group was compared to the EC group. Results are shown as a supplement in Appendix 3. Results 
show that both skin test antigens are immunologically active in target populations. MLSA-LAM 
low dose elicits a response in twice the number of BT/TT leprosy patients as HC and does not 
react with BL/LL leprosy or TB patients. MLCwA low dose stimulates BT/TT leprosy patients 
and HC nearly equally, but also some TB patients. Interestingly, this was the only antigen dose 
that did not elicit a response in EC, despite 67% reacting with Tuberculin PPD.  
The high doses of both leprosy skin test antigens elicited a response in HC and TB patients 
greater than BT/TT leprosy patients. The reason is unknown, but suggests that either BT/TT 
leprosy patients are cured and their CMI against M. leprae has waned, or they have some degree 
of specific T-cell anergy. One BL/LL subject in the MLSA-LAM high dose group reacted with 
an induration of 20 mm. This subject was a 46 year old male with LL leprosy, who had been 
treated with MDT for a period of 1 month before enrolling in the high dose study. This 
participant was smear positive, had a bacterial index of 4.0, did not have a history of Type I or 
ENL reactions, had a single BCG scar, and, was taking concomitant hormones/steroids for the 
treatment of eczema.  
Comparison of mean induration measurements across all subjects showed a higher response 
in the BT/TT leprosy patients compared to HC with both antigens at the low dose. Antigens at 
the high dose showed a lower response in BT/TT leprosy patients compared to HC and TB 
patients. The mean induration of only positive responders has been graphed in box plots in 
Figure 16. Either by antigen or antigen dosage, BT/TT leprosy patients respond with the highest 




patients with high dose antigens. No difference in response across groups was seen with 
Tuberculin PPD. 
 
Figure 16. Mean Induration of Positive Responders  
Mean induration of the positive responders in each subject group represented in box plot format. 
 
  













































































































































































With different responses being recognized between the two skin test antigens and dosages, 
results were compared by linear regression in Figure 17 to look for correlations using the BT/TT 
group, albeit with few responders. The highest correlation was found between the two leprosy 
antigens at the low dose with a covariance (r
2
) value of 0.81, followed by the high dose with a 
covariance of 0.67. There was not a correlation between MLSA-LAM high and low dose or 
either antigen at either dose against Tuberculin PPD (results shown for MLSA-LAM low dose).   
 
Figure 17. Antigen and Antigen Dose Correlations 
Antigens were compared by unilateral linear regression to assess correlation. Covariation was 
calculated by the Pearson correlation coefficient (r
2
) and did not improve with transformation of 
data. Analysis was performed on reactions from the BT/TT group with A) both antigens at the 
low dose, B) both antigens at the high dose, C) MLSA-LAM high dose vs low dose, and D) 
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Definition of a Positive Skin Test.  
A frequency distribution of induration size was used to compare BT/TT to EC and TB groups 
to identify a cutoff point, if possible. The distribution curve shown in Figure 18 was difficult to 
interpret due to limited sample size and few reactors in the BT/TT groups. The EC response 
served as the baseline, while the TB response provided the worst case scenario with individuals 
infected with a related mycobacterial species. The projected cut off point is at the anti-mode, or 
the point at which the control groups no longer respond and the patient groups begin responding. 
MLSA-LAM and MLCwA low dose presented an anti-mode at 8mm and 10 mm, respectively. 
The curves for the high dose antigens did not present a biomodal distribution; therefore, a cutoff 
point could not be determined. ROC curve analysis calculated the cut off point for MLSA-LAM 
and MLCwA low dose to be greater than 5.2 mm and 9.5 mm, respectively. The likelihood ratios 
were high; however, p-values were not significant (p = 0.28 and 0.46, respectively) due to 
limited BT/TT group responses. A larger sample size is needed to properly evaluate this 
parameter. 
Specificity and Sensitivity.  
Diagnostic statistics provide a measurable assessment of the leprosy skin test antigens. [18] 
Four statistics provide the foundation for assessing a diagnostic test: 1) sensitivity; 2) specificity; 
3) positive predictive value; and, 4) negative predictive value. Sensitivity (Se) is the likelihood to 
detect the presence of disease; specificity (Sp) is the likelihood to detect absence of disease; 
positive predictive value (PPV) is the likelihood that if a subject tests positive, they will have 
disease; and, negative predictive value (NPV) is the likelihood that if a subject tests negative, 







Figure 18. Biomodal Distribution of Induration 
Frequency distribution graphs were used to establish cut off points for each skin test antigen at 
each dosage tested. Frequency of induration reaction (mm) of EC and TB groups were graphed 
against BT/TT and BL/LL leprosy groups. The anti-mode between the control and leprosy 
patient group represents the cut off for each antigen and antigen. 
 
Diagnostics statistics have been calculated for the two new antigens and antigen doses in 
Table 10. Caution was taken when interpreting these values, because of the small sample sizes 
and limited BT/TT responders. Results showed that MLSA-LAM and MLCwA at the low dose 
were highly specific (100% and 95%), but lacked sensitivity (20% and 25%). Worst-case PPV 
was 100% and NPV was 56% with the low dose of MLSA-LAM. NPV is related to sensitivity, 
which must be enhanced to develop a viable diagnostic test. Tuberculin PPD as a diagnostic for 
tuberculosis was sensitive (90%), but not specific (41%).  
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PPV  NPV NPV 
EC + TB 
(worst case) 





(4/20) 20% (0/20) 0% (50/50) 100% (20/20) 100% (4/4) 100% (70/86) 81% (20/36) 56% 
MLCwA  
Low 
(5/20) 25% (0/20) 0% (50/50) 100% (19/20) 95% (5/6) 83% (69/84) 82% (19/34) 56% 
MLSA-LAM 
High 
(2/20) 10% (1/20) 5% (43/50) 86% (14/20) 70% (2/15) 13% (57/75) 76% (14/32) 44% 
MLCwA 
High 
(3/20) 15% (0/20) 0% (47/50) 94% (12/20) 60% (3/14) 21% (59/76) 78% (12/29) 41% 
 
Diagnostic test statistics were calculated for each test method. Sensitivity (Se) is the likelihood to detect the presence of disease 
(TP/TP+FN). Specificity (Sp) is the likelihood to detect absence of disease (TN/TN+FP). Positive Predictive Value (PPV) is the 
likelihood that if a subject tests positive, they will have disease (TP/TP+FP). Negative Predictive Value (NPV) is the likelihood that if 
a subject tests negative, they will not have disease (TN/ TN + FN). Tuberculin PPD served as an antigen control. Statistics for 




IGRA Results.  Stage C-1a (high dose) and C-1b (low dose) IGRA data are listed as a 
supplement in Appendix 3. A dot plot of IGRA results is shown in Figure 19.  The low dose 
antigens show a slightly higher background with the TB group, but overall the number of 
responders is higher.  The mean induration of positive responders above a concentration of 0.1 
IU/mL IFN-γ has been graphed in Figure 20.  The cut off value was chosen based on the ROC 
Curve Analysis.  The assay was not optimized for antigen concentration, because this assay was 
a direct comparison to the skin test antigen method, where doses were chosen based on prior 
knowledge with Rees MLSA skin test antigen in humans and new skin test antigen reactivity in 
guinea pigs.  
PGL-I Antibody Assay Results. Stage C-1a (high dose) and C-1b (low dose) PGL Antibody 
data are listed as a supplement in Appendix 3. The lateral flow immunodiffusion cassettes were 
prepared with Neo Disaccharide O-linked Human Serum Albumin (NDO-BSA) prepared by Dr. 
Delphi Chatterjee, Colorado State University, Fort Collins, Colorado, USA for the detection of 
antibodies against this M. leprae specific surface antigen.  The intensity of the positive reaction 
was visually observed and assigned a number, 1 was a weak response, 2 was a moderate 
response, and 3 was a strong response.  Results were then graphed in a dot plot matrix in Figure 
21.  The LP group has a significant number of strong reactors, compared to multiple mild and 
weak responders in other groups.  Stage C-1b (high dose group) had more responders in the TB 
group than was seen in the stage C-1a (low dose group).  This suggested that some of the TB 
subjects were possibly co-infected with M. leprae.   
Comparison of In vivo and In vitro Test Methods.  The diagnostic performance of a particular 
test to differentiate individuals with disease from individuals without disease was evaluated 
















































































































Figure 19. IGRA Test Method Dot Plot Results 
IFN-γ production was measured by the QuantiFERON CMI Test kit (Cellestis, Valentia, CA) 
after culturing undiluted whole blood with skin test antigen MLSA-LAM or MLCwA at the high 
(1.0 µg) or low (0.1 µg) dose, PPD 2TU, or mitogen for 24 h at 37°C.  Tests were performed in a 
single replicate. Reported values were extrapolated from an IFN-γ standard curve and subtracted 
from the medium control. Subject groups included TD, LP, HC, and TB.   Single replicate Graph 

































































































Figure 20. IGRA positive reactors only 





positive rate (Sp) for different cut-off points.  The output is a Se/Sp prediction for each cut-off 
point.  Accuracy of the test increases as Se and Sp approach 100%.  The positive likelihood ratio 
is the probability of a positive test result given the presence of the disease over the probability of 
a positive test result given the absence of the disease.  A p value <0.05 suggests that the area 
under the curve (AUC) is significantly different from a true population AUC of 0.5, and 
therefore there is evidence that the test has the ability to distinguish between the two groups. The 
AUC for ROC curve analysis is equal to the probability that an individual randomly chosen from 
the positive group will test positive compared to a randomly chosen individual from the negative 
group.  When there is no difference between the distributions, the area will be equal to 0.5.  With 
this planned analysis in-hand, test methods were compared individually and combinatorial to 
look for synergistic effects.  The TD group was compared to the TB group across antigens and 
antigen doses, except for the PGL antibody assay, which  included a comparison of the LP group 
compared to the TB group across stage C-1a (high dose) and stage C-1b (low dose) groups.  The 
results of the ROC analysis can be found in Table 11.   
The skin test high dose group results showed high sensitivity (90% and 85%) for MLSA-
LAM and MLCwA, respectively; however, the cut off values derived from the curve were not 
realistic induration values at < 4.0 mm and < 9.5 mm.  The low likelihood ratios, high p values, 
and low AUC values were indicators that something was flawed.   On the contrary, the low dose 
group results showed high specificity with a cut off at > 5.2 mm and > 9.5 mm, with a strong 
likelihood ratio, but low p value and AUC.  Specificities were similar to what had been 
determined using the biomodal distribution to identify the cut off values and calculations by 


































































Figure 21. PGL-I Antibody Test Method Dot Plot Results 
Presence of the M. leprae specific PGL-I antibody was measured with serum by lateral flow 
immunodiffusion using the Rapid PGL-I Antibody Test kit (Dr. Sang Nae Cho, Yonsei 
University, Seoul, South Korea).  Results were stratified to allow graphing (0 – negative, 1 – 
weak positive, 2 – moderate positive, and 3 – strong positive).   
 





 The results seen with the IGRA compared to the skin test assay were further elucidated with 
the ROC analysis.  Both high dose antigens showed excellent specificity (95% each), albeit poor 
sensitivity (47% and 32%) with very high likelihood ratios (9.47 and 6.32), significant p values 
(0.001 and 0.03), and excellent AUC values (0.80 and 0.70) at low cut off values (> 0.14 and > 
0.22).  The sensitivity was however, 27% better than the skin test method.   When considering 
the low dose of each antigen, sensitivity improved dramatically, especially with MLSA-LAM 
(83%) at a higher cut off value (> 1.30), while specificity dropped to 53%.  The likelihood ratio 
was low (1.77), while the p value was good, it was not significant (0.15) and the AUC was poor 
(0.64).  The reason for this inverted data compared to the skin test method is unknown.  This 
phenomenon will need to be verified.  Dose optimization may identify a dose that provides both 
good specificity and sensitivity. 
Comparing the LP group to the TB group across both the high and low dose studies, the PGL 
antibody assay shows the best diagnostic statistics.  With a cut off  greater than moderate (3 
intensity level), sensitivity is moderate (77%) and specificity is also moderate (80%) with a high 
likelihood ratio (3.85), highly significant p value (< 0.0001) and excellent AUC (0.80).  For 
diagnostic accuracy of TD subjects, the best cut off value was greater than mild  (2 or 3 intensity 
level), with moderate specificity (75%), but poor sensitivity (41%) and poor diagnostic statistics.  
These results were as expected, since the PGL antibody test is excellent at classifying clinical 
disease.  The question is the utility for early diagnosis.  From the HC low dose and high dose 
groups, there were 3 individuals that had a PGL test result of “3” and  2 individuals that had a 
test result of “2”.  Verification that these 5 individuals develop leprosy would be accomplished 





Based on the ROC curve analysis results, the three test methods were compared individually 
and together to determine if one was adequately useful or if more than one was better in 
diagnosing clinical leprosy.  The best antigen and dose were used and the cut off was based on 
the best likelihood ratio.  The number of positive subjects based on cut off values was tallied and 
the percent positive was graphed.  MLSA-LAM low dose at > 5.2 mm cut off was used for the 
skin test method, MLSA-LAM low dose at > 1.30 IU/mL was used for the IGRA method, and a 
cut off of 3 was used for the PGL method.  Adding MLSA-LAM high dose at > 0.14 cut off was 
evaluated and found to probably add no additional value.  The TD group would have had 3 
additional positive subjects, one of which was positive by PGL.  The LP group would have had 
13 additional positives, ten of which were positive by PGL.  The HC group would have had 4 
additional positives, none of which were positive by either skin test or PGL assay.  The TB 
group would have had 7 additional positives, none of which were positive by either the skin test 
or PGL assay.  Results are shown in Figure 22.   The best scenario is the combination of the 
IGRA and PGL assays, which is better than either assay alone.  Addition of the skin test did not 
improve the number of positive individuals detected.  On the other hand, the combination of the 
skin test and PGL antibody test resulted in the least background reactors from the TB group.  In 
the comparison with antigens at the high dose, all have background reactors, except IGRA with 
MLSA-LAM high dose. 
Efficacy Analysis.  
Results from the stage C-1a/b clinical trial showed that both new leprosy skin test antigens 
are immunologically potent as skin test antigens when tested in leprosy patients and their 
household contacts. The low doses of both antigens were found to cause minimal induration in 
EC and TB groups and a baseline was able to be determined for the low dose antigens only. 




value was 9.5 mm, when compared to TB subjects. Both skin test antigens at the low dose were 
found to be highly specific, but poorly sensitive.  
 
Figure 22. Comparison of Test Methods 
Percent of positive reactors within each test group were graphed by test method.  Individual test 
method was compared to combined test methods to assess the value of one or more test methods. 
 
The IGRA test was found to be highly specific at the high dose and moderately specific at the 
low dose with both antigens.  PGL antibody test once again proves to be both specific and 
sensitive in diagnosing BL/LL patients with clinical leprosy, rarely diagnosed by skin testing.  
Under these conditions, some household contacts were also identified as being positive to the 
PGL assay, suggesting the test may be useful for early diagnosis with a higher cut off.  
Combinatorial analysis of the three test methods showed that the best candidates for 
epidemiological screening may be the IGRA combined with the PGL assay, as the skin test 
method did not seem to add value to the total true positive subjects identified.   
DISCUSSION 
The phase II, stage C-1a clinical trial commenced in December 2006 and was completed in 




2009. Two protocol amendments were filed, one in May 2007 to decrease the control antigen 
dose; and, one in March 2009 to reduce the study size and to add comparative in vitro tests. 
These trials reflect the first testing of MLSA-LAM and MLCwA in leprosy patients, household 
contacts of leprosy patients and tuberculosis patients in an endemic region for leprosy. A final 
Clinical Study Report was submitted to the study sponsor by the data control center (The Emmes 
Corporation, Rockville, MD) on February 2012.  
Study results were presented as trends, due to small scale sample sizes. Both antigens and 
antigen dosages have been shown to be safe for use in BT/TT and BL/LL leprosy patients, HC of 
lepromatous leprosy patients, and TB patients. The diagnostic accuracy of both skin test antigens 
at the low dose (0.1 µg) was found to be inadequate in terms of sensitivity, but excellent in terms 
of specificity. MLSA-LAM was shown to have slightly higher specificity than MLCwA at the 
low dose when comparing BT/TT leprosy patients against individuals infected with M. 
tuberculosis. At the high dose (1.0 µg) both antigens were limited in both sensitivity and 
specificity. Leprosy skin test antigens were found to be unresponsive in BL/LL leprosy patients 
confirming M. leprae specific anergy, yet capable of eliciting a response in some HC of BL/LL 
leprosy patients advocating promise for these antigens as early diagnostic tools for leprosy. A 
cut-off point for each antigen and antigen dose could not be determined with significance, due to 
limited positive responders in the BT/TT leprosy group.  
Sensitivity and specificity were lacking with the Rees and Convit soluble antigens when 
tested in 2,602 Indian subjects. [20] A biomodal distribution of induration was seen with both 
antigens, but newly diagnosed leprosy patients, contacts, and non-contacts responded equally. In 
Northern Malawi, 15,630 subjects were tested with 5 batches of the Rees MLSA antigen 




paucibacillary (similar to BT/TT) [22] leprosy patients was seen in 76% and 38% of the subjects, 
respectively; however, endemic controls responded in 42% and 32% of the subjects, resulting in 
a difference of 34% and 6% detection rates, respectively. These percentages represent responders 
over baseline and are close to the 10-20% detection rates seen with low dose MLSA-LAM and 
MLCwA antigens.  
The low detection rate of known BT/TT leprosy patients with these antigens suggests that 
they are not suitable for detection of clinical leprosy.  They do however; elicit a response in 10-
20% of HC suggesting that they might be suitable for detection of subclinical leprosy. The 
proportion of positive HC responding in these studies was consistent with documented risk of 
infection from a high bacillary index case at one in seven (14%) of 178 households studied. [23] 
Whole blood IFN-γ assay studies with MLSA-LAM and MLCwA showed nearly identical 
results to these skin test studies, except that HC responded with a higher geometric mean than 
BT/TT leprosy patients; EC and TB patients did not respond. [24] The authors also found that 
recent exposure resulted in substantially stronger responses.  
At the high dose compared to the low dose, both antigens elicited a response in a higher 
number of HC, TB, and EC subjects, but the number of BT/TT responders remained the same. 
These phenomena maybe related to that observed when Leprosin A (Rees antigen) was shown to 
immunologically suppress the skin test response to Tuberculin PPD in both BT/TT and BL/LL 
leprosy patients. [25] This data supports the idea that there may be a difference in the antigenic 
profile that stimulates a response in subclinical, but not clinical leprosy.   
The immunological environment of subclinical leprosy is unknown; however, advances have 
been made in understanding the innate and adaptive immune mediated pathways that promote 




immunity, which provides a window to establish a successful infection. Disease progression in 
tuberculosis, like leprosy, is then dependent on the immunological status of the host. [28]. 
Striking similarities of the immunology and pathology between these two diseases suggest that 
TT leprosy could be a latent form of disease, under the control of the immune system, whereas 
LL leprosy is known to be the active form of disease with T-cell hyporesponsiveness. [29] 
Borderline forms are immunologically unstable and can downgrade depending on the 
immunologically position of the host. [17] This continuum of immunological events probably 
occur prior to and during manifestation of clinical symptoms, providing opportunities for a 
subclinical diagnostic tool. 
Antigen specificity at the low dose was thought to be related to the removal of lipoglycans, 
including the immunosuppressive and cross-reactive LAM, LM, PIM, and other lipids and 
lipoproteins. [30-32] Remaining proteins were numerous, but many shared sequence homology 
with M. tuberculosis. [33] Nonetheless, of the 100 EC tested, 77% had been vaccinated with 
BCG and 67% reacted with Tuberculin PPD, while only 2% reacted to the low dose leprosy 
antigens (2 with MLSA-LAM and 0 with MLCwA). Of the 20 TB subjects tested in the phase II, 
stage C-1b study, 95% (n=19) reacted to Tuberculin PPD, but only 10% (n=2) reacted to 
MLCwA and none reacted to MLSA-LAM. Another possibility is that the dose alone, or in 
combination with the removal of lipoglycans resulted in high specificity. At the low dose, M. 
leprae specific proteins may be available for recognition; whereas at the high dose those same 
proteins may be overpowered by ubiquitous mycobacterial proteins lending to cross-reactive 
responses with TB patients and EC exposed to environmental mycobacteria or vaccinated with 




The IGRA test and PGL antibody test did exhibit both sensitivity and specificity and when 
combined demonstrated enhanced sensitivity for detecting both tuberculoid and lepromatous 
leprosy patients in both known patients and household contacts.  The skin test assay was 
compared to an interferon-gamma release assay and PGL antibody assay to see if either or a 
combination of in vitro tests could provide an alternative to the in vivo skin test.  The interferon 
test at the high dose was found to be highly specific for tuberculoid leprosy patients and the low 
dose was found to be reasonably sensitive.  A dose optimization between the high and low dose 
may lead to a single dose that is both sensitive and specific for detecting tuberculoid leprosy.  
The PGL antibody test was found to be both sensitive and specific for lepromatous leprosy at a 
particular cut off value.  The combination of the interferon and PGL antibody test was found to 
be synergistic in detecting known leprosy patients. 
The strength of these studies was in the verification that new refined leprosy skin test 
antigens were immunologically potent in BT/TT leprosy patients, anergic in BL/LL leprosy 
patients, and highly specific in BT/TT leprosy patients. The skin test method was simple, easy 
for field use, and minimally invasive, affording a feasible early diagnostic test tool. Limitations 
of these studies were difficulties shipping materials through customs, lengthy document review 
and approvals, multiple stages in the phase II protocol; prolonged duration to complete the study; 
political turmoil in the endemic country; and, intermittent communication services. Likewise, 
clues regarding efficacy were somewhat stymied by lack of subject numbers. Although the 
decrease in subject numbers was decided based on pragmatic reasons, increased numbers as 
established for the original study for statistical significance could have been achieved and would 




As a result of these studies, the MLSA-LAM antigen at the 0.1 µg dose was found to be the 
best skin test antigen candidate and although the test configuration resulted in  exceptional 
specificity it was paired with extremely poor sensitivity.  Since sensitivity did not increase with 
the higher dose, optimizing the dose will probably not help improve the accuracy of the skin test 
diagnostic.  The interferon release assay also favored the MLSA-LAM antigen at the 0.1 µg dose 
for sensitivity, but the 1.0 µg dose for specificity.  Antigen concentration optimization should 
result in an improved diagnostic test with one antigen concentration.  Finally, this study 
confirmed the sensitivity and specificity of PGL antibody assay in detecting clinical lepromatous 
leprosy; however, it also provides information of cut off values that may aid in enhancing 
specificity for use as an early diagnostic tool to complement a cell mediated diagnostic for 
detecting tuberculoid subjects.   Albeit monumental, the definitive goal of developing an early 
diagnostic test for leprosy is to detect lepromatous leprosy patients early, because they are at 
greater risk of developing disabilities and spreading disease.  This study suggests that combining 
an optimized interferon assay with the PGL assay provides an alternative to an in vivo test with 
the most potential for detecting early infection. 
Further testing in a large scale randomized study of HC with follow-up is needed to reveal 
whether these skin test antigens could tip the balance toward intercepting transmission. Inclusion 
of a dose optimization study may improve sensitivity, but compromise specificity. Combinatorial 
testing of the skin test method against the in vitro IFN-γ test and phenolic glycolipid-I (PGL-I) 
antibody test may provide options to enhance sensitivity. [34] Recent testing of multiple proteins 
and peptides using the IFN-γ assay has shown promising results. [35-37] Finally, use of these 
skin test antigens may help in elucidation of the early immunological response following 
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CHAPTER FIVE: CONCLUSIONS  
 
SUMMARY 
Translation of two new leprosy skin test antigens, MLSA-LAM and MLCwA, under the 
Leprosy Skin Test Initiative has been completed. Achievements are outlined in Table 12. Both 
antigens and antigen dosages (0.1 µg and 1.0 µg) were found to be safe for use in humans and 
were highly specific for tuberculoid leprosy, but lacked sensitivity for tuberculoid and 
lepromatous leprosy. Due to small sample sizes and limited response by tuberculoid leprosy 
patients to the skin test antigens, efficacy results were not statistically significant and therefore 
are presented only as promising trends. 
Several other important findings were identified.  Firstly, lepromatous leprosy patients were 
anergic to these M. leprae specific antigens, as expected.  Secondly, the response to both skin 
test antigens correlated reasonably well at the low dose, but not at the high dose; and, the 
response to PPD did not correlate with either leprosy antigen at either dose, even though most 
subjects across all groups recognized PPD. Thirdly, the interferon gamma release method using 
both antigens at the high dose provided the best diagnostic accuracy. Finally, the PGL Antibody 
Assay was a very good diagnostic test for lepromatous leprosy patients, which were not detected 
with the skin test or interferon test.   
In summary, both new leprosy antigens were found to be specific to tuberculoid leprosy 
patients at the low dose.  This is the first documented report of a specific leprosy skin test 
antigen.  Recognition of high specificity was likely the result of using a low dose and the 
removal of cross-reactive lipoglycans.  Although specific, they were not adequately sensitive. 




of diagnostic antigens in these preparations, or poor choice of test method; however, household 
contacts did respond at a rate which aligns with infectivity noted in the literature.  Overall, 
MLSA-LAM low dose showed better specificity in the skin test, but the MLSA-LAM high dose 
provided the best diagnostic accuracy in the interferon assay.  The PGL-I Antibody assay 
showed good diagnostic accuracy for lepromatous patients, but the cut off value is qualitative 
using the lateral flow immunodiagnostic kit.   
EVALUATION 
The results of this research partially prove the hypothesis that the new leprosy skin test 
antigens, MLSA-LAM and MLCwA, at doses of 1.0μg and/or 0.1μg, would be safe and 
efficacious as diagnostic- tools to detect leprosy and allow treatment of patients earlier and to 
measure the extent of leprosy infection in human subjects living in a leprosy endemic area.  
Specific aim 1 findings supported the safe use of these antigens and antigen dosages in 
leprosy patients, household contacts of leprosy patients, and tuberculosis patients living in an 
endemic region for leprosy. Moreover, in the small sample size studies, both antigens were found 
to be specific for tuberculoid leprosy, but not specific as skin test antigens when evaluating 
clinical leprosy patients who were either being treated concurrently or had completed treatment 
for leprosy. Both antigens at both dosages did elicit a response in some household contacts, 
suggesting that these antigens might be possible candidates for early diagnostic tools for leprosy. 
Specific aim 2 was successfully completed the comparison of the skin test method against the 
IGRA and PGL Antibody Assay.  These studies suggested that the IGRA with MLSA-LAM low 
dose was the best antigen, dose, and test method provided the best diagnostic accuracy for 





Table 12. Leprosy Skin Test Initiative Achievements 
Stage Date Task 
Discovery 1992 Target antigens identified 
Draft IND 
January, 1994 Submitted to Sponsor 
April 20, 1994 FDA comments received 
Manufacturing May 12, 1997 
Clinical grade MLSA-LAM and 
MLCwA 
Investigator’s Brochure September 18, 1998 Submitted to Sponsor 
Final IND/Phase I Protocol September 23, 1998 Submitted to Sponsor 
Phase I 
December 28, 1998 Trial commenced 
February 16, 1999 Trial completed 
June 7, 1999 Final Report 
Phase II Protocol June 25, 2001 
Submitted to Sponsor (version 
6.1) 
Phase II, Stage A 
April 30, 2002 Trial commenced 
July 10, 2002 Trial completed 
September 10, 2002 Safety Monitoring Report 
Phase II Protocol October 29, 2002 Amendment (version 6.2) 
Phase II, Stage B 
May 11, 2003 Trial commenced 
January 6, 2004 Trial completed 
August 31, 2004 Safety Monitoring Report 
Phase II Protocol March 8, 2006 Amendment (version 7.0) 
Phase II, Stage C-1a December 12, 2006 Trial commenced 
Phase II Protocol May 25, 2007 Amendment (version 8.0) 
Phase II, Stage C-1a 
March 30, 2008 Trial completed 
September 25, 2008 Safety Monitoring Report 
Phase II Protocol March 2, 2009 Amendment (version 9.0) 
Phase II, Stage C-1b 
May 27, 2009 Trial commenced 
September 13, 2009 Trial completed 
Final Clinical Study Report February 17, 2012 
Submitted to Study Sponsor by 
the Data Coordinating Center 
 
the IGRA method; however, the PGL Antibody Assay showed promise using a high cut off 




Antibody Assay as a primary epidemiological screen,  following up with MLSA-LAM low dose 
skin test for confirmation of tuberculoid leprosy patients provides an option.  Moreover, 
optimization of MLSA-LAM concentration in the IGRA may improve diagnostic accuracy in 
both areas of sensitivity and specificity. 
Specific aim 3 was successfully completed by translating these two skin test antigens in an 
academic environment; moving the antigens from the bench to clinical trials to assess their utility 
as safe and efficacious diagnostic tools. Although the early steps of product translation were not 
covered under the auspice of his dissertation, the reporting of the translational process was a 
culmination of this research. This research proves that the translation of a product from 
discovery, through manufacturing under cGMP, submission of an IND, and testing products in 
human clinical trials can be done under government sponsorship in a university setting. 
Likewise, the teaching potential for such an endeavor is tremendous for undergraduate and 
graduate students leaving the university with an interest in pharmaceutical drug discovery.   
FUTURE DIRECTIONS 
Results from these research studies provide new translational knowledge and opportunities 
for further investigation and combinatorial approaches to reach the unmet need of developing 
and implementing an early diagnosis test for leprosy.  Further testing is required to optimize the 
IGRA dose to increase sensitivity, while maintaining reasonable specificity. Once optimized and 
proof of concept has been appropriately tested in clinical studies, the combination of the IGRA 
and PGL-I Antibody Assay may provide epidemiological value to assess the true incidence of 







APPENDIX 1: PHASE II CLINICAL SITE, STAFF, AND LEPROSY PATIENTS 
PHOTOGRAPHS 
A) Anandaban Hospital, Kathmandu, Nepal.  Site of Phase II, Stage C Clinical Trial.  
Founded in 1957 by The Leprosy Mission International (TLMI) as the main referral hospital for 
leprosy in the central region of Nepal. B) Leprosy patient with hand neuropathy and bone 
resorption, which may require surgery and physical therapy, C) Leprosy patient with foot support 
to assist with movement and prevent further disabilities, D) Dr. Rachel Hawksworth, Clinical 






CONTINUED APPENDIX 1 
A) Dr. Yadav (Internal Safety Monitor) and Dr. Gelber (Safety Monitoring Committee, Chair) at 
Patan Hospital, where tuberculosis patients were recruited, B) Mr. Kapil Neupane, Administrator 
and Gold Standard reader, C) Mrs. Bangdel (Radha Bangdel, Assistant, Lalitpur Nursing 
College, Sanepa, Kathmandu), Dr. Murdo Macdonald (Clinical Study Coordinator, Anandaban 
Hospital), and Dr. Patrick Brennan (Research Principal Investigator) standing in the 
injection/reading room, which is adjacent to an exit into the courtyard where an ambulance was 
stationed during the study, and E) Skin test injectors and readers from left to right:  HA 
Krishnaman Shrestha, LT Subash C. Silwal (not shown), LT Ishwor Raj Shrestha, Sr. Niru 








APPENDIX 2: CHAPTER THREE SUPPLEMENTARY DATA  
 








Intervention Rees Saline 
0.1 µg 1.0 µg 2.5 µg 1.0 µg N/A 
2 1 MLCwA 0 0 0 0 0 
3 2 MLCwA 0 0 0 0 0 
6 3 MLCwA 0 0 9 7 0 
8 4 MLCwA 0 0 0 0 0 
10 5 MLCwA 0 0 0 0 0 
1 6 
MLSA-
LAM 0 0 0 0 0 
4 7 
MLSA-
LAM 0 0 0 0 0 
7 8 
MLSA-
LAM 0 0 0 0 0 
9 9 
MLSA-
LAM 0 0 0 0 0 
11 10 
MLSA-
LAM 0 0 0 0 0 
The 48 and 72 hour induration measurements were very similar and since the 48 hour response 
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 Intervention  Tuberculin Saline 
 0.1 µg 1.0 µg 5TU N/A 
 2 1 MLCwA 0 0 0 0 * 
3 2 MLCwA 0 0 31 0 *** 
5 3 MLCwA 0 0 21 0 *** 
6 4 MLCwA 0 16.5 19 0 **** 
9 5 MLCwA 0 0 11 0 *** 
1 6 
MLSA-
LAM 0 0 21 0 *** 
4 7 
MLSA-
LAM 0 0 10 0 *** 
7 8 
MLSA-
LAM 0 0 34 0 *** 
8 9 
MLSA-
LAM 0 20 0 0 ** 
10 10 
MLSA-
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 Intervention  Tuberculin 
 0.1 µg 1.0 µg 5TU 
 12 6 MLCwA 0 0 19.5 *** 
16 7 MLCwA 0 0 0 * 
18 8 MLCwA 0 0 18.5 *** 
19 9 MLCwA 0 17 17.5 **** 
20 10 MLCwA 0 8.5 14.5 **** 
22 11 MLCwA 0 16.5 25 **** 
24 12 MLCwA 0 7 28 **** 
25 13 MLCwA 0 9 8.5 **** 
26 14 MLCwA 0 0 21 *** 
29 15 MLCwA 0 0 0 * 
33 16 MLCwA 0 0 19 *** 
34 17 MLCwA 0 0 13.5 *** 
35 18 MLCwA 0 0 0 * 
36 19 MLCwA 0 0 34 *** 
40 20 MLCwA 0 0 29 *** 
41 21 MLCwA 0 0 21 *** 
42 22 MLCwA 0 0 20 *** 
44 23 MLCwA 0 0 30 *** 
47 24 MLCwA 0 0 0 * 
50 25 MLCwA 0 0 19.5 *** 
53 26 MLCwA 0 3.5 14.5 **** 
54 27 MLCwA 0 0 14 *** 
56 28 MLCwA 0 0 0 * 
57 29 MLCwA 0 0 0 * 
59 30 MLCwA 0 0 0 * 
64 31 MLCwA 0 0 27.5 *** 
65 32 MLCwA 0 0 0 * 
66 33 MLCwA 0 0 16 *** 
68 34 MLCwA 0 0 0 * 
70 35 MLCwA 0 0 10 *** 
71 36 MLCwA 0 0 20 *** 
72 37 MLCwA 0 0 19 *** 
75 38 MLCwA 0 0 9 *** 
79 39 MLCwA 0 0 12 *** 











 Intervention  Tuberculin 
 0.1 µg 1.0 µg 5TU 
 81 41 MLCwA 0 0 0 * 
82 42 MLCwA 0 0 0 * 
85 43 MLCwA 0 0 0 * 
86 44 MLCwA 0 7 0 ** 
90 45 MLCwA 0 0 0 * 
91 46 MLCwA 0 0 22 *** 
94 47 MLCwA 0 0 10.5 *** 
97 48 MLCwA 0 0 0 * 
99 49 MLCwA 0 0 16.5 *** 
100 50 MLCwA 0 0 0 * 
11 56 MLSA-LAM 0 0 24.5 *** 
13 57 MLSA-LAM 0 0 0 * 
14 58 MLSA-LAM 2.5 4.5 12 **** 
15 59 MLSA-LAM 0 0 0 * 
17 60 MLSA-LAM 0 0 7 *** 
21 61 MLSA-LAM 0 0 15.5 *** 
23 62 MLSA-LAM 0 8 9.5 **** 
27 63 MLSA-LAM 0 0 9.5 *** 
28 64 MLSA-LAM 0 0 11 *** 
30 65 MLSA-LAM 0 0 17.5 *** 
31 66 MLSA-LAM 0 0 0 * 
32 67 MLSA-LAM 0 8.5 12.5 **** 
37 68 MLSA-LAM 0 0 19 *** 
38 69 MLSA-LAM 0 0 0 * 
39 70 MLSA-LAM 0 10.5 13 **** 
43 71 MLSA-LAM 7.5 22.5 27 **** 
45 72 MLSA-LAM 0 0 9 *** 
46 73 MLSA-LAM 0 0 22 *** 
48 74 MLSA-LAM 0 0 0 * 
49 75 MLSA-LAM 0 0 13.5 *** 
51 76 MLSA-LAM 0 0 16.5 *** 
52 77 MLSA-LAM 0 0 0 * 
55 78 MLSA-LAM 0 0 0 * 
58 79 MLSA-LAM 0 0 18 *** 
60 80 MLSA-LAM 0 0 13.5 *** 
61 81 MLSA-LAM 0 0 11 *** 
62 82 MLSA-LAM 0 0 0 * 











 Intervention  Tuberculin 
 0.1 µg 1.0 µg 5TU 
 67 84 MLSA-LAM 0 0 18 *** 
69 85 MLSA-LAM 0 0 0 * 
73 86 MLSA-LAM 0 0 26 *** 
74 87 MLSA-LAM 0 0 25 *** 
76 89 MLSA-LAM 0 11.5 0 ** 
77 90 MLSA-LAM 0 0 0 * 
78 91 MLSA-LAM 0 0 0 * 
83 92 MLSA-LAM 0 8.5 10 **** 
84 93 MLSA-LAM 0 0 0 * 
87 94 MLSA-LAM 0 0 7.5 *** 
89 95 MLSA-LAM 0 0 0 * 
92 96 MLSA-LAM 0 0 15 *** 
93 97 MLSA-LAM 0 0 19.5 *** 
95 98 MLSA-LAM 0 0 13.5 *** 
96 99 MLSA-LAM 0 3.5 13 **** 
98 100 MLSA-LAM 0 0 0 * 
101 101 MLSA-LAM 0 7 15 **** 
In the phase II, stage A study, the 48 and 72 hour induration measurements were very similar, 
and since the 48 hour response was dropped from stage B, only the 72 hour values are provided 
for comparison.  (*) a total of 30 individuals did not respond to either the intervention or to 
Tuberculin PPD, (**) a total of 3 individuals responded to one or the other antigens, but not 
Tuberculin, (***) a total of 52 individuals responded to Tuberculin PPD only, and (****) a total 






APPENDIX 3: CHAPTER FOUR SUPPLEMENTARY DATA 
Maximum Reactogenicity
a
 by Subject Across all Visits (BT/TT) 
a
 Maximum reactogenicity is the no. of subjects exhibiting specific reactions across all visits.  
 
  
BT/TT No. Subjects with Reactions Across All Study Visits 
 









1.0 µg 1.0 µg 5 TU 0.1 µg 0.1 µg 2 TU 
Induration 
2 3 12 (1-
AE) 
4 5 13 
Erythema 4 5 13 (2-
AE) 
5 8 14 
Pruritis (itching) 0 1 5 1 2 8 
Pain 0 1 7 0 0 1 
Bleeding 0 0 0 0 0 0 
Urticaria (hives) 0 0 0 0 0 0 
Infection 0 0 0 0 0 0 
Blistering 0 0 0 0 0 0 
  Total No. Sites 20 20 20 20 20 20 
  Total No. 
Events 
6 10 37 10 15 36 




CONTINUED APPENDIX 3 
Maximum Reactogenicity
a
 by Subject Across all Visits (BL/LL) 
a
 Maximum reactogenicity is the no. of subjects exhibiting specific reactions across all visits.  
 
  
BL/LL No. Subjects with Reactions Across All Study Visits 
 









1.0 µg 1.0 µg 5 TU 0.1 µg 0.1 µg 2 TU 
Induration 1 0 11 0 0 7 
Erythema 2 2 12 (2-AE) 4 4 10 
Pruritis (itching) 0 0 5 0 0 0 
Pain 1 1 6 0 0 3 
Bleeding 0 0 0 0 0 0 
Urticaria (hives) 0 0 0 0 0 0 
Infection 0 0 0 0 0 0 
Blistering 0 0 2 (2-AE) 0 0 0 
  Total No. Sites 20 20 20 20 20 20 
  Total No. 
Events 
4 3 36 4 4 20 
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Maximum Reactogenicity
a
 by Subject Across all Visits (HC) 
a
 Maximum reactogenicity is the no. of subjects exhibiting specific reactions across all visits.  
  
HC No. Subjects with Reactions Across All Study Visits 
 









1.0 µg 1.0 µg 5 TU 0.1 µg 0.1 µg 2 TU 
Induration 5 10 16 2 4 16 (1-AE) 
Erythema 11 8 17 (1-AE) 4 6 17 (1-AE) 
Pruritis (itching) 4 5 9 1 1 5 
Pain 1 1 5 1 0 3 
Bleeding 0 0 0 1 0 0 
Urticaria (hives) 0 0 0 1 0 0 
Infection 0 0 0 1 0 0 
Blistering 0 0 1 1 0 1 (1-AE) 
  Total No. Sites 20 20 20 20 20 20 
  Total No. 
Events 
21 24 48 12 11 42 
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Maximum Reactogenicity
a
 by Subject Across all Visits (TB) 
a
 Maximum reactogenicity is the no. of subjects exhibiting specific reactions across all visits.  
 
  
TB No. Subjects with Reactions Across All Study Visits 
 









1.0 µg 1.0 µg 5 TU 0.1 µg 0.1 µg 2 TU 
Induration 8 9 18 0 3 19 
Erythema 12 14 20 (2-AE) 2 5 20 (1-AE) 
Pruritis (itching) 1 6 14 0 0 12 
Pain 0 2 9 0 0 3 
Bleeding 0 0 0 0 0 0 
Urticaria (hives) 1 0 0 0 0 0 
Infection 1 0 0 0 0 0 
Blistering 1 0 0 0 0 0 
  Total No. Sites 20 20 20 20 20 20 
  Total No. 
Events 
24 31 61 2 8 54 
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Stage C-1a (Antigen High Dose) Induration at 72 h 
Stage 
C-1 a BT/TT 
Stage 








LAM PPD Rxn 
1 0 0 18 *** 1 0 20 0 ** 
2 0 0 19.5 *** 2 0 0 0 * 
3 0 0 0 * 3 0 0 29.5 *** 
4 0 0 28.5 *** 4 0 0 28 *** 
5 0 0 0 * 5 0 0 0 * 
6 21.5 23 27.5 **** 6 0 0 11 *** 
7 0 0 11.5 *** 7 0 0 0 * 
8 0 0 28 *** 8 0 0 18 *** 
9 0 0 0 * 9 0 0 19.5 *** 
10 0 0 24 *** 10 0 0 16 *** 
11 0 0 18.5 *** 11 0 0 11 *** 
12 0 0 19.5 *** 12 0 0 22.5 *** 
13 0 0 19.5 *** 13 0 0 0 * 
14 0 0 16.5 *** 14 0 0 0 * 
15 0 0 0 * 15 0 0 0 * 
16 0 0 0 * 16 0 0 13.5 *** 
17 0 0 13 *** 17 0 0 0 * 
18 0 0 0 * 18 0 0 13 *** 
19 20 19.5 0 ** 19 0 0 0 * 
20 19 0 0 ** 20 0 0 16 *** 
Mean 3.03 2.13 12.20 
  
Mean 0.00 1.00 9.90 
  
Median 0.00 0.00 14.75 Median 0.00 0.00 11.00 
Std 
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Stage 
C-1 a HC 
Stage 










1 0 0 15.5 *** 1 14 8 20 **** 
2 13 0 15.5 **** 2 14.5 0 15 **** 
4 11.5 15.5 22.5 **** 3 0 0 22 *** 
5 0 0 0 * 4 0 0 21 *** 
6 0 0 18 *** 5 0 0 22 *** 
7 0 0 16.5 *** 6 13 10 17 **** 
8 11.5 0 8 **** 7 15.5 0 7.5 **** 
9 0 5.5 11.5 **** 8 0 20 25 **** 
10 15 0 26.5 **** 9 0 0 18.5 *** 
11 0 0 11.5 *** 10 26.5 18 28 **** 
12 16.5 15 16 **** 11 18.5 17.5 23 **** 
13 17.5 0 9.5 **** 12 0 15.5 25 **** 
14 0 0 21 *** 13 0 0 0 * 
15 7.5 0 10.5 **** 14 0 0 17.5 *** 
16 9.5 0 0 ** 15 10 0 18.5 **** 
17 24 23.5 26 **** 16 10.5 10 18.5 **** 
18 0 0 22.5 *** 17 0 0 0 * 
19 0 0 0 * 18 9 0 24 **** 
20 14.5 12.5 16 **** 19 0 0 16.5 *** 
21 0 0 24 *** 20 0 0 22 *** 
Mean 7.03 3.60 14.55   Mean 6.58 4.95 18.05   
Median 3.75 0.00 15.75 Median 0.00 0.00 19.25 
Std 




Error + 1.84 + 1.66 + 1.70 
95% 
CI + 3.46 + 3.09 
+ 
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Stage C-1b (Antigen Low Dose) Induration at 72 h 
Stage 
C-1 b BT/TT 
Stage 








LAM PPD Rxn 
21 0 0 0 * 21 0 0 9.5 *** 
22 0 0 12 *** 22 0 0 24.5 *** 
23 0 0 15 *** 23 0 0 18 *** 
24 0 0 17 *** 24 0 0 23 *** 
25 0 0 0 * 25 0 0 0 * 
26 14.5 10.5 0 ** 26 0 0 0 * 
27 0 0 20 *** 27 0 0 19.5 *** 
28 0 0 22.5 *** 28 0 0 10 *** 
29 0 0 25 *** 29 0 0 0 * 
30 0 0 7 *** 30 0 0 0 * 
31 20 18 16 *** 31 0 0 0 * 
32 0 0 20 *** 32 0 0 0 * 
33 0 0 21 *** 33 0 0 0 * 
34 17.5 12.5 0 ** 34 0 0 0 * 
35 0 0 22 *** 35 0 0 0 * 
36 11 15 18 **** 36 0 0 0 * 
37 0 0 0 * 37 0 0 25 *** 
38 0 0 0 * 38 0 0 0 * 
39 0 0 0 * 39 0 0 0 * 
40 11 0 15.5 **** 40 0 0 0 * 
Mean 3.70 2.80 11.55 
 
Mean 0.00 0.00 6.48 
 
Median 0.00 0.00 15.25 Median 0.00 0.00 0.00 
Std 
Error 1.53 1.32 2.13 
Std 
Error 0.00 0.00 2.18 
95% CI + 2.99 + 2.58 
+ 
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Stage 
C-1 b HC 
Stage 










22 0 0 21 *** 21 0 0 20 *** 
23 0 0 0 * 22 0 0 17 *** 
24 0 0 6.5 *** 23 0 0 17 *** 
25 0 0 26 *** 24 6 0 20.5 **** 
26 0 0 8 *** 25 0 0 19.5 *** 
27 0 0 0 * 26 0 0 20.5 *** 
28 0 0 16 *** 27 0 0 19 *** 
29 0 0 9 *** 28 0 0 20 *** 
30 0 0 19.5 *** 29 0 0 0 * 
31 0 0 18 *** 30 0 0 17.5 *** 
32 0 0 9.5 *** 31 0 0 25 *** 
33 0 0 40 *** 32 0 0 28.5 *** 
34 10 11.5 20 **** 33 0 0 17.5 *** 
35 0 0 15 *** 34 0 0 16.5 *** 
36 5 0 15 *** 35 0 0 14 *** 
37 0 0 20.5 *** 36 9 0 20 **** 
38 0 0 0 * 37 0 0 21 *** 
39 0 0 0 * 38 0 0 25 *** 
40 15 10 18.5 **** 39 0 0 25 *** 
41 16 0 18.5 **** 40 10 0 30 **** 
Mean 2.30 1.08 14.05   Mean 1.25 0.00 19.68   
Median 0.00 0.00 15.50 Median 0.00 0.00 20.00 
Std 




Error + 0.70 + 0.00 
+ 
1.38 
95% CI + 2.25 + 1.45 
+ 
4.45 95% CI + 1.37 + 0.00 
+ 
2.71 
Response patterns for individual subjects have been marked (*) no reaction to either intervention 
or PPD, (**) reaction to one or both interventions, but not to PPD, (***)  reaction to PPD only, 
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EC 2/50 4.0 na na 0.2 na na 
BT/TT 4/20 20.0 20.0/4.0 5.0 2.8 2.8/0.2 14.0 
BL/LL 0/20 0.0 0.0/4.0 0.0 0.0 0.0/0.2 0.0 
HC 2/20 10.0 10.0/4.0 2.5 1.1 1.1/0.2 5.5 
TB 0/20 0.0 0.0/4.0 0.0 0.0 0.0/0.2 0.0 
MLCwA 
 Low Dose 
EC 0/50 1.0
a
 na na 0.1
 a
 na na 
BT/TT 5/20 25.0 25.0/1.0 25.0 3.7 3.7/0.1 37.0 
BL/LL 0/20 0.0 0.0/1.0 0.0 0.0 0.0/0.1 0.0 
HC 4/20 20.0 20.0/1.0 20.0 2.3 2.3/0.1 23.0 
TB 3/20 15.0 15.0/1.0 15.0 1.3 1.3/0.1 13.0 
MLSA-LAM 
High Dose 
EC 10/50 20.0 na na 2.1 na na 
BT/TT 2/20 10.0 10.0/20.0 0.5 2.1 2.1/2.1 1.0 
BL/LL 1/20 5.0 5.0/20.0 0.3 1.0 1.0/2.1 0.48 
HC 5/20 25.0 25.0 /20.0 1.3 3.6 3.6/2.1 1.7 
TB 7/20 35.0 35.0 /20.0 1.8 5.0 5.0/2.1 2.4 
MLCwA 
 High Dose 
EC 8/50 16.0 na na 1.7 na na 
BT/TT 3/20 15.0 15.0/16.0 0.9 3.0 3.0/1.7 1.8 
BL/LL 0/20 0.0 0.0/16.0 0.0 0.0 0.0/1.7 0.0 
HC 10/20 50.0 50.0/16.0 3.1 7.0 7.0/1.7 4.1 
TB 9/20 45.0 45.0/16.0 2.8 6.6 6.6/1.7 3.9 
a 
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Whole Blood IGRA Data 
Stage C-1a (Antigen High Dose) 
Stage C-1a 
TD Raw Data (IFN-γ IU/ml) 





LAM PPD Aim V MLCwA 
MLSA-
LAM PPD 
1 0 0 1.22 0 0 0 1.22 
2 0 0 5.32 0 0 0 5.32 
3 0 0 0.66 0 0 0 0.66 
4 0 0.17 8.37 0 0 0.17 8.37 
5 1.28 1.18 2.05 0 1.28 1.18 2.05 
6 9.11 8.41 9.99 0.83 8.28 7.58 9.16 
7 1.52 1.53 9.99 0.49 1.03 1.04 9.5 
8 9.99 9.99 9.99 9.999 0 0 0 
9 0.31 0.49 1.44 0.51 -0.2 -0.02 0.93 
10 0.25 0.13 7.43 0 0.25 0.13 7.43 
11 0.48 0.69 3.84 0.54 0 0.15 3.3 
12 0.63 0.78 9.99 0.55 0.08 0.23 9.44 
13 0.52 0.33 1.17 0.82 -0.3 -0.49 0.35 
14 0.48 0.55 1.38 0.47 0.01 0 0.91 
15 0.31 0.35 0 0.15 0.16 0.2 -0.15 
16 0 0 0 0 0 0 0 
17 0 0 1.09 0 0 0 1.09 
18 1.99 5.69 2.72 1.52 0.47 4.17 1.2 
19 0.58 0.94 1.28 0 0.58 0.94 1.28 
20               
Mean         0.61  0.80  3.3  
Median          0.00 0.13  1.20  
Std 
Error         + 0.44 + 0.44 + 0.83 
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Stage C-1a 
LP Raw Data (IFN-γ IU/ml) 





LAM PPD Aim V MLCwA 
MLSA-
LAM PPD 
1 0 0 9.99 0 0 0 9.99 
2 0 0 1 0 0 0 1 
3 0.67 0.13 9.99 0.59 0 -0.46 9.4 
4 0.15 0 9.99 0 0.15 0 9.99 
5 1.52 0.75 5.54 0.2 1.32 0.55 5.34 
6 3.09 2.1 9.99 2.64 0.45 -0.54 7.35 
7 0.66 1 0.98 0.54 0.12 0.46 0.44 
8 0.52 0.4 3.74 0.27 0.25 0.13 3.47 
9 0.12 0 0.76 0 0.12 0 0.76 
10 0.44 0.28 0.58 0.16 0.28 0.12 0.42 
11 0 0 0 0 0 0 0 
12 1.18 1.04 5.3 0.67 0.51 0.37 4.63 
13 0 0 0 0 0 0 0 
14 0 0 0 0 0 0 0 
15 0.25 0.25 0.24 0.45 -0.2 -0.2 -0.21 
16 1.21 0.65 2.41 1.2 0.01 -0.55 1.21 
17 0.14 0.16 0.55 0 0.14 0.16 0.55 
18 0.29 0.27 6.38 0.21 0.08 0.06 6.17 
19               
20 0.42 0.36 6.72 0.52 -0.1 -0.16 6.2 
Mean         0.16 0.00 3.50 
Median         0.08 0.00 1.20 
Std 
Error         + 0.08 + 0.07 + 0.86 
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Stage C-1a 
HC Raw Data (IFN-γ IU/ml) 





LAM PPD Aim V MLCwA 
MLSA-
LAM PPD 
1 5.62 4.93 9.99 1.26 4.36 3.67 8.73 
2 0.64 0.7 3.04 0 0.64 0.7 3.04 
4 2.42 1.48 9.99 0.67 1.75 0.81 9.32 
5 0 0 0.53 0.16 -0.16 -0.16 0.37 
6 0.12 0 3.98 0 0.12 0 3.98 
7 0.57 0 0.4 0.28 0.29 -0.28 0.12 
8 1.47 2.06 3.09 0.93 0.54 1.13 2.16 
9 0 0 0.3 0 0 0 0.3 
10 0.24 0 0 0.71 -0.47 -0.71 -0.71 
11 0.32 0.54 0.97 0.16 0.16 0.38 0.81 
12 0.56 0.35 1.23 0.13 0.43 0.22 1.1 
13 0.67 0.58 2.61 0.14 0.53 0.44 2.47 
14 0.16 0.19 2.6 0 0.16 0.19 2.6 
15 0.89 1.11 5.48 0.45 0.44 0.66 5.03 
16 9.99 0.55 1.31 0.46 9.53 0.09 0.85 
17 2.87 3.02 9.99 0.35 2.52 2.67 9.64 
18 0.41 0.43 3.48 0.37 0.04 0.06 3.11 
19 0.64 0.35 1.13 0.67 -0.03 -0.32 0.46 
20 0 0.12 0.13 0.22 -0.22 -0.1 -0.09 
21 0.28 0.24 1.04 0.13 0.15 0.11 0.91 
Mean          1.00 0.48  2.70  
Median          0.23 0.15  1.60  
Std 
Error         + 0.51 + 0.23  + 0.71  
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Stage C-1a 
TB Raw Data (IFN-γ IU/ml) 





LAM PPD Aim V MLCwA 
MLSA-
LAM PPD 
1 0 0 3.36 1.19 -1.19 -1.19 2.17 
2 0.15 0.13 0.64 0.16 -0.01 -0.03 0.48 
3 0.23 0.4 8.99 0.27 -0.04 0.13 8.72 
4 0.17 0.14 5.64 0.19 -0.02 -0.05 5.45 
5 9.99 0.31 9.99 0.35 9.64 -0.04 9.64 
6 0.5 0.5 5.19 0.81 -0.31 -0.31 4.38 
7 0.18 0.2 0.68 0.21 -0.03 0 0.47 
8 0.28 0.28 2.94 0.26 0.02 0.02 2.68 
9 2.4 3.94 4.84 5.13 -2.73 -1.19 -0.29 
10 0.34 0.41 2.56 0.41 -0.07 0 2.15 
11 1.72 2.51 9.99 1.53 0.19 0.98 8.46 
12 0.4 0.33 1.13 0.41 0.00 -0.08 0.72 
13 0.49 0.35 0.42 1.25 -0.76 -0.9 -0.83 
14 0.21 0.2 0.34 0.23 -0.02 -0.03 0.11 
15 0.4 0.36 3.22 0.27 0.13 0.09 2.95 
16 0.41 0.42 3.46 0.29 0.12 0.13 3.17 
17 3.89 2.28 9.69 3.74 0.15 -1.46 5.95 
18 0.22 0.22 2.49 0.22 0 0 2.27 
19 0.27 0.48 0.92 0.76 -0.49 -0.28 0.16 
20 0.22 0.17 2.15 0.2 0.02 -0.03 1.95 
Mean          0.23 -0.21  3.0  
Median          -0.15 -0.03  2.2  
Std Error         + 0.52  + 0.13  + 0.70  






CONTINUED APPENDIX 3 
Stage C-1b (Antigen Low Dose) 
Stage C-1b 
TD Raw Data (IFN-γ IU/ml) 





LAM PPD Aim V MLCwA 
MLSA-
LAM PPD 
21               
22               
23 1.76 1.41 15 0.22 1.54 1.19 14.78 
24 0.54 0.43 3.14 0.23 0.31 0.2 2.91 
25 1.47 1.44 3.06 0.12 1.35 1.32 2.94 
26 15 6.21 12 0.25 14.75 5.96 11.75 
27 1.46 1.84 15 0.12 1.34 1.72 14.88 
28 7.6 6.92 15 0.12 7.48 6.8 14.88 
29 6.62 8.61 15 0.12 6.5 8.49 14.88 
30 1.48 1.44 2.51 0.12 1.36 1.32 2.39 
31 15 15 3.32 0.12 14.88 14.88 3.2 
32 0.12 0.12 11.51 0.12 0 0 11.39 
33 0.98 1.65 10.38 0.21 0.77 1.44 10.17 
34 3.21 44.04 0.25 0.12 3.09 43.92 0.13 
35 0.61 1.79 15 0.12 0.49 1.67 14.88 
36 15 14.75 15 0.12 14.88 14.63 14.88 
37 3.76 5.68 4.48 0.12 3.64 5.56 4.36 
38 4.72 3.24 1.18 0.18 4.54 3.06 1 
39 2.03 1.31 0.77 0.15 1.88 1.16 0.62 
40 0.67 0.6 2.71 0.16 0.51 0.44 2.55 
Mean          4.41 6.32  7.92  
Median         1.71 1.70  7.27  
Std Error         + 1.23  + 2.46  + 1.43  





CONTINUED APPENDIX 3 
Stage C-1b 
LP Raw Data (IFN-γ IU/ml) 





LAM PPD Aim V MLCwA 
MLSA-
LAM PPD 
21 0.39 0.5 8.27 0.14 0.25 0.36 8.13 
22 0.16 0.22 2.48 0.12 0.04 0.1 2.36 
23 1.06 0.28 9.84 0.12 0.94 0.16 9.72 
24 0.65 0.23 15 0.12 0.53 0.11 14.88 
25 0.82 0.36 2.8 0.21 0.61 0.15 2.59 
26 0.28 0.28 1.7 0.13 0.15 0.15 1.57 
27 0.53 0.44 15 0.16 0.37 0.28 14.84 
28 0.26 0.23 1.22 0.12 0.14 0.11 1.1 
29 0.84 1.13 2.49 0.14 0.7 0.99 2.35 
30               
31 2.24 2.21 5.7 0.14 2.1 2.07 5.56 
32 1.63 2.06 4.96 0.12 1.51 1.94 4.84 
33 0.48 0.68 0.48 0.12 0.36 0.56 0.36 
34 0.14 0.23 1.45 0.14 0 0.09 1.31 
35 0.92 0.49 2.24 0.19 0.73 0.3 2.05 
36 0.12 0.12 0.12 0.12 0 0 0 
37 0.9 0.9 15 0.27 0.63 0.63 14.73 
38 2.26 1.43 10.27 0.19 2.07 1.24 10.08 
39 0.98 1.21 3.06 0.31 0.67 0.9 2.75 
40 0.12 0.12 0.12 0.12 0 0 0 
Mean          0.62 0.53  5.22  
Median         0.53  0.28  2.59  
Std Error          + 0.15 + 0.14 + 1.20  





CONTINUED APPENDIX 3 
Stage C-1b 
HC Raw Data (IFN-γ IU/ml) 





LAM PPD Aim V MLCwA 
MLSA-
LAM PPD 
22 15 13.56 15 0.19 14.81 13.37 14.81 
23 4.32 1.57 5.69 0.19 4.13 1.38 5.5 
24               
25               
26               
27 3.03 1.75 5.18 0.12 2.91 1.63 5.06 
28 6.61 6.15 15 0.2 6.41 5.95 14.8 
29 1.22 0.85 1.66 0.12 1.1 0.73 1.54 
30 1.36 1.9 7.85 0.38 0.98 1.52 7.47 
31 3.35 2.79 15 0.12 3.23 2.67 14.88 
32 1.19 0.81 1.88 0.12 1.07 0.69 1.76 
33 3.85 8.14 15 0.12 3.73 8.02 14.88 
34 2.99 3.23 15 0.12 2.87 3.11 14.88 
35 3.36 2.43 9.14 0.13 3.23 2.3 9.01 
36 6.38 0.92 3.32 0.12 6.26 0.8 3.2 
37 0.84 0.56 3.72 0.12 0.72 0.44 3.6 
38 3.5 1.9 3.25 0.44 3.06 1.46 2.81 
39 1.73 1.71 1.81 0.12 1.61 1.59 1.69 
40 5.83 5.74 15 0.37 5.46 5.37 14.63 
41 5.68 12.45 7.16 0.25 5.43 12.2 6.91 
Mean          3.94  3.72 8.08  
Median          3.23 1.63 6.91  
Std Error         + 0.81 + 0.97  + 1.34  





CONTINUED APPENDIX 3 
Stage C-1b 
TB Raw Data (IFN-γ IU/ml) 





LAM PPD Aim V MLCwA 
MLSA-
LAM PPD 
21               
22               
23               
24 10.58 4.27 15 0.29 10.29 3.98 14.71 
25 1.6 1.06 6.28 0.2 1.4 0.86 6.08 
26 1.08 2.02 15 0.26 0.82 1.76 14.74 
27 6.74 2.8 15 0.14 6.6 2.66 14.86 
28 1.3 2.09 6.9 0.24 1.06 1.85 6.66 
29 0.69 0.57 4.28 0.12 0.57 0.45 4.16 
30 0.44 0.46 2.14 0.12 0.32 0.34 2.02 
31 15 4.74 15 0.13 14.87 4.61 14.87 
32 14.38 5.43 15 0.3 14.08 5.13 14.7 
33 0.83 1 9.91 0.15 0.68 0.85 9.76 
34 1.07 0.92 5.1 0.19 0.88 0.73 4.91 
35 0.75 0.94 6.63 0.15 0.6 0.79 6.48 
36 2.14 2.57 15 0.22 1.92 2.35 14.78 
37 1.98 1.37 15 0.27 1.71 1.1 14.73 
38 0.4 0.37 3.83 0.12 0.28 0.25 3.71 
39 0.12 0.12 1.22 0.12 0 0 1.1 
40 9.64 8.41 15 0.19 9.45 8.22 14.81 
Mean          3.86 2.11  9.59  
Median          1.06 1.10 9.76  
Std Error         + 1.24  + 0.54  + 1.30  





CONTINUED APPENDIX 3 
PGL-I Antibody Assay Data 
Reactivity Scale 
0 negative 
1 weak positive 
2 moderate positive 
3 strong positive 
Stage C-1a (Antigen High Dose) 
Stage C-1a – PGL Antibody Results 










1 2 1 1 1 3 1 1 
2 2 2 3 2 0 2 3 
3 2 3 1 4 1 3 3 
4 2 4 3 5 0 4 1 
5 0 5 3 6 1 5 3 
6 3 6 3 7 1 6 1 
7 1 7 3 8 1 7 1 
8 3 8 2 9 3 8 1 
9 3 9 3 10 2 9 3 
10 0 10 3 11 1 10 3 
11 0 11 3 12 1 11 1 
12 3 12 3 13 0 12 0 
13 0 13 3 14 1 13 3 
14 0 14 3 15 0 14 3 
15 0 15 3 16 0 15 0 
16 0 16 3 17 0 16 1 
17 2 17 3 18 0 17 3 
18 1 18 3 19 0 18 0 
19 2 19 3 20 1 19 1 








Median 2 3 1 1 
Std 
Error 
0.28 0.14 0.21 0.26 






CONTINUED APPENDIX 3 
Stage C-1b (Antigen Low Dose) 
Stage C-1b– PGL Antibody Results 













21 0 21 0 22 3 21 0 
22 0 22 3 23 0 22 0 
23 2 23 3 24 0 23 0 
24 3 24 0 25 0 24 2 
25 0 25 3 26 1 25 0 
26 0 26 3 27 0 26 1 
27 3 27 3 28 0 27 0 
28 0 28 3 29 0 28 0 
29 3 29 3 30 1 29 0 
30 0 30   31 0 30 0 
31 3 31 0 32 0 31 1 
32 0 32 3 33 0 32 0 
33 0 33 3 34 0 33 0 
34 3 34 3 35 0 34 0 
35 1 35 0 36 0 35 0 
36 0 36 3 37 0 36 0 
37 1 37 3 38 0 37 0 
38 0 38 3 39 2 38 0 
39 0 39 2 40 0 39 0 








Median 0.00 3.00 0.00 0.00 
Std 
Error 0.29 0.31 0.18 0.12 












One of six centers of the U.S. FDA under the U.S. DHHS.  CBER is 
responsible for assuring the safety, purity, potency, and effectiveness of 
biologics (such as vaccines, blood products, and monoclonal antibodies) 




Formal document created to record specific data during a clinical trial.  





A delayed inflammatory reaction observed 48-72 hours after antigen 
exposure.  TH1 effector cells recognizes the antigen and release cytokines 
IL-2, IFN-γ, and TNF, which act on vascular endothelium causing 
erythema and recruitment of T-cells, phagocytes, fluid, and protein which 
causes a measurable Type IV DTH induration response.    A lack of DTH 




 The international standards for organization provide recommendations 
and guidelines to ensure that products and services are safe, reliable and of 




Macromolecules consisting of lipids and polysaccharides, derived from the 
cell envelope of mycobacteria or cell wall of gram-negative bacteria 
(LPS).  Lipoglycans contain pathogen-associated molecular patterns 
(PAMPS) and are shown to be TLR2 agonists in mycobacteria and other 
related genera within the actinomycetales phylogenetic order.  In 
mycobacteria, LAM, LM, and PIM are common lipoglycans extracted with 




Medical dictionary consisting of terms used to classify adverse events 
resulting from the intervention of biopharmaceuticals and other medical 
products.  Adverse events are coded to a standard set of Medra® system 
organ classification (SOC) terms for sharing and analysis of safety data 
among the biopharmaceutical industry.  Medra® was created by the ICH 









A granulomatous reaction observed 21 days after an intradermal injection 
of Lepromin (inactivated M. leprae suspension), first described by 
Kensuke Mitsuda in 1919.  The Mitsuda Reaction is elicited in BT or TT 
leprosy patients, but not BL or LL leprosy patients.  It is useful in 




A document created for the clinical site that covers policies and procedures 
for execution of the clinical study.  The manual contains descriptions of 
responsibilities, staff qualifications, list of authorities and resources, 





Likelihood of detecting the presence of disease (number of true 
positives/number of true positives plus the number of false negatives), or 
the probability of a positive test when the subject has disease.  




Likelihood to detect the absence of disease (number of true 
negatives/number of true negatives plus the number of false positives), or 
the probability of a negative test when the subject does not have disease.  








LIST OF ABBREVIATIONS 
 
Acronymn Full Name 
AE Adverse Event 
ATCC American Type Culture Collection 
AUC Area Under the Curve 
BB Borderline (Ridley Jopling Classification) 
BCA Bicinchoninic Acid  
BCG Mycobacterium bovis, strain Bacillus Calmette Guerin  
BL Borderline Lepromatous (Ridley Jopling Classification) 
BT Borderline Tuberculoid (Ridley Jopling Classification) 
CBER Center for Biological Evaluation and Research 
CFR Code of Federal Regulations 
cGMP  current Good Manufacturing Practice 
CMC Chemistry Manufacturing Control 
CMI Cell Mediated Immunity 
CMO Contract Manufacturing Organization 
CPE Cytopathic Effect 
CRF Case Report Form 
CSU Colorado State University 
DCC Data Coordinating Center 
DHHS Department of Human Health Services 
DTH Delayed Type Hypersensitivity 
EC Endemic Control (Study Acronymn) 
EPI Electronic Password Information 
FALGPA N-(3-[2-Furyl]Acryloyl)-Leu-Gly-Pro-Ala  
FDA Food and Drug Administration 
FIT Florida Institute of Technology 
FPR False Positive Rate 
FWA Federal Wide Assurance 
GCP Good Clinical Practice 
GDP Good Documentation Practice 
GLP Good Laboratory Practice 
GMP Good Manufacturing Practice 
GroEL Large Chaparone Protein from the GroE Operon 
GroES Small Chaparone Protein from the GroE Operon 
GWLHDC Gillis W. Long Hansen’s Disease Center  
HBV Hepatitis B Virus 
HC 
Household Contact of BL/LL Leprosy Patient (Study 
Acronymn) 




HIV Human Immunodeficiency Virus 
HVAC Heating, Ventilation, and Air Conditioning 
IAUCU Institutional Animal Care & Use Committee 
IFN-γ Interferon gamma 
IGRA Interferon Gamma Release Assay 
IND Investigational New Drug  
IRB Institutional Review Board 
ISM Internal Safety Monitor 
ISO International Standards Organization 
LAM Lipoarabinomannan 
LL Lepromatous Leprosy (Ridley Jopling Classification) 
LM Lipomannan 
LP Lepromatous Leprosy Patient (Study Acronymn) 
LSTA Leprosy Skin Test Antigens 
MAB Monoclonal Antibody 
MB Multibacillary (WHO Leprosy Classification) 
MDT Multiple Drug Therapy  
Medra®  Medical Dictionary for Regulatory Activities 
MI Morphological Index 
MLCwA 
M. leprae Cell Wall Associated Antigens devoid of 
lipoglycans 
MLMA M. leprae Membrane Antigens  
MLMA-LAM M. leprae Membrane Antigens devoid of lipoglycans 
MLSA M. leprae Soluble Antigen 
MLSA-LAM M. leprae Cytosolic Antigens devoid of lipoglycans 
mm millimeters 
MMP-I Major Membrane Protein - I 
MOO Manual of Operation 
MRL Mycobacterial Research Laboratories 
NBT-BCIP 
nitro blue tetrazolium - (5-bromo-4-chloro-3-indolyl-
phosphate)   
NCR No Carbon Required 
ND-O-HSA Natural Disaccharide Octyl Bovine Serum Albumin  
NHRC Nepal Health Research Council 
NIAID National Institute of Allergy and Infectious Diseases 
NIH National Institutes of Health 
NPV Negative Predictive Value 
OHRP Office of Human Research Protections 
PB Paucibacillary (WHO Leprosy Classification) 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
PDM Product Development and Manufacturing 




PGL-I Phenolic Glycolipid-I 
PHS Public Health Services 
PIM  Phosphatidylinositol Mannoside  
PPD Purified Protein Derivative 
PPV Positive Predictive Value 
RMRCE Rocky Mountain Regional Center of Excellence 
ROC Receiver Operating Characteristics 
SA Soluble Antigen 
SAE Serious Adverse Event 
SDS Sodium Dodecyl Sulfate  
SDS-PAGE 
Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis 
Se Sensitivity 
SMC Safety Monitoring Committee 
SOC System Organ Class 
SOD Superoxide Dismutase 
SOP Standard Operating Procedure 
Sp Specificity 
SPA Soluble Protein Antigen 
TB Tuberculosis Patient (Study Acronymn) 
TD Tuberculoid Leprosy Patient (Study Acronymn) 
TPR True Positive Rate 
TSA Trypticase Soy Agar 
TSB Trypticase Soy Broth 
TT Tuberculoid Leprosy (Ridley Jopling Classification) 
TU Tuberculin Units 
TX-114 Triton X-114 
UCSF University of California, San Francisco 
WHO World Health Organization 
 
 
